UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 10-K
ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE
SECURITIES EXCHANGE ACT OF 1934
For fiscal year ended December 31, 2013
Commission file number: 000-50644
Cutera, Inc.
(Exact name of registrant as specified in its charter)
|
Delaware
|
|
77-0492262
|
|
(State or other jurisdiction of incorporation or organization)
|
|
(I.R.S. Employer Identification Number)
|
3240 Bayshore Blvd.
Brisbane, California 94005
(415) 657-5500
(Address, including zip code, and telephone number, including area code, of registrant’s principal executive offices)
Securities registered pursuant to Section 12(b) of the Act:
|
Title of Each Class
|
|
Name of Each Exchange on Which Registered
|
|
Common Stock, $0.001 par value per share
|
|
The NASDAQ Stock Market, LLC
|
Securities Registered Pursuant to Section 12(g) of the Act: None
Indicate by check mark if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Yes ¨ No x
Indicate by check mark if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act. Yes ¨ No x
Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period than the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes x No ¨
Indicate by check mark whether the registrant has submitted electronically and posted on its corporate Web site, if any, every Interactive Data File required to be submitted and posted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit and post such files). Yes x No o
Indicate by check mark if disclosure of delinquent filers pursuant to Item 405 of Regulation S-K (§229.405 of this chapter) is not contained herein, and will not be contained, to the best of the registrant’s knowledge, in definitive proxy or information statements incorporated by reference in Part III of this Form 10-K or any amendment to this Form 10-K. ¨
Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, or a non-accelerated filer. See the definition of “large accelerated filer”, “accelerated filer” and “smaller reporting company” in Rule 12b-2 of the Exchange Act (check one):
|
Large accelerated
filer ¨
|
Accelerated
filer x
|
Non-accelerated filer (Do not check if a smaller reporting company) ¨
|
Smaller reporting
company ¨
|
Indicate by check mark whether registrant is a shell company (as defined in Rule 12b-2 of the Act). Yes ¨ No x
The aggregate market value of the registrant’s common stock, held by non-affiliates of the registrant as of June 30, 2013 (which is the last business day of registrant’s most recently completed second fiscal quarter) based upon the closing price of such stock on the NASDAQ Global Select Market on June 28, 2013, was approximately $99 million. For purposes of this disclosure, shares of common stock held by entities and individuals who own 5% or more of the outstanding common stock and shares of common stock held by each officer and director have been excluded in that such persons may be deemed to be “affiliates” as that term is defined under the Rules and Regulations of the Securities Exchange Act of 1934. This determination of affiliate status is not necessarily conclusive.
The number of shares of Registrant’s common stock issued and outstanding as of February 28, 2014 was 14,040,107.
DOCUMENTS INCORPORATED BY REFERENCE
Part III incorporates by reference certain information from the registrant’s definitive proxy statement for the 2014 Annual Meeting of Stockholders.
|
|
|
Page
|
|
PART I
|
|
|
|
|
|
|
|
Item 1.
|
3
|
|
|
Item 1A.
|
17
|
|
|
Item 1B.
|
28
|
|
|
Item 2.
|
28
|
|
|
Item 3.
|
28
|
|
|
Item 4.
|
28
|
|
|
|
|
|
|
PART II
|
|
|
|
|
|
|
|
Item 5.
|
29
|
|
|
Item 6.
|
30
|
|
|
Item 7.
|
32
|
|
|
Item 7A.
|
43
|
|
|
Item 8.
|
44
|
|
|
Item 9.
|
73
|
|
|
Item 9A.
|
73
|
|
|
Item 9B.
|
74
|
|
|
|
|
|
|
PART III
|
|
|
|
|
|
|
|
Item 10.
|
74
|
|
|
Item 11.
|
74
|
|
|
Item 12.
|
74
|
|
|
Item 13.
|
75
|
|
|
Item 14.
|
75
|
|
|
|
|
|
|
PART IV
|
|
|
|
|
|
|
|
Item 15.
|
76
|
PART I
We are a global medical device company headquartered in Brisbane, California specializing in the design, development, manufacture, marketing and servicing of laser and other energy based aesthetics systems for practitioners worldwide. We offer easy-to-use products based on four primary platforms / systems —Xeo®, GenesisPlusTM, ExcelVTM, and truSculptTM — each of which enables physicians and other qualified practitioners to perform safe and effective aesthetic procedures for their customers. Each of our laser and other energy-based platforms consists of one or more hand pieces and a console that incorporates a universal graphical user interface, a laser or other energy-based module, control system software and high voltage electronics. However, depending on the application, the laser or other energy-based module is sometimes instead contained in the hand piece itself. A description of each of our hand pieces, and the aesthetic conditions they are designed to treat, is contained in the section below entitled “Products” and a summary of the features of our primary products is as follows:
| · | Xeo- In 2003, we introduced the Xeo platform, which can combine pulsed light and laser applications in a single system. The Xeo is a multi-application platform on which a customer can purchase hand piece applications for the removal of unwanted hair, treatment of vascular lesions, and skin rejuvenation by treating discoloration, improving texture, reducing pore size, and treating fine lines and laxity. This multi-application platform represents the largest contributor to our Product revenue. |
| · | GenesisPlus- In 2010, we introduced the GenesisPlus platform, which is a dedicated laser system for performing aesthetic skin procedures and for the temporary increase of clear nail in patients with onychomycosis, or toenail fungus. This system features a hand piece that includes real time temperature monitoring of the treatment area, as well as a non-contact distance gauge using dual aiming beams that enhances ease of use. In addition, this system can be used to treat patients with skin concerns such as fine wrinkles, diffuse redness and rosacea. |
| · | ExcelV- In February 2011, we introduced our ExcelV platform, a high-performance, vascular platform designed specifically for the core-market of Dermatologists and Plastic Surgeons. This platform provides a combination of the 532 nm green laser with Cutera’s award-winning 1064 nm Nd:YAG technology, to provide a single, compact and efficient system that treats the entire range of cosmetic vascular conditions, without the need for costly consumables. |
| · | truSculpt- In August 2012, we commenced shipments of our truSculpt platform with a 25cm2 hand piece. truSculpt is a high-powered radio frequency (“RF”) platform designed for the non-invasive body contouring market. This system is designed to treat all body areas and with its unique electrode design is able to achieve comfortable, uniform heating of the subcutaneous fat. In the fourth quarter of 2012, we commenced shipping a larger 40cm2 hand piece that enables faster treatments of larger areas. In the third quarter of 2013, we commenced shipping a smaller 16 cm2 hand piece. |
Other than the above mentioned four primary systems, we continue to generate revenue from our legacy products such as CoolGlide®, Solera®, VariliteTM, and a third-party sourced system called myQTM for the Japanese market.
We offer our customers the ability to select the systems and applications that best fit their practice and to subsequently upgrade their systems to add new applications. This upgrade path allows our customers to cost-effectively build their aesthetic practices and provides us with a source of incremental revenue.
In addition to systems and upgrades, we generate revenue from the sale of post warranty services, Titan hand piece refills, and dermal fillers and cosmeceuticals.
The Structure of Skin and Conditions that Affect Appearance
The skin is the body’s largest organ and is comprised of two layers called the epidermis and dermis. The epidermis is the outer layer, and serves as a protective barrier for the body. It contains cells that determine pigmentation, or skin color. The underlying layer of skin, the dermis, contains hair follicles and large and small blood vessels that are found at various depths below the epidermis. Collagen, also found within the dermis, provides strength and flexibility to the skin.
Many factors, including advancing age, smoking, and sun damage, can result in aesthetically unpleasant changes in the appearance of the skin. These changes can include:
| · | Undesirable hair growth; |
| · | Enlargement or swelling of blood vessels due to circulatory changes that become visible at the skin’s surface in the form of unsightly veins; |
| · | Deterioration of collagen, leading to uneven texture, increased pore size, wrinkles and skin laxity; |
| · | Uneven pigmentation or sun spots due to long-term sun exposure. |
In addition to these skin conditions, people seek removal of unwanted tattoos as well as removal of fat in certain body areas in order to improve their appearance and confidence.
The Market for Non-Surgical Aesthetic Procedures
The market for non-surgical aesthetic procedures has grown significantly over the past several years. The American Society of Plastic Surgeons estimates that in 2012 there were over 13.0 million minimally-invasive aesthetic procedures performed in North America, a 6% increase over 2011 and a 137% increase over 2000.
We believe there are several factors contributing to the growth of these aesthetic procedures:
| · | Aging of the U.S. Population- The “baby boomer” demographic segment ─ ages 49 to 67 in 2013 ─ represented approximately 75 million people, or nearly 25%, of the U.S. population in 2013. The size and wealth of this aging segment, and its desire to retain a youthful appearance, has contributed to the growth for aesthetic procedures. |
| · | Broader Range of Safe and Effective Treatments- Technical developments have led to safe, effective, easy-to-use and low-cost treatments with fewer side effects, resulting in broader adoption of aesthetic procedures by practitioners. In addition, technical developments have enabled practitioners to offer a broader range of treatments. These technical developments have reduced the required treatment and recovery times, which in turn have led to greater patient demand. |
| · | Broader Base of Customers- Managed care and government payer reimbursement restrictions in the U.S., and similar payment related constraints outside the U.S., may help motivate qualified practitioners from differing specialties to establish or expand their elective aesthetic practices with procedures that are paid for directly by patients. As a result, in addition to the core users such as dermatologists and plastic surgeons, many other non-core practitioners, such as gynecologists, family practitioners, primary care physicians, physicians offering aesthetic treatments in non-medical offices, and other qualified practitioners are offering aesthetic procedures. |
| · | Wide acceptance of aesthetic procedures and increased focus on body image and appearance. According to an ASAPS survey in 2010, 51% of Americans (including 53% of women and 49% of men) approved of cosmetic surgery, and 67% of Americans responded that they would not be embarrassed if their friends or family knew they had undergone a cosmetic procedure. Broader social acceptance of aesthetic treatments, and reducing average cost of treatments resulting from competition, has also driven the growth in aesthetic procedures. |
Non-Surgical Aesthetic Procedures for Improving the Skin’s Appearance and Their Limitations
Many alternative therapies are available for improving a person’s appearance by treating specific structures within the skin. These procedures utilize injections or abrasive agents to reach different depths of the dermis and the epidermis. In addition, non-invasive and minimally-invasive treatments have been developed that employ laser and other energy-based technologies to achieve similar therapeutic results. Some of these more common therapies and their limitations are described below.
Hair Removal- Techniques for hair removal include waxing, depilatories, tweezing, shaving, electrolysis and laser and other energy-based hair removal. The only techniques that provide a long-lasting solution are electrolysis and other energy-based hair removal. Electrolysis is usually painful, time-consuming and expensive for large areas, but is the most common method for removing light-colored hair. During electrolysis, an electrologist inserts a needle directly into a hair follicle and activates an electric current in the needle. Since electrolysis only treats one hair follicle at a time, the treatment of an area as small as an upper lip may require numerous visits and many hours of treatment. In addition, electrolysis can cause blemishes and infection related to needle use.
Leg and Facial Veins- Current aesthetic treatment methods for leg and facial veins include sclerotherapy and laser and other energy-based treatments. With these treatments, patients seek to eliminate visible veins and improve overall skin appearance. Sclerotherapy requires a skilled practitioner to inject a saline or detergent-based solution into the target vein, which breaks down the vessel causing it to collapse and be absorbed into the body. The need to correctly position the needle on the inside of the vein makes it difficult to treat smaller veins, which limits the treatment of facial vessels and small leg veins. The American Society of Plastic Surgeons estimates that approximately 358,000 sclerotherapy procedures were performed in 2012.
Skin Rejuvenation- Skin rejuvenation treatments include a broad range of popular alternatives, including Botox and collagen injections, chemical peels, microdermabrasions, radio frequency treatments and lasers and other energy-based treatments. With these treatments, patients hope to improve overall skin tone and texture, reduce pore size, tighten skin and remove other signs of aging, including mottled pigmentation, diffuse redness and wrinkles. All of these procedures are temporary solutions and must be repeated within several weeks or months to sustain their effect, thereby increasing the cost and inconvenience to patients. For example, the body absorbs Botox and collagen and patients require supplemental injections every three to six months to maintain the benefits of these treatments.
Some skin rejuvenation treatments, such as chemical peels and microdermabrasions, can have undesirable side effects. Chemical peels use acidic or caustic solutions to peel away the epidermis, and microdermabrasion generally utilizes sand crystals to resurface the skin. These techniques can lead to stinging, redness, irritation and scabbing. In addition, more serious complications, such as changes in skin color, can result from deeper chemical peels. Patients that undergo these deep chemical peels are also advised to avoid exposure to the sun for several months following the procedure. The American Society of Plastic Surgeons estimates that in 2012, approximately 6.1 million injections of Botulinum Toxin and 1.99 million injections of collagen and other soft-tissue fillers were administered; and 1.13 million chemical peels and 973,000 microdermabrasion procedures were performed.
In radio frequency tissue tightening, energy is applied to heat the dermis of the skin with the goal of shrinking and tightening collagen fibers. This approach may result in a more subtle and incremental change to the skin than a surgical facelift. Drawbacks to this approach may include surface irregularities that may however resolve over time, and the risk of burning the treatment area.
Laser and other energy-based non-surgical treatments for hair removal, veins, skin rejuvenation and body contouring are discussed in the following section and in the section entitled “Our Applications and Procedures,” below.
Laser and Other Energy-Based Aesthetic Treatments
Laser and other energy-based aesthetic treatments can achieve therapeutic results by affecting structures within the skin. The development of safe and effective aesthetic treatments has created a well-established market for these procedures.
Ablative skin resurfacing is a method of improving the appearance of the skin by removing the outer layers of the skin. Ablative skin resurfacing procedures are considered invasive or minimally invasive, depending on how much of the epidermis is removed during a treatment. Non-ablative skin resurfacing is a method of improving the appearance of the skin by treating the underlying structure of the skin without damaging the outer layers of the skin. Practitioners can use laser and other energy-based technologies to selectively target hair follicles, veins or collagen in the dermis, as well as cells responsible for pigmentation in the epidermis, without damaging surrounding tissue. They can also use these technologies to safely remove portions of the epidermis and deliver heat to the dermis as a means of generating new collagen growth.
Safe and effective laser and energy-based treatments require an appropriate combination of the following four parameters:
| · | Energy Level- the amount of light or radio frequency emitted to heat a target; |
| · | Pulse Duration- the time interval over which the energy is delivered; |
| · | Spot Size or Electrode Size- the diameter of the energy beam, which affects treatment depth and area; and |
| · | Wavelength or Frequency- the position in the electromagnetic spectrum which impacts the absorption and therefore the effective depth of the energy delivered. |
For example, in the case of hair removal, by utilizing the correct combination of these parameters, a practitioner can use a laser or other light source to selectively target melanin within the hair follicle to absorb the laser energy and destroy the follicle, without damaging other delicate structures in the surrounding tissue. Wavelength and spot size permit the practitioner to target melanin in the base of the hair follicle, which is found in the dermis. The combination of pulse duration and energy level may vary, depending upon the thickness of the targeted hair follicle. A shorter pulse length with a high energy level is optimal to destroy fine hair, whereas coarse hair is best treated with a longer pulse length with lower energy levels. If treatment parameters are improperly set, non-targeted structures within the skin may absorb the energy thereby eliminating or reducing the therapeutic effect. In addition, improper setting of the treatment parameters or failure to protect the surface of the skin may cause burns, which can result in blistering, scabbing and skin discoloration.
Technology and Design of Our Systems
Our unique Xeo, GenesisPlus, ExcelV, and truSculpt platforms provide the long-lasting benefits of laser and other energy-based aesthetic treatments. Our technology allows for a combination of a wide variety of applications available in a single system. Key features of our solutions include:
| · | Multiple Applications Available in a Single System- Our platforms feature multiple-applications that enable practitioners to perform a variety of aesthetic procedures using a single device. These procedures include hair removal, vascular treatments and skin rejuvenation ─ including the treatment of discoloration, laxity, fine lines, pore size reduction, and uneven texture. Because practitioners can use our systems for multiple indications, the cost of a unit may be spread across a potentially greater number of patients and procedures and therefore may be more rapidly recovered. |
| · | Technology and Design Leadership- We offer innovative laser and other energy-based solutions for the aesthetic market. Our laser technology combines long wavelength, adjustable energy levels, variable spot sizes and a wide range of pulse durations, allowing practitioners to customize treatments for each patient and condition. Our proprietary pulsed light hand pieces for the treatment of discoloration, hair removal and vascular treatments optimize the wavelength used for treatments and incorporate a monitoring system to increase safety. Our Titan hand pieces utilize a novel light source that had not been previously used for aesthetic treatments. Our Pearl and Pearl Fractional hand pieces, with proprietary YSGG technology, represent the first application of the 2790 nm wavelength for minimally-invasive cosmetic dermatology. Further, our GenesisPlus platform performs aesthetic skin procedures and temporarily increases clear nail in patients with onychomycosis. The GenesisPlus platform contains a hand piece that includes real time temperature monitoring of the treatment area, as well as a non-contact distance gauge using dual aiming beams, for improving the clinical result of the treatment. ExcelV is a stand-alone laser device that combines a new high power green laser with Cutera's award winning Nd:YAG technology, to provide a system that treats the entire range of cosmetic vascular conditions, without the need for costly consumables. truSculpt is a mono-polar radio frequency platform and has a unique electrode design that delivers high-powered energy at 1 MHz for the deep and uniform heating of the subcutaneous fat tissues at sustained therapeutic temperatures. This system includes real-time skin temperature sensing and a large 40cm2 surface area for faster treatments over large areas of the body. |
| · | Upgradeable Platform- We have designed some of our products to allow our customers to cost-effectively upgrade to our multi-application systems (Solera and Xeo), which provide our customers with the option to add additional applications to their existing systems and provides us with a source of incremental revenue. We believe that product upgradeability allows our customers to take advantage of our latest product offerings and provide additional treatment options to their patients, thereby expanding the opportunities for their aesthetic practices. |
| · | Treatments for Broad Range of Skin Types and Conditions- Our products remove hair safely and effectively on patients of all skin types, including harder-to-treat patients with dark or tanned skin. In addition, the wide parameter range of our systems allows practitioners to effectively treat patients with both fine and coarse hair. Practitioners may use our products to treat spider and reticular veins (unsightly small veins in the leg) and small facial veins; perform skin rejuvenation procedures for discoloration, texture, pore size, fine lines, and laxity on any type of skin; and treat toenail fungus. The ability to customize treatment parameters enables practitioners to offer safe and effective therapies to a broad base of their patients. |
| · | Ease of Use- We design our products to be easy to use. Our proprietary hand pieces are lightweight and ergonomic, minimizing user fatigue, and allow for clear views of the treatment area, reducing the possibility of unintended damage and increasing the speed of application. Our control console contains a universal graphical user interface with three simple, independently adjustable controls from which to select a wide range of treatment parameters to suit each patient’s profile. The clinical navigation user interface on the Xeo platform provides recommended clinical treatment parameter ranges based on patient criteria entered. And our Pearl and Pearl Fractional hand pieces include a scanner with multiple scan patterns to allow simple and fast treatments of the face. Risks involved in the use of our products include risks common to other laser and other energy-based aesthetic procedures, including the risk of burns, blistering and skin discoloration. |
Strategy
Our goal is to maintain and expand our position as a leading, worldwide, provider of energy-based aesthetic devices and complementary aesthetic products by executing the following strategies:
| · | Continue to Expand our Product Offering- Though we believe that our current portfolio of products is comprehensive, our research and development group has a pipeline of potential products under development that we expect to commercialize in the future. We launched GenesisPlus in 2010, ExcelV in 2011,truSculpt in 2012 and the ProWave LX and truSculpt 16 cm2 hand pieces in 2013. Such products will allow us to leverage our existing customer call points and provide us with new customer call points which will enhance the productivity of our distribution channels. |
| · | Increasing Revenue and Improving Productivity- We believe that the market for aesthetic systems will continue to offer growth opportunities. We continue to build brand recognition, add additional products to our international distribution channel, and are focused on enhancing our global distribution network, all of which we expect will increase our revenue. |
| · | Increasing Focus on Practitioners with Established Medical Offices- We believe there is growth opportunity in targeting our products to a broad customer base. However, in response to the 2009 to 2010 global recession, we shifted our focus to core practitioners and physicians with established medical offices. We believe that our customers’ success is largely dependent upon having an existing medical practice, in which our systems provide incremental revenue sources to augment their practice revenue. The success of our ExcelV platform has resulted from strong adoption by core customers in dermatology and plastic and reconstructive surgery. |
| · | Leveraging our Installed Base - With the introduction of ExcelV and now truSculpt, we are able to effectively offer additional platforms into our existing installed base. In addition, each of these platforms allows for potential future upgrades to offer additional indications or capabilities. We believe this program aligns our interest in generating revenue with our customers’ interest in improving the return on their investment by expanding the range of applications that can be performed in their practice. |
| · | Generating Revenue from Services and Refillable Hand Pieces- Our Titan and pulsed-light hand pieces are refillable products, which provide us with a source of recurring revenue from our existing customers. We offer post-warranty services to our customers either through extended service contracts to cover preventive maintenance or through direct billing for parts and labor. These post-warranty services serve as additional sources of recurring revenue. |
Products
Our CoolGlide, Xeo, Solera, GenesisPlus, ExcelV, truSculpt and myQ platforms allow for the delivery of multiple laser and energy-based aesthetic applications from a single system. With our Xeo and Solera platforms, practitioners can purchase customized systems with a variety of our multi-technology applications.
The following table lists our products and each checked box represents the applications that were included in the product in the years noted.
|
Applications:
|
Hair
Removal:
|
Vascular
Lesions:
|
Skin Rejuvenation
|
Non Invasive Body Contouring:
|
||||||||||||||||
|
System
Platforms:
|
Products:
|
Year:
|
Energy
Source:
|
Dyschromia:
|
Texture,
Lines and
Wrinkles:
|
Skin
Laxity:
|
Melasma &Tattoo
Removal:
|
|||||||||||||
|
CoolGlide
|
|
CV
|
|
2000
|
|
a
|
|
x
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Excel
|
|
2001
|
|
a
|
|
x
|
|
x
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Vantage
|
|
2002
|
|
a
|
|
x
|
|
x
|
|
|
|
x
|
|
|
|
|
|
|
|
Xeo
|
|
Nd:YAG
|
|
2003
|
|
a
|
|
x
|
|
x
|
|
|
|
x
|
|
|
|
|
|
|
|
|
|
OPS600
|
|
2003
|
|
b
|
|
|
|
|
|
x
|
|
|
|
|
|
|
|
|
|
|
|
LP560
|
|
2004
|
|
b
|
|
|
|
|
|
x
|
|
|
|
|
|
|
|
|
|
|
|
Titan S
|
|
2004
|
|
c
|
|
|
|
|
|
|
|
|
|
x
|
|
|
|
|
|
|
|
ProWave 770
|
|
2005
|
|
b
|
|
x
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
AcuTip 500
|
|
2005
|
|
b
|
|
|
|
x
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Titan V/XL
|
|
2006
|
|
c
|
|
|
|
|
|
|
|
|
|
x
|
|
|
|
|
|
|
|
LimeLight
|
|
2006
|
|
b
|
|
|
|
|
|
x
|
|
|
|
|
|
|
|
|
|
|
|
Pearl
|
|
2007
|
|
d
|
|
|
|
|
|
x
|
|
x
|
|
|
|
|
|
|
|
|
|
Pearl Fractional
|
|
2008
|
|
d
|
|
|
|
|
|
|
|
x
|
|
|
|
|
|
|
|
|
|
ProWave LX
|
|
2013
|
|
b
|
|
x
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Solera
|
|
Titan S
|
|
2004
|
|
c
|
|
|
|
|
|
|
|
|
|
x
|
|
|
|
|
|
|
|
ProWave 770
|
|
2005
|
|
b
|
|
x
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
OPS 600
|
|
2005
|
|
b
|
|
|
|
|
|
x
|
|
|
|
|
|
|
|
|
|
|
|
LP560
|
|
2005
|
|
b
|
|
|
|
|
|
x
|
|
|
|
|
|
|
|
|
|
|
|
AcuTip 500
|
|
2005
|
|
b
|
|
|
|
x
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Titan V/XL
|
|
2006
|
|
c
|
|
|
|
|
|
|
|
|
|
x
|
|
|
|
|
|
|
|
LimeLight
|
|
2006
|
|
b
|
|
|
|
|
|
x
|
|
|
|
|
|
|
|
|
|
GenesisPlus
|
|
|
|
2010
|
|
a
|
|
|
|
|
|
|
|
x
|
|
|
|
|
|
|
|
ExcelV
|
|
|
|
2011
|
|
e
|
|
|
|
x
|
|
x
|
|
x
|
|
|
|
|
|
|
|
myQ
|
|
|
|
2011
|
|
e
|
|
|
|
|
|
|
|
|
|
|
|
x
|
|
|
|
VariLite
|
|
|
|
2012
|
|
f
|
|
|
|
x
|
|
x
|
|
|
|
|
|
|
|
|
|
truSculpt
|
|
|
|
2012
|
|
g
|
|
|
|
|
|
|
|
|
|
|
|
|
|
x
|
Energy Source: a. 1064nm Nd:YAG laser; b. flashlamp; c. Infrared laser; d. 2790 nm YSGG laser; e. combined frequency 532 nm and 1064 nm Nd:YAG laser; f. Combined frequency 532 nm and 940 nm diode laser; g. Radio frequency at 1 MHz
Each of our products consists of a control console and one or more hand pieces, depending on the model.
Control Console
Our control console includes a universal graphical user interface, control system software and high voltage electronics. All CoolGlide systems, GenesisPlus, VariLite, ExcelV and some models of the Xeo platform, include our laser module which consists of electronics, a visible aiming beam, a focusing lens, and an Nd:YAG and/or flashlamp laser that functions at wavelengths that permit penetration over a wide range of depths and is effective across all skin types. The interface allows the practitioner to set the appropriate laser or flashlamp parameters for each procedure through a user-friendly format. The control system software ensures that the operator’s instructions are properly communicated from the graphic user interface to the other components within the system. Our high voltage electronics produce over 10,000 watts of peak laser energy, which permits therapeutic effects at short pulse durations. Our Solera console platform comes in two configurations—Opus and Titan—both of which include a universal graphical user interface, control system software and high voltage electronics. The Solera Opus console is designed specifically to drive our flashlamp hand pieces while the Solera Titan console is designed specifically to drive the Titan hand pieces. The control system software is designed to ensure that the operator’s instructions are properly communicated from the graphical user interface to the other components within the system and includes real-time calibration to control the output energy as the pulse is delivered during the treatment. Our truSculpt control console includes a high-powered, mono-polar RF generator at 1MHz capable of delivering up to 300 watts of energy. The truSculpt system dynamically adjusts current, voltage and power during treatment as needed to reach and maintain the appropriate treatment levels.
Hand Pieces
1064 nm Nd:YAG Hand Piece- Our 1064nm Nd:YAG hand piece delivers laser energy to the treatment area for hair removal, leg and facial vein treatment, and skin rejuvenation procedures to treat skin texture and fine lines, and reduce pore size. The 1064nm Nd:YAG hand piece consists of an energy-delivery component, consisting of an optical fiber and lens, and a copper cooling plate with imbedded temperature monitoring. The hand piece weighs approximately 14 ounces, which is light enough to be held with one hand. The lightweight nature and ergonomic design of the hand piece allows the operation of the device without user fatigue. Its design allows the practitioner an unobstructed view of the treatment area, which reduces the possibility of unintended damage to the skin and can increase the speed of treatment. The 1064nm Nd:YAG hand piece also incorporates our cooling system, providing integrated pre- and post-cooling of the treatment area through a temperature-controlled copper plate to protect the outer layer of the skin. The hand piece is available in either a fixed 10 millimeter spot size for our CoolGlide CV system, or a user-controlled variable 3, 5, 7 or 10 millimeter spot size for our CoolGlide Excel and CoolGlide Vantage systems.
ExcelV Hand Piece- The ExcelV system introduced in February 2011 delivers 1064 nm and 532 nm laser energy to the treatment area for vascular treatments. The ExcelV system supports two hand pieces, both consisting of an energy-delivery component housing an optical fiber and lens. One hand piece includes a sapphire window cooling plate with temperature monitoring. The second hand piece does not have a cooling plate and includes a non-contact temperature sensor to monitor the treatment area temperature. In addition, this second hand piece includes dual aiming beams that facilitate consistent treatments by maintaining the correct distance of the hand piece to the skin. Both hand pieces offer a spot size range from 1.5 to 12 mm in 0.1 mm increments. Each hand piece is capable of delivering either the 1064 nm or 532 nm laser energy.
GenesisPlus Hand Piece- Our GenesisPlus system launched in 2010 delivers 1064 nm laser energy to the treatment area for the temporary increase of clear nail in patients with onychomycosis and for the treatment of fine wrinkles, diffuse redness and rosacea. This lightweight1064nm Nd:YAG hand piece consists of an energy-delivery component, housing an optical fiber and lens. The hand piece includes a non-contact temperature sensor to monitor the treatment area temperature. In addition, the hand piece includes dual aiming beams that facilitate consistent treatments by maintaining the correct distance of the hand piece to the skin. This hand piece offers a single 5 mm spot size.
Pulsed Light Hand Piece- The LP560, ProWave 770, ProWave LX, AcuTip 500, and LimeLight hand pieces are designed to produce a pulse of light over a wavelength spectrum to treat discoloration such as age and sun spots and other dyschromia, hair removal, and superficial facial vessels. The hand pieces each consist of a custom flashlamp, proprietary wavelength filter, closed-loop power control and embedded temperature monitor, and weigh approximately 13 ounces. The filter in the AcuTip 500 eliminates long and short wavelengths, transmitting only the therapeutic range required for safe and effective treatment. The filter in the LP560, ProWave 770, ProWave LX, and LimeLight eliminates short wavelengths, allowing longer wavelengths to be transmitted to the treatment area. In addition, the wavelength spectrum of the ProWave 770 and the LimeLight can be shifted based on the setting of the control console. Our power control includes a monitoring system to ensure that the desired energy level is delivered. The hand pieces protect the epidermis by regulating the temperature of the hand piece window through the embedded temperature monitor. These hand pieces are available on the Xeo and Solera platforms.
Titan Hand Piece- The Titan hand pieces are designed to produce a sustained pulse of light over a wavelength spectrum tailored to induce heating in the dermis to treat skin laxity (although it is cleared in the U.S. by the U.S. Food and Drug Administration, or FDA, only for deep dermal heating). The hand piece consists of a custom light source, proprietary wavelength filter, closed-loop power control, sapphire cooling window and embedded temperature monitor, and weighs approximately three pounds. The temperature of the epidermis is controlled by using a sapphire window to provide cooling before, during and after the delivery of energy to the treatment site. We offer two different Titan hand pieces—Titan V and Titan XL.
| · | Titan V- Titan V has a treatment tip that extends beyond the hand piece housing to provide enhanced visibility of the skin’s surface to effectively treat delicate areas such as the skin around the eyes and nose. |
| · | Titan XL- Titan XL, like the Titan V, has a treatment tip that extends beyond the housing for improved visibility. It also has a larger treatment spot size to treat larger body areas faster, such as the arms, abdomen and legs. |
The Titan hand pieces can be used on the Xeo and Solera platforms. The Titan hand piece requires a periodic “refilling” process, which includes the replacement of the optical source, after a set number of pulses have been used. This provides us with a source of recurring revenue.
Pearl Hand Piece- The Pearl hand piece, introduced in 2007, is designed to treat fine lines, uneven texture and dyschromia through the application of proprietary YSGG laser technology. This hand piece can safely remove a small portion of the epidermis, while coagulating the remaining epidermis, leading to new collagen growth. The Pearl hand piece consists of a custom monolithic laser source, scanner and power monitoring electronics. The scanner includes multiple scan patterns to allow simple and fast treatments of the face. The hand piece includes an attachment for a smoke evacuator, allowing the practitioner to use one hand during treatment.
Pearl Fractional Hand Piece- The Pearl Fractional hand piece, introduced in 2008, also uses proprietary YSGG technology and is designed to treat wrinkles and deep dermal imperfections (although it is cleared in the U.S. by the FDA only for skin resurfacing and coagulation). This hand piece penetrates the deep dermis producing a series of microcolumns across the skin, which can result in the removal of damaged tissue and the production of new collagen. The Pearl Fractional hand piece consists of a custom monolithic laser source, scanner and power monitoring electronics. The scanner includes multiple scan patterns to allow simple and fast treatments of the face. The hand piece includes an attachment for a smoke evacuator, allowing the practitioner to use one hand during treatment.
truSculpt Hand Pieces- The truSculpt product introduced in August 2012 is used for the non-invasive heating of subcutaneous fat tissue. We sold three different truSculpt hand pieces in 2013. The original 25cm2 hand piece (now discontinued), 40 cm2 for larger body parts and the 16cm2 for smaller parts of the body. Each of the truSculpt hand pieces is light weight and ergonomically designed for operator comfort, which allows for the uniform heat distribution delivered by the hand pieces. In addition, the hand pieces have a built-in, real time, temperature sensing system to monitor the temperature during the treatment.
Upgrades
Our Solera and Xeo platforms are multi-application products that are designed to allow our customers to cost-effectively upgrade to our newest technologies, which provide our customers the option to add applications to their system and provides us with a source of recurring revenue.
Service
We offer post-warranty services to our customers either through extended service contracts ─ that cover preventive maintenance and/or replacement parts and labor ─ as well as direct billing for detachable hand piece replacements, parts and labor. These post-warranty services serve as additional sources of recurring revenue from our installed base.
Titan and truSculpt Hand Piece Refills
When customers purchase a replacement Titan or truSculpt hand piece, we treat that as “refill” revenue, which provides us with a source of recurring revenue from existing customers. Following the launch of truSculpt product in 2012, we charged customers for hand piece refills, however, beginning in the third quarter of 2013 we included truSculpt refills as part of our standard warranty and service contract product offerings.
Fillers and Cosmeceuticals
We distribute Merz’s Radiesse® dermal filler product and ZO Skin Health, Inc.’s (“ZO”) prescription-based, topical skin health systems (or ‘cosmeceuticals’) to physicians in the Japanese market. Since the first quarter of 2010 we had been distributing Obagi Medical Products, Inc.’s (“Obagi”) cosmeceuticals. Effective December 31, 2013 we no longer distribute the Obagi cosmeceuticals and have fully transitioned to the ZO product line.
Our Applications and Procedures
Our products are designed to allow the practitioner to select an appropriate combination of energy level, spot size and pulse duration for each treatment. The ability to manipulate the combinations of these parameters allows our customers to treat the broadest range of conditions available with a single energy-based system.
Hair Removal- Our laser technology allows our customers to treat all skin types and hair thicknesses. Our 1064 nm Nd:YAG laser permits energy to safely penetrate through the epidermis of any skin type and into the dermis where the hair follicle is located. Using the universal graphic user interface on our control console, the practitioner sets parameters to deliver therapeutic energy with a large spot size and variable pulse durations, allowing the practitioner to treat fine or coarse hair. Our 1064nm Nd:YAG hand piece allows our customers to treat all skin types, while our ProWave 770 and ProWave LX hand pieces, with pulsed light technology, treat the majority of skin types quickly and effectively.
To remove hair using a 1064nm Nd:YAG hand piece, the treatment site on the skin is first cleaned and shaved. The practitioner then applies a thin layer of gel to glide across the skin, and next applies the hand piece directly to the skin to cool the area to be treated and then delivers a laser pulse to the pre-cooled area. To remove hair using the ProWave 770 and ProWave LX hand pieces, mineral oil is used instead of gel, and cooling is provided by a sapphire window placed directly on the skin, allowing the pulse of light to be applied while the treatment area is being cooled. In the case of both hand pieces, delivery of light which is converted to heat destroys the hair follicles and prevents hair re-growth. This procedure is then repeated at the next treatment site on the body, and can be done in a gliding motion to increase treatment speed. Patients receive on average three to six treatments. Each treatment can take between five minutes to one hour depending on the size of the area and the condition being treated. On average, there are six to eight weeks between treatments.
Vascular Lesions- Our laser technology allows our customers to treat the widest range of aesthetic vein conditions, including spider and reticular veins and small facial veins. Our CoolGlide and Xeo 1064nm Nd:YAG hand piece’s adjustable spot size of 3, 5, 7 or 10 millimeters, or the ExcelV 1064 nm and 532 nm hand piece with adjustable spot sizes from 1.5 to 12 mm, allows the practitioner to control treatment depth to target different sized veins. Selection of the appropriate energy level and pulse duration ensures effective treatment of the intended target. Our AcuTip 500 hand piece, with its 6 millimeter spot size, uses pulsed-light technology and is designed for the treatment of facial vessels.
The vein treatment procedure when using the 1064nm Nd:YAG hand piece is performed in a substantially similar manner to the laser hair removal procedure. The laser hand piece is used to cool the treatment area both before and after the laser pulse has been applied. With the ExcelV hand piece, the cooling can be performed pre, during and post delivery of the laser pulse. With the AcuTip 500 hand piece, the pulse of light is delivered while the treatment area is being cooled with the sapphire tip. The delivered energy damages the vein and, over time, it is absorbed by the body. Patients receive on average between one and six treatments, with six weeks or longer between treatments.
Skin Rejuvenation- Our Nd:YAG laser and other energy based technologies allow our customers to perform non-invasive and minimally-invasive treatments that reduce redness, pore size, fine lines and laxity, improve skin texture, and treat other aesthetic conditions. Our myQ Q-switched laser can be used for the treatment of superficial and deep pigmented lesions (i.e., melasma), skin rejuvenations, laser skin toning and tattoo removal.
Texture; Lines and Wrinkles- When using a 1064nm Nd:YAG laser to improve skin texture, reduce pore size and treat fine lines, cooling is not applied and the hand piece is held directly above the skin. A large number of pulses are directed at the treatment site, repeatedly covering an area, such as the cheek. By delivering many pulses of laser light to a treatment area, a gentle heating of the dermis occurs and collagen growth is stimulated to rejuvenate the skin and reduce wrinkles. Patients typically receive four to six treatments for this procedure. The treatment typically takes less than a half hour and there are typically two to four weeks between treatments.
When treating texture and fine lines with a Pearl hand piece, the hand piece is held at a controlled distance from the skin and the scanner delivers a preset pattern of spots to the treatment area. Cooling is not applied to the epidermis during the treatment. The energy delivered by the hand piece ablates a portion of the epidermis while leaving a coagulated portion that will gently peel off over the course of a few days. Heat is also delivered into the dermis which can result in the production of new collagen. Treatment of the full face can usually be performed in 15 to 30 minutes. Patients receive on average between one and three treatments at monthly intervals.
When treating wrinkles and deep dermal imperfections with a Pearl Fractional hand piece, the hand piece is held at a controlled distance from the skin and the scanner delivers a preset pattern of spots to the treatment area. Cooling is not applied to the epidermis during the treatment. The energy delivered by the hand piece penetrates the deep dermis producing a series of microcolumns across the skin, which can result in the removal of damaged tissue and the production of new collagen. Treatment of the full face can usually be performed in less than an hour. Patients receive on average between one and three treatments at monthly intervals.
Our CE Mark allows us to market Pearl Fractional in the European Union, Australia and certain other countries outside the U.S. for the treatment of wrinkles and deep dermal imperfections. However, in the U.S. we have a 510(k) clearance for only skin resurfacing and coagulation.
Toenail Fungus- In addition to performing skin rejuvenation, we have FDA, Health Canada and CE Mark approvals for GenesisPlus that allows us to market it for onychomycosis (“toenail fungus”). Tiny pulses of light from an Nd:YAG laser pass through the toenail to the fungus underneath, which is irradiated without any damage to the surrounding nail or skin. The GenesisPlus has dual aiming beams that facilitate consistent treatments by maintaining the correct distance of the hand piece to the skin. In addition, during the treatment an integrated sensor is used to actively monitor the temperature of the treatment area.
Dyschromia- Our pulsed-light technologies allow our customers to safely and effectively treat red and brown dyschromia, which is skin discoloration, pigmented lesions, and rosacea. The practitioner delivers a narrow spectrum of light to the surface of the skin through our LP560 or LimeLight hand pieces. These hand pieces include one of our proprietary wavelength filters, which reduce the energy level required for therapeutic effect and minimize the risk of skin injury.
In treating pigmented lesions with a pulsed-light technology, the hand piece is placed directly on the skin and then the light pulse is triggered. The cells forming the pigmented lesion absorb the light energy, darken and then flake off over the course of two to three weeks. Several treatments may be required to completely remove the lesion. The treatment takes a few minutes per area treated and there are typically three to four weeks between treatments.
The 532 nm wavelength green laser option on the ExcelV and VariLite can also be used to treat pigmented lesions in substantially the same way as described above with the pulsed light devices.
Practitioners can also treat dyschromia and other skin conditions with our Pearl hand piece. During these treatments, the heat delivered by the Pearl hand piece will remove the outer layer of the epidermis while coagulating a portion of the epidermis. That coagulated portion will gently peel off over the course of a few days, revealing a new layer of skin underneath. Treatment of the full face can usually be performed in 15 to 30 minutes. Patients receive on average between one and three treatments at monthly intervals.
Skin Laxity- Our Titan technology allows our customers to use deep dermal heating to tighten lax skin. The practitioner delivers a spectrum of light to the skin through our Titan hand piece. This hand piece includes our proprietary light source and wavelength filter which tailors the delivered spectrum of light to provide heating at the desired depth in the skin.
In treating skin laxity, the hand piece is placed directly on the skin and then the light pulse is triggered. A sustained pulse causes significant heating in the dermis. This heating can cause immediate collagen contraction while also stimulating long-term collagen re-growth. Several treatments may be required to obtain the desired degree of tightening of the skin. The treatment of a full face can take over an hour and there are typically four weeks between treatments.
Our CE Mark allows us to market the Titan in the European Union, Australia and certain other countries outside the U.S. for the treatment of wrinkles through skin tightening. However, in the U.S. we have a 510(k) clearance for only deep dermal heating.
Non-Invasive Body Contouring- our truSculpt technology allows physicians to apply a hand piece directly to the skin and deliver high-powered RF energy that results in the deep and uniform heating of the subcutaneous fat tissue at sustained therapeutic temperatures. This heating can cause selective destruction of fat cells, which are eliminated from the treatment area through the body’s natural wound healing processes. The treatment takes approximately 45 minutes and two or more treatments may be required to obtain the desired aesthetic results.
Our CE Mark allows us to market the truSculpt in the European Union, and certain other countries outside the U.S. for fat reduction, body shaping and body contouring. In the U.S. we have 510(k) clearance for deep dermal heating for the temporary relief of minor muscle and joint pain and the temporary improvement in the appearance of cellulite.
Sales and Marketing
In the U.S. we market and sell our products primarily through a direct sales organization. Generally, each direct sales employee is assigned a specific territory. As of December 31, 2013, we had a U.S. direct sales force of 29 employees. We internally manage our U.S. and Canadian sales organization as one North American sales region with 34 territories as of December 31, 2013. In addition to direct sales employees, we have a distribution relationship with PSS World Medical that operates medical supply distribution service centers with over 700 sales representatives serving physician offices throughout the U.S. Revenue from PSS was $0.4 million in 2013, $1.1 million in 2012, and $1.6 million in 2011.
International sales are generally made through a worldwide distributor network in over 60 countries, as well as a direct international sales force of 24 employees, as of December 31, 2013. As of December 31, 2013, we had direct sales offices in Australia, Belgium, Canada, France and Japan. Our international revenue as a percentage of total revenue represented 58% in 2013, 59% in 2012 and 61% in 2011.
We also sell certain items like Titan hand piece refills and marketing brochures via the internet.
Although specific customer requirements can vary depending on applications, customers generally demand quality, performance, ease of use, and high productivity in relation to the cost of ownership. We have responded to these customer demands by introducing new products focused on these requirements in the markets we serve. Specifically, we believe that we introduce new products and applications that are innovative, address the specific aesthetic procedures in demand, and are upgradeable on our customers’ existing systems. In addition, we provide attractive upgrade pricing to new product families and are responsive to our customers’ financing preferences. To increase market penetration, in addition to marketing to the core specialties of plastic surgeons and dermatologists, we also market to the non-core aesthetic practices consisting of gynecologists, primary care physicians, family practitioners, physicians offering aesthetic treatments in non-medical offices, podiatrists and other qualified practitioners.
We seek to establish strong ongoing relationships with our customers through the upgradeability of our products, sales of extended service contracts, the refilling of Titan hand pieces, ongoing training and support, and distributing (in Japan only) cosmeceutical and dermal filler products. We primarily target our marketing efforts to practitioners through office visits, workshops, trade shows, webinars and trade journals. We also market to potential patients through brochures, workshops and our website. In addition, we offer clinical forums with recognized expert panelists to promote advanced treatment techniques using our products to further enhance customer loyalty and uncover new sales opportunities.
Competition
Our industry is subject to intense competition. Our products compete against conventional non-energy-based treatments, such as electrolysis, Botox and collagen injections, chemical peels, microdermabrasion and sclerotherapy. Our products also compete against laser and other energy-based products offered by public companies, such as Cynosure, Elen (in Italy), Lumenis, Syneron and Zeltiq, as well as private companies, including, Alma, Sciton, and several others.
Competition among providers of laser and other energy-based devices for the aesthetic market is characterized by extensive research efforts and innovative technology. While we attempt to protect our products through patents and other intellectual property rights, there are few barriers to entry that would prevent new entrants or existing competitors from developing products that would compete directly with ours. There are many companies, both public and private, that are developing innovative devices that use both energy-based and alternative technologies. Some of these competitors have greater resources than we do or product applications for certain sub-markets in which we do not participate. Additional competitors may enter the market, and we are likely to compete with new companies in the future. To compete effectively, we have to demonstrate that our products are attractive alternatives to other devices and treatments by differentiating our products on the basis of performance, brand name, service and price. We have encountered, and expect to continue to encounter, potential customers who, due to existing relationships with our competitors, are committed to, or prefer the products offered by these competitors. Competitive pressures may result in price reductions and reduced margins for our products.
Research and Development
Our research and development group develops new products and applications and builds clinical support to address unmet or underserved market needs. As of December 31, 2013, our research and development activities were conducted by a staff of 32 employees with a broad base of experience in lasers, optoelectronics, software and other fields. We have developed relationships with outside contract engineering and design consultants, giving our team additional technical and creative breadth. We work closely with thought leaders and customers, to understand unmet needs and emerging applications in aesthetic medicine. Research and development expenses were approximately $9.2 million in 2013, $8.4 million in 2012 and $9.1 million in 2011.
Service and Support
Our products are engineered to enable quick and efficient service and support. There are several separate components of our products, each of which can easily be removed and replaced. We believe that quick and effective delivery of service is important to our customers. As of December 31, 2013, we had a 43-person global service department. Internationally, we provide direct service support through our Australia, Canada, France and Japan offices, and also through the network of distributors and third-party service providers in over 60 countries. In February 2012, we acquired Iridex’s aesthetic business, which resulted in an increase in our service and support team and service revenue.
We provide a standard one-year warranty coverage for all of our systems. We provide initial warranties on our products to cover parts and service and offer extended service plans that vary by the type of product and the level of service desired. Our standard warranty on system consoles covers parts and service for a standard period of one year. From time to time, we also have promotions whereby we include a post-warranty service contract with the sale of our products. Customers are notified before their initial warranty expires and are able to choose from two different extended service plans covering preventative maintenance or replacement parts and labor. With effect from the third quarter of 2013, we included the refilling of truSculpt hand pieces in the initial warranty as well as service contracts offered to customers.
In the event a customer does not purchase an extended service plan, we will offer to service the customer’s system and charge the customer for time and materials. With respect to the truSculpt and other hand pieces, if a customer’s system is out of warranty and they have not purchased an extended service contract that covers hand piece replacements, then the customer is charged for their replacement hand piece.
Our Titan hand pieces generally include a warranty for a set number of shots, instead of for a period of time.
We have invested substantial financial and management resources to develop a worldwide infrastructure to meet the service needs of our customers through our direct operations in the U.S., Australia, Belgium (which commenced operations in the fourth quarter of 2013), Canada, France, and Japan. In countries where we are represented by distributor partners, our customers are serviced through the distributor network.
Manufacturing
We manufacture our products with components and subassemblies supplied by vendors. We assemble and test each of our products at our Brisbane, California facility. Quality control, cost reduction and inventory management are top priorities of our manufacturing operations.
We purchase certain components and subassemblies from a limited number of suppliers. We have flexibility with our suppliers to adjust the number of components and subassemblies as well as the delivery schedules. The forecasts we use are based on historical demands and sales projections. Lead times for components and subassemblies may vary significantly depending on the size of the order, time required to fabricate and test the components or subassemblies, specific supplier requirements and current market demand for the components and subassemblies. We reduce the potential for disruption of supply by maintaining sufficient inventories and identifying additional suppliers. The time required to qualify new suppliers for some components, or to redesign them, could cause delays in our manufacturing. To date, we have not experienced significant delays in obtaining any of our components or subassemblies.
We use small quantities of common cleaning products in our manufacturing operations, which are lawfully disposed of through a normal waste management program. We do not forecast any material costs due to compliance with environmental laws or regulations.
We are required to manufacture our products in compliance with the FDA’s Quality System Regulation, or QSR. The QSR covers the methods and documentation of the design, testing, control, manufacturing, labeling, quality assurance, packaging, storage and shipping of our products. The FDA enforces the QSR through periodic unannounced inspections. We had an FDA audit of compliance with laser performance standards in 2010 and a full quality system audit plus laser performance standard audit in August 2011. There were no significant findings as a result of these audits and our responses have been accepted by the FDA. Our failure to maintain compliance with the QSR requirements could result in the shutdown of our manufacturing operations and the recall of our products, which would have a material adverse effect on business. In the event that one of our suppliers fails to maintain compliance with our quality requirements, we may have to qualify a new supplier and could experience manufacturing delays as a result. We have opted to maintain quality assurance and quality management certifications to enable us to market our products in the U.S., the member states of the European Union, the European Free Trade Association and countries which have entered into Mutual Recognition Agreements with the European Union. In January 2014, we passed our surveillance audit establishing compliance with the most current requirements of EN ISO 13485:2012, CAN/CSA ISO 13485:2003, and MDD 93/42/EEC. Our manufacturing facility is ISO 13485 certified.
Patents and Proprietary Technology
We rely on a combination of patent, copyright, trademark and trade secret laws, and non-disclosure, confidentiality and invention assignment agreements to protect our intellectual property rights. As of December 31, 2013, we had 30 issued U.S. patents and 11 pending U.S. patent applications. In the U.S. and several foreign countries, we have registered our Company name and several of our product names as trademarks, including Cutera, Acutip 500, CoolGlide, CoolGlide Excel, Limelight, myQ, Pearl, ProWave 770, ProWave LX, Solera, Titan, Xeo and truSculpt. We may have common law rights in other product names, including ExcelV, Pearl Fractional, Solera Titan and VariLite. We intend to file for additional patents and trademarks to continue to strengthen our intellectual property rights.
We license certain patents from Palomar (acquired by Cynosure in 2013) and pay ongoing royalties based on sales of applicable hair-removal products. The royalty rate on these products ranges from 3.75% to 7.50% of revenue. One patent expired in February 2013 and the remaining patents are set to expire in February 2015. Our revenue from systems that do not include hair-removal capabilities (such as our Solera Titan, Xeo SA, GenesisPlus, VariLite, myQ and ExcelV), and other revenue from service contracts, Titan, Fillers and cosmeceuticals, are not subject to these royalties. In addition, in 2006 we capitalized $1.2 million as an intangible asset representing the ongoing license for these patents, which is being amortized on a straight-line basis over their expected useful life of 9-10 years.
Our employees and technical consultants are required to execute confidentiality agreements in connection with their employment and consulting relationships with us. We also require them to agree to disclose and assign to us all inventions conceived in connection with the relationship. We cannot provide any assurance that employees and consultants will abide by the confidentiality or assignability terms of their agreements. Despite measures taken to protect our intellectual property, unauthorized parties may copy aspects of our products or obtain and use information that we regard as proprietary.
Government Regulation
Our products are medical devices subject to extensive and rigorous regulation by the U.S. Food and Drug Administration, as well as other regulatory bodies. FDA regulations govern the following activities that we perform and will continue to perform to ensure that medical products distributed domestically or exported internationally are safe and effective for their intended uses:
| · | Product design and development; |
| · | Product testing; |
| · | Product manufacturing; |
| · | Product safety; |
| · | Product labeling; |
| · | Product storage; |
| · | Recordkeeping; |
| · | Pre-market clearance or approval; |
| · | Advertising and promotion; |
| · | Production; |
| · | Product sales and distribution; and |
| · | Complaint Handling. |
FDA’s Pre-market Clearance and Approval Requirements
Unless an exemption applies, each medical device we wish to commercially distribute in the U.S. will require either prior 510(k) clearance or pre-market approval from the FDA. The FDA classifies medical devices into one of three classes. Devices deemed to pose lower risks are placed in either class I or II, which requires the manufacturer to submit to the FDA a pre-market notification requesting permission to commercially distribute the device. This process is generally known as 510(k) clearance. Some low risk devices are exempted from this requirement. Devices deemed by the FDA to pose the greatest risk, such as life-sustaining, life-supporting or implantable devices, or devices deemed not substantially equivalent to a previously cleared 510(k) device, are placed in class III, requiring pre-market approval. All of our current products are class II devices.
510(k) Clearance Pathway
When a 510(k) clearance is required, we must submit a pre-market notification demonstrating that our proposed device is substantially equivalent to a previously cleared 510(k) device or a device that was in commercial distribution before May 28, 1976 for which the FDA has not yet called for the submission of Pre-Market Approval, or PMA, applications. By regulation, the FDA is required to clear or deny a 510(k), pre-market notification within 90 days of submission of the application. As a practical matter, clearance often takes significantly longer. The FDA may require further information, including clinical data, to make a determination regarding substantial equivalence. Laser devices used for aesthetic procedures, such as hair removal, have generally qualified for clearance under 510(k) procedures.
The following table details the indications for which we received a 510(k) clearance for our products and when these clearances were received.
|
FDA Marketing Clearances:
|
|
Date Received:
|
|
Laser-based products:
|
|
|
|
- treatment of vascular lesions
|
|
June 1999
|
|
- hair removal
|
|
March 2000
|
|
- permanent hair reduction
|
|
January 2001
|
|
- treatment of benign pigmented lesions and pseudo folliculitis barbae, commonly referred to as razor bumps, and for the reduction of red pigmentation in scars
|
|
June 2002
|
|
- treatment of wrinkles
|
|
October 2002
|
|
- treatment of Onychomycosis for the clearance of nails
|
April 2011
|
|
|
- addition of Alexandrite 755 nm laser wavelength for hair removal, permanent hair reduction and the treatment of vascular and benign pigmented lesions
|
|
December 2013
|
|
|
|
|
|
Pulsed-light technologies:
|
|
|
|
- treatment of pigmented lesions
|
|
March 2003
|
|
- hair removal and vascular treatments
|
|
March 2005
|
|
Infrared Titan technology for deep dermal heating for the temporary relief of minor muscle and joint pain and for the temporary increase in local circulation where applied
|
|
February 2004
|
|
Solera tabletop console:
|
|
|
|
- for use with the Titan hand piece
|
|
October 2004
|
|
- for use with our pulsed-light hand pieces
|
|
January 2005
|
|
Pearl product for the treatment of wrinkles
|
|
March 2007
|
|
Pearl Fractional product for skin resurfacing and coagulation
|
|
August 2008
|
|
|
|
|
|
truSculpt radio frequency (“RF”) product for deep dermal heating for the temporary relief of minor muscle and joint pain and for a temporary improvement in the appearance of cellulite
|
|
|
|
- 16cm2 to 25cm2 hand pieces for smaller body parts
|
|
April 2008
|
|
- 16cm2 to 40cm2 hand pieces for larger body parts
|
|
November 2012
|
Pre-Market Approval (“PMA”) Pathway
A PMA must be submitted to the FDA if the device cannot be cleared through the 510(k) process. A PMA must be supported by extensive data, including but not limited to, technical, preclinical, clinical trials, manufacturing and labeling to demonstrate to the FDA’s satisfaction the safety and effectiveness of the device. No device that we have developed to date has required pre-market approval, although development of future devices or indications may require pre-market approval.
Product Modifications
We have modified aspects of our products since receiving regulatory clearance, but we believe that new 510(k) clearances are not required for these modifications. After a device receives 510(k) clearance or a PMA, any modification that could significantly affect its safety or effectiveness, or that would constitute a major change in its intended use, will require a new clearance or approval. The FDA requires each manufacturer to make this determination initially, but the FDA can review any such decision and can disagree with a manufacturer’s determination. If the FDA disagrees with our determination not to seek a new 510(k) clearance or PMA, the FDA may retroactively require us to seek 510(k) clearance or pre-market approval. The FDA could also require us to cease marketing and distribution and/or recall the modified device until 510(k) clearance or pre-market approval is obtained. Also, in these circumstances, we may be subject to significant regulatory fines or penalties.
Clinical Trials
When FDA approval of a class I, class II or class III device requires human clinical trials, and if the device presents a “significant risk,” as defined by the FDA, to human health, the device sponsor is required to file an Investigational Device Exemption, or IDE, application with the FDA and obtain IDE approval prior to commencing the human clinical trial. If the device is considered a “non-significant” risk, IDE submission to the FDA is not required. Instead, only approval from the Institutional Review Board, or IRB, overseeing the clinical trial is required. Human clinical studies are generally required in connection with approval of class III devices and may be required for class I and II devices. The IDE application must be supported by appropriate data, such as animal and laboratory testing results, showing that it is safe to test the device in humans and that the testing protocol is scientifically sound. The IDE must be approved in advance by the FDA for a specified number of patients. Clinical trials for a significant risk device may begin once the application is reviewed and cleared by the FDA and the appropriate institutional review boards at the clinical trial sites. Future clinical trials of our products may require that we submit and obtain clearance of an IDE from the FDA prior to commencing clinical trials. The FDA, and the IRB at each institution at which a clinical trial is being performed, may suspend a clinical trial at any time for various reasons, including a belief that the subjects are being exposed to an unacceptable health risk.
Pervasive and Continuing Regulation
After a device is placed on the market, numerous regulatory requirements apply. These include:
| · | Quality system regulations, which require manufacturers, including third-party manufacturers, to follow stringent design, testing, control, documentation and other quality assurance procedures during all aspects of the manufacturing process; |
| · | Labeling regulations and FDA prohibitions against the promotion of products for un-cleared, unapproved or “off-label” uses; |
| · | Medical device reporting regulations, which require that manufacturers report to the FDA if their device may have caused or contributed to a death or serious injury or malfunctioned in a way that would likely cause or contribute to a death or serious injury if the malfunction were to recur; and |
| · | Post-market surveillance regulations, which apply when necessary to protect the public health or to provide additional safety and effectiveness data for the device. |
The FDA has broad post-market and regulatory enforcement powers. We are subject to unannounced inspections by the FDA and the Food and Drug Branch of the California Department of Health Services, or CDHS, to determine our compliance with the QSR and other regulations, and these inspections may include the manufacturing facilities of our subcontractors. In the past, our prior facility has been inspected, and observations were noted. There were no findings that involved a material violation of regulatory requirements. Our responses to these observations have been accepted by the FDA and CDHS, and we believe that we are in substantial compliance with the QSR. Our current manufacturing facility has been inspected by the FDA and the CDHS. The FDA and the CDHS noted observations, but there were no findings that involved a material violation of regulatory requirements. Our responses to those observations have been accepted by the FDA and CDHS.
We are also regulated under the Radiation Control for Health and Safety Act, which requires laser products to comply with performance standards, including design and operation requirements, and manufacturers to certify in product labeling and in reports to the FDA that their products comply with all such standards. The law also requires laser manufacturers to file new product and annual reports, maintain manufacturing, testing and sales records, and report product defects. Various warning labels must be affixed and certain protective devices installed, depending on the class of the product.
Failure to comply with applicable regulatory requirements can result in enforcement action by the FDA, which may include any of the following sanctions:
| · | Warning letters, fines, injunctions, consent decrees and civil penalties; |
| · | Repair, replacement, recall or seizure of our products; |
| · | Operating restrictions or partial suspension or total shutdown of production; |
| · | Refusing our requests for 510(k) clearance or pre-market approval of new products, new intended uses, or modifications to existing products; |
| · | Withdrawing 510(k) clearance or pre-market approvals that have already been granted; and |
| · | Criminal prosecution. |
The FDA also has the authority to require us to repair, replace or refund the cost of any medical device that we have manufactured or distributed. If any of these events were to occur, they could have a material adverse effect on our business.
We are also subject to a wide range of federal, state and local laws and regulations, including those related to the environment, health and safety, land use and quality assurance. We believe that compliance with these laws and regulations as currently in effect will not have a material adverse effect on our capital expenditures, earnings and competitive and financial position.
International
International sales of medical devices are subject to foreign governmental regulations, which vary substantially from country to country. The time required to obtain clearance or approval by a foreign country may be longer or shorter than that required for FDA clearance or approval, and the requirements may be different.
The primary regulatory environment in Europe is that of the European Union, which consists of a 27 countries encompassing most of the major countries in Europe. The member states of the European Free Trade Association have voluntarily adopted laws and regulations that mirror those of the European Union with respect to medical devices. Other countries, such as Switzerland, have entered into Mutual Recognition Agreements and allow the marketing of medical devices that meet European Union requirements. The European Union has adopted numerous directives and European Standardization Committees have promulgated voluntary standards regulating the design, manufacture, clinical trials, labeling and adverse event reporting for medical devices. Devices that comply with the requirements of a relevant directive will be entitled to bear CE conformity marking, indicating that the device conforms with the essential requirements of the applicable directives and, accordingly, can be commercially distributed throughout the member states of the European Union, the member states of the European Free Trade Association and countries which have entered into a Mutual Recognition Agreement. The method of assessing conformity varies depending on the type and class of the product, but normally involves a combination of self-assessment by the manufacturer and a third-party assessment by a Notified Body, an independent and neutral institution appointed by a country to conduct the conformity assessment. This third-party assessment may consist of an audit of the manufacturer’s quality system and specific testing of the manufacturer’s device. An assessment by a Notified Body in one member state of the European Union, the European Free Trade Association or one country which has entered into a Mutual Recognition Agreement is required in order for a manufacturer to commercially distribute the product throughout these countries. ISO 9001 and ISO 13845 certification are voluntary harmonized standards. Compliance establishes the presumption of conformity with the essential requirements for a CE Marking. In February 2000, our facility was awarded the ISO 9001 and EN 46001 certification. In March 2003, we received our ISO 9001 updated certification (ISO 9001:2000) as well as our certification for ISO 13485:1996 which replaced our EN 46001 certification. In March 2004, we received our ISO 13485:2003 certification and in March 2006, March 2010, February 2011 and January 2012 we passed our ISO 13485 recertification audits. In January 2014, we passed our surveillance audit establishing compliance with the most current requirements of EN ISO 13485:2012, CAN/CSA ISO 13485:2003, and MDD 93/42/EEC.
Employees
As of December 31, 2013, we had 238 employees, compared to 227 employees as of December 31, 2012. Of the 238 employees at December 31, 2013, 89 were in sales and marketing, 52 in manufacturing operations, 43 in technical service, 32 in research and development and 22 in general and administrative. We believe that our future success will depend in part on our continued ability to attract, hire and retain qualified personnel. None of our employees are represented by a labor union, and we believe our employee relations are good.
Available Information
We are subject to the reporting requirements under the Securities Exchange Act of 1934. Consequently, we are required to file reports and information with the Securities and Exchange Commission, or SEC, including reports on the following forms: annual report on Form 10-K, quarterly reports on Form 10-Q, current reports on Form 8-K, and amendments to those reports filed or furnished pursuant to Section 13(a) or 15(d) of the Securities Exchange Act of 1934. These reports and other information concerning the company may be accessed through the SEC’s website at www.sec.gov. Such filings, as well as our charters for our Audit and Compensation Committees and our Code of Ethics are available on our website at www.cutera.com. In the event that we grant a waiver under our Code of Ethics to any of our officers and directors, we will publish it on our website.
We operate in a rapidly changing economic and technological environment that presents numerous risks, many of which are driven by factors that we cannot control or predict. The following discussion, as well as our discussion in Management’s Discussion and Analysis of Financial Condition and Results of Operations (Item 7), highlights some of these risks. The risks described below are not exhaustive and you should carefully consider these risks and uncertainties before investing in our securities.
In 2013, our U.S. revenue decreased by approximately 1% compared to 2012. Unless our U.S. revenue improves, we could experience a material adverse effect on our total revenue, profitability, employee retention and stock price.
Our U.S. revenue decreased by 1% in 2013, compared to 2012. Our U.S. revenue has declined due to several factors, including:
| · | We experienced significant sales force turnover, which was a distraction and negatively impacted our revenue and employee productivity in 2013. Due in part to the softness experienced in the Podiatry market into which we sell our GenesisPlus product, we consolidated the Podiatry focused sales force into our mainstream aesthetic field sales group. This resulted in an even higher field sales employee turnover in 2013, as some of our Podiatry specialists left our company. |
| · | Historically, following a new product introduction, we experience revenue growth, compared to the same period in the prior year. However, even though we have experienced increased revenue from our ExcelV and truSculpt products, this revenue increase has not offset declines in some of our legacy product and upgrade business, as well as the lower ASPs. |
| · | Lower product and upgrade average selling prices (“ASPs”) as a result of customers purchasing fewer applications for systems and lower pricing resulting from competitive discounting. |
There can be no assurance that we will continue to introduce new products each year, or that the new product introductions will translate into increased revenue in the long term in the U.S, or that the new direct sales employees and management hired to replace the recently departed sales employees will be effective and result in improved sales productivity. Further, if the current economic recovery does not continue, or there is another recession in the U.S., our future revenue would be adversely impacted.
If our U.S. revenue does not improve, we could experience a material adverse effect on our total revenue, profitability, employee retention and stock price.
In the past five years we have only had two profitable quarters and we are unable to predict whether we will return to sustained quarterly profits in the future.
Although we had a profitable fourth quarter in 2009 and 2012, we have had net quarterly losses in each quarter since the third quarter of 2008. There is no guarantee that we will be profitable in the future and you should not rely on our operating results for any prior quarterly or annual periods as an indication of our future operating performance. Any predictions about the performance of our operations in the future may not be as accurate as they could be if we had a longer history of profitability.
Revenue growth in our business is driven by several factors and one such factor is new product introductions. While sales of our ExcelV platform increased in 2013, compared with the prior year, sales of our truSculpt product introduced in 2012 have not gained a share of that market segment to the degree we had expected. We are making several product improvements to the truSculpt product, adding new applicators to this platform and plan to seek additional regulatory approvals for new indications to address the slower than expected penetration in the body contouring market. If our revenue does not grow in 2014, compared to 2013, we may not be able to become profitable in future quarters.
Our ability to sustain profitability depends on the extent to which we can increase revenue and control our costs in order to, among other things, counter any unforeseen difficulties, complications, product delays or other unknown factors that may require additional expenditures. Because of the numerous risks and uncertainties associated with our growth prospects, product development, sales and marketing and other efforts, we are unable to predict the extent of our future profitability or losses. If our revenue does not achieve adequate growth in the future, we may continue to incur a quarterly net loss and could consume cash in our operations in the future.
We rely heavily on our sales professionals to market and sell our products worldwide. If we are unable to hire, effectively train, manage, improve the productivity of, and retain the sales professionals, our business will be harmed, which would impair our future revenue and profitability.
Our success largely depends on our ability to hire, train, manage and improve the productivity levels of our sales professionals worldwide. Because of our focus on the non-core market in the past, several of our sales professionals do not have established relationships with core market physicians (dermatologists and plastic surgeons) or where those relationships exist, they are not very strong. We have experienced high sales employee turnover, partly due to the consolidation of our specialty podiatry sales force into the mainstream aesthetic sales group. Further, some of our sales management has either been recently hired or recently transferred into different roles. These factors have heavily impacted the revenue we derived from our products and upgrades in fiscal 2013.
In 2013 we once again restructured our direct sales force and sales management and we are in the process of increasing the number of direct sales employees in North America in response to our revenue results and changes in our sales organization. However, at present we have a number of vacant sales territories in North America and are in the process of hiring sales professionals for them. The sales employee turnover in 2013 negatively impacted our revenue and productivity. We have increased our efforts to hire high quality experienced sales professionals but there can be no guarantee that we will be able to locate and employ such qualified individuals. Our industry is characterized by a few established companies that compete vigorously for talented sales professionals. Further, as the economy in North America has rebounded from the recent recession years, some of those sales professionals have left our Company for jobs that they perceive to be better opportunities both within and outside of the aesthetic industry.
We train our existing and recently recruited sales professionals to better understand our existing and new product technologies and how they can be positioned against our competitors’ products. These initiatives are intended to improve the productivity of our sales professionals, our revenue and profitability. It takes time for the sales professionals to become productive following their training and there can be no assurance that the recently recruited sales professionals will be adequately trained in a timely manner, or our direct sales productivity will improve, or that we will not experience significant levels of attrition in the future. If we are not able to improve the productivity and retention of our North American and international sales professionals, then our total revenue, profitability and stock price may be adversely impacted.
Measures we implement in an effort to retain, train and manage our sales professionals, strengthen their relationships with core market physicians, and improve their productivity may not be successful and may instead contribute to instability in our operations, additional departures from our sales organization, or further reduce our revenue and harm our business.
If our revenue does not improve, or if our cost of revenue and/ or operating expenses increase by a greater percentage than our revenue, our gross margins and operating margins may be adversely impacted, our loss from operations will increase, and our cash used in operating activities will increase, which could reduce our assets and have a material adverse effect on our stock price.
Our gross margin (revenue less cost) improved to 56% in 2013, compared to 54% in 2012. Our gross margin is impacted by the revenue that we generate and the costs incurred to generate the revenue. To the extent that our revenue declines, it is difficult to improve our gross margins as our fixed costs must be spread over a lower revenue base. Our future revenue may be adversely affected by a number of factors including, the competitive market environment in which we operate, which may result in a decrease in the number of units sold, a decrease in the number of applications per system purchased by customers, a decrease in the average selling prices achieved for our product sales, a shift in our product mix towards products with lower average selling prices, or a shift in our product mix towards products with lower margin.
Our cost of revenue may also be adversely impacted by various factors such as obsolescence of our inventory, increased expenses associated with repairing defective products covered by our warranty program, utilization of our relatively fixed manufacturing costs, and a shift in our product mix towards products that have a higher cost of manufacturing.
We have also been investing significant resources in our research and development and sales and marketing activities. We are in the process of expanding our global direct sales force, and it may take time before our new sales professionals become productive and for the revenue that they generate to become accretive to our operating income. We plan to continue making such investments in order to bring new products to market and to distribute them effectively. If these investments do not yield in increased revenue, we may continue to generate losses and consume cash.
If our revenue does not to improve, or if our cost of revenue increases by a greater percentage than our revenue, or if we are not able to reduce expenses in the event of a decline in revenue, we may continue to generate losses from operations and use cash, which could reduce our assets and have a material adverse effect on our operations and stock price.
The aesthetic equipment market is characterized by rapid innovation. To compete effectively, we must develop and/or acquire new products, market them successfully, and identify new markets for our technology.
We have created products to apply our technology to body contouring, hair removal, treatment of veins and skin rejuvenation, including the treating of diffuse redness, skin laxity, fine lines, wrinkles, skin texture, pore size and pigmented lesions, etc. In 2012, we launched truSculpt for the body contouring market and acquired VariLite for vascular and pigmented lesions. In 2011, we launched our vascular laser product – ExcelV – and began distribution of a Q-switched laser in Japan that Cutera is sourcing from a third party OEM for superficial and deep pigmented lesions (i.e., melasma), skin rejuvenation, laser skin toning and tattoo removal. Currently, these applications represent the majority of offered laser and other energy-based aesthetic procedures. In addition, since the first quarter of 2010, we have been distributing cosmeceuticals and dermal fillers in the Japanese market. To grow in the future, we must continue to develop and/or acquire new and innovative aesthetic products and applications, identify new markets, and successfully launch the newly acquired or developed product offerings.
To successfully expand our product offerings, we must, among other things:
|
·
|
Develop and acquire new products that either add to or significantly improve our current product offerings;
|
|
·
|
Convince our existing and prospective customers that our product offerings would be an attractive revenue-generating addition to their practice; |
|
·
|
Sell our product offerings to a broad customer base;
|
|
·
|
Identify new markets and alternative applications for our technology; |
|
·
|
Protect our existing and future products with defensible intellectual property; and |
|
·
|
Satisfy and maintain all regulatory requirements for commercialization. |
Historically, product introductions have been a significant component of our financial performance. To be successful in the aesthetics industry, we need to continue to innovate. Our business strategy has therefore been based, in part, on our expectation that we will continue to increase our product offerings. We need to continue to devote substantial research and development resources to make new product introductions, which can be costly and time consuming to our organization.
We also believe that, to increase revenue from sales of new products, we need to continue to develop our clinical support, further expand and nurture relationships with industry thought leaders and increase market awareness of the benefits of our new products. However, even with a significant investment in research and development, we may be unable to continue to develop, acquire or effectively launch and market new products and technologies regularly, or at all. If we fail to successfully commercialize new products, our business may be harmed.
While we attempt to protect our products through patents and other intellectual property, there are few barriers to entry that would prevent new entrants or existing competitors from developing products that compete directly with ours. We expect that any competitive advantage we may enjoy from current and future innovations may diminish over time as companies successfully respond to our, or create their own, innovations. Consequently, we believe that we will have to continuously innovate and improve our products and technology to compete successfully. If we are unable to innovate successfully, our products could become obsolete and our revenue could decline as our customers and prospects purchase our competitors’ products.
Demand for our products in any of our markets could be weakened by several factors, including:
|
·
|
Our ability to develop and market our products to the core market specialties of dermatologists and plastic surgeons; |
|
·
|
Poor financial performance of market segments that try introducing aesthetic procedures to their businesses; |
|
·
|
The inability to differentiate our products from those of our competitors; |
|
·
|
Reduced patient demand for elective aesthetic procedures; |
|
·
|
Failure to build and maintain relationships with opinion leaders within the various market segments; |
|
·
|
An increase in malpractice lawsuits that result in higher insurance costs; and |
|
·
|
The lack of credit financing for some of our potential customers. |
If we do not achieve anticipated demand for our products, it could have a material adverse effect on our total revenue, profitability, employee retention and stock price.
Macroeconomic political and market conditions, and catastrophic events may adversely affect our business, results of operations, financial condition and stock price.
Our business is influenced by a range of factors that are beyond our control, including:
|
·
|
General economic and business conditions; |
|
·
|
The overall demand for our products by the core market specialties of dermatologists and plastic surgeons; |
|
·
|
Governmental budgetary constraints or shifts in government spending priorities; |
|
·
|
General political developments; |
|
·
|
Natural disasters, such as the March 2011 earthquake and tsunami in Japan; and |
|
·
|
Currency exchange rate fluctuations. |
Macroeconomic developments like the global recession and the debt crisis in the U.S. and certain countries in the European Union, could negatively affect our business, operating results or financial condition which, in turn, could adversely affect our stock price. A general weakening of, and related declining corporate confidence in, the global economy or the curtailment in government or corporate spending could cause current or potential customers to reduce their budgets or be unable to fund product or upgrade application purchases, which could cause customers to delay, decrease or cancel purchases of our products and services or cause customers not to pay us or to delay paying us for previously purchased products and services.
In addition, political unrest in regions like the Middle East, terrorist attacks around the globe and the potential for other hostilities in various parts of the world, potential public health crises and natural disasters continue to contribute to a climate of economic and political uncertainty that could adversely affect our results of operations and financial condition, including our revenue growth and profitability. For example, the March 2011 earthquake and tsunami and other collateral events in Japan adversely affected the demand for our products and services in the Japanese market.
Macroeconomic declines, negative political developments, adverse market conditions and catastrophic events may cause a decline in our revenue, negatively affect our operating results, adversely affect our cash flow and could result in a decline in our stock price.
To successfully market and sell our products internationally, we must address many issues that are unique to our international business.
International revenue represented 58% of our total revenue in 2013 compared to 59% in 2012. International revenue is a material component of our business strategy. We depend on third-party distributors and a direct sales force to sell our products internationally, and if they underperform, we may be unable to increase or maintain our level of international revenue.
We have experienced significant turnover of our European sales team in the past. While we continue to have a direct sales and service organization in France and Belgium (which commenced operations in 2013), a significant portion of our European revenue is generated through our network of distributors. Though we continue to evaluate and replace non-performing distributors and are restructuring parts of our European business towards the utilization of more distributors, there can be no assurance given that these initiatives will result in improved European-sourced revenue or profitability in the future
To grow our business, we will need to improve productivity in current sales territories and expand into new territories. However, direct sales productivity may not improve and distributors may not accept our business or commit the necessary resources to market and sell our products to the level of our expectations. If we are not able to increase or maintain international revenue growth, our total revenue, profitability and stock price may be adversely impacted.
We believe, as we continue to manage our international operations and develop opportunities in additional international territories, our international revenue will be subject to a number of risks, including:
|
·
|
Difficulties in staffing and managing our foreign operations; |
|
·
|
Export restrictions, trade regulations and foreign tax laws; |
|
·
|
Fluctuating foreign currency exchange rates; |
|
·
|
Foreign certification and regulatory requirements; |
|
·
|
Lengthy payment cycles and difficulty in collecting accounts receivable; |
|
·
|
Customs clearance and shipping delays; |
|
·
|
Political and economic instability; |
|
·
|
Lack of awareness of our brand in international markets; |
|
·
|
Preference for locally-produced products; and |
|
·
|
Reduced protection for intellectual property rights in some countries. |
If one or more of these risks were realized, it could require us to dedicate significant resources to remedy the situation; and if we were unsuccessful at finding a solution, we may not be able to sell our products in a particular market and, as a result, our revenue may decline.
We are subject to fluctuations in the exchange rate of the U.S. dollar and foreign currencies.
Foreign currency fluctuations could result in volatility of our revenue. We do not actively hedge our exposure to currency rate fluctuations. While we transact business primarily in U.S. Dollars, and a significant proportion of our revenue is denominated in U.S. Dollars, a portion of our costs and revenue is denominated in other currencies, such as the Euro, Japanese Yen, Australian Dollar and Canadian Dollar. As a result, changes in the exchange rates of these currencies to the U.S. Dollar will affect our results from operations. For example, as a result of the recent strengthening of the U.S. Dollar, relative to many other major currencies, our products priced in U.S. dollars have become more expensive relative to products of our foreign competitors. In addition, our revenue earned in foreign currencies, such as our locally generated revenue in Japan, has been negatively impacted upon translation into U.S. dollars. Both these factors had a negative impact on our international revenue in 2013, compared to 2012.
Future foreign currency fluctuations could adversely impact and increase the volatility of our revenue, profitability and stock price.
Our ability to effectively compete and generate additional revenue from new and existing products depend upon our ability to distinguish our company and our products from our competitors and their products, and to develop and effectively market new and existing products. Our success is dependent on many factors, including the following:
|
·
|
Speed of new and innovative product development;
|
|
·
|
Effective strategy and execution of new product launches;
|
|
·
|
Identify and develop clinical support for new indications of our existing products;
|
|
·
|
Product performance;
|
|
·
|
Product pricing;
|
|
·
|
Quality of customer support;
|
|
·
|
Development of successful distribution channels, both domestically and internationally; and
|
|
·
|
Intellectual property protection.
|
To compete effectively, we have to demonstrate that our new and existing products are attractive alternatives to other devices and treatments, by differentiating our products on the basis of such factors as innovation, performance, brand name, service, and price. This is difficult to do, especially in a crowded aesthetic market. Some of our competitors have newer or different products and more established customer relationships than we do, which could inhibit our market penetration efforts. For example, we have encountered, and expect to continue to encounter, situations where, due to pre-existing relationships, potential customers decided to purchase additional products from our competitors. Potential customers also may need to recoup the cost of products that they have already purchased from our competitors and may decide not to purchase our products, or to delay such purchases.
If we are unable to increase our market penetration or compete effectively, our revenue and profitability will be adversely impacted.
We compete against companies that offer alternative solutions to our products, or have greater resources, a larger installed base of customers and broader product offerings than ours. If we are not able to effectively compete with these companies, it may harm our business.
Our industry is subject to intense competition. Our products compete against similar products offered by public companies, such as Cynosure, Elen (in Italy), Lumenis, Solta (acquired by Valeant Pharmaceuticals International, Inc. in January 2014), Syneron, as well as private companies such as Alma, Sciton and several other companies. Recently, there has been consolidation in the aesthetic industry leading to companies combining their resources. For example, Valeant acquired Solta in January 2014, Cynosure acquired Palomar in June 2013 and the aesthetic laser business of HOYA ConBio in June 2011; Syneron acquired Ultrashape in March 2012 and Candela in September 2009; we acquired the aesthetic business unit of Iridex in February 2012; and Solta (previously Thermage) acquired Aesthera in February 2010 and Reliant in December 2008. We are likely to compete with new companies in the future. Competition with these companies could result in reduced selling prices, reduced profit margins and loss of market share, any of which would harm our business, financial condition and results of operations.
The energy-based aesthetic market faces competition from non-energy-based medical products, such as Botox, an injectable compound used to reduce wrinkles, and collagen injections. Other alternatives to the use of our products include electrolysis, a procedure involving the application of electric current to eliminate hair follicles, and chemical peels. We may also face competition from manufacturers of pharmaceutical and other products that have not yet been developed.
If there is not sufficient consumer demand for the procedures performed with our products, practitioner demand for our products could be inhibited, resulting in unfavorable operating results and reduced growth potential.
Continued expansion of the global market for laser and other-energy-based aesthetic procedures is a material assumption of our business strategy. Most procedures performed using our products are elective procedures not reimbursable through government or private health insurance, with the costs borne by the patient. The decision to utilize our products may therefore be influenced by a number of factors, including:
|
·
|
Consumer disposable income and access to consumer credit, which as a result of the unstable economy, may have been significantly impacted; |
|
·
|
The cost of procedures performed using our products;
|
|
·
|
The cost, safety and effectiveness of alternative treatments, including treatments which are not based upon laser or other energy-based technologies and treatments which use pharmaceutical products; |
|
·
|
The success of our sales and marketing efforts; and
|
|
·
|
The education of our customers and patients on the benefits and uses of our products, compared to competitors’ products and technologies. |
If, as a result of these factors, there is not sufficient demand for the procedures performed with our products, practitioner demand for our products could be reduced, which could have a material adverse effect on our business, financial condition, revenue and result of operations.
The U.S. Food and Drug Administration (the “FDA”), federal and state agencies and international regulatory bodies have broad enforcement powers. If we fail to comply with applicable regulatory requirements, it could result in enforcement action by the FDA, federal and state agencies or international regulatory bodies.
The FDA, state authorities and international regulatory bodies have broad enforcement powers. For example, in July 2012, we received a warning letter from the FDA concerning the promotional labeling for our GenesisPlus laser. The FDA determined that some of the claims, such as the one related to Skin Rejuvenation, constituted new Indications for Use and required additional 510(k) clearances. The FDA subsequently requested that we review the promotional labeling for all of our products to ensure our claims were within regulatory clearances and that we submit updated promotional labeling for our products to the FDA for their review. We are in the process of complying with the FDA’s request.
If we fail to comply with any U.S. law or any of the applicable regulatory requirements of the FDA, or federal or state agencies, or one of the international regulatory bodies, it could result in enforcement action by the agencies, which may include any of the following sanctions:
|
·
|
Warning letters, fines, injunctions, consent decrees and civil penalties;
|
|
·
|
Repair, replacement, refund, recall or seizure of our products;
|
|
·
|
Operating restrictions or partial suspension or total shutdown of production;
|
|
·
|
Refusing our requests for 510(k) clearance or pre-market approval of new products, new intended uses, or modifications to existing products; |
|
·
|
Withdrawing 510(k) clearance or pre-market approvals that have already been granted; and
|
|
·
|
Criminal prosecution.
|
If we fail to obtain or maintain necessary FDA clearances for our products and indications, if clearances for future products and indications are delayed or not issued, if there are federal or state level regulatory changes or if we are found to have violated applicable FDA marketing rules, our commercial operations would be harmed.
Our products are medical devices that are subject to extensive regulation in the U.S. by the FDA for manufacturing, labeling, sale, promotion, distribution and shipping. Before a new medical device, or a new use of or labeling claim for an existing product, can be marketed in the U.S., it must first receive either 510(k) clearance or pre-marketing approval from the FDA, unless an exemption applies. Either process can be expensive and lengthy. In the event that we do not obtain FDA clearances or approvals for our products, our ability to market and sell them in the U.S. and revenue derived from there may be adversely affected.
Medical devices may be marketed in the U.S. only for the indications for which they are approved or cleared by the FDA. For example, up until April 2011 our recently introduced GenesisPlus product had a number of general indications for use in the U.S. that allowed us to market the product in the U.S.; however we could only market it internationally for the treatment of toenail fungus as it has a CE Mark approval. In April 2011, we received FDA clearance to market GenesisPlus in the U.S. for the clearance of nails that are infected with toenail fungus. Another example is our Pearl Fractional product which is cleared only for skin resurfacing in the U.S. and our Titan product only for deep heating for the temporary relief of muscle aches and pains in the U.S. Therefore, we are prevented from promoting or advertising Titan and Pearl Fractional in the U.S. for any other indications. If we fail to comply with these regulations, it could result in enforcement action by the FDA which could lead to such consequences as warning letters, adverse publicity, criminal enforcement action and/or third-party civil litigation, each of which could adversely affect us.
We have obtained 510(k) clearance for the indications for which we market our products. However, our clearances can be revoked if safety or effectiveness problems develop. We also are subject to Medical Device Reporting regulations, which require us to report to the FDA if our products cause or contribute to a death or serious injury, or malfunction in a way that would likely cause or contribute to a death or serious injury. Our products are also subject to state regulations, which are, in many instances frequently changing. Changes in state regulations may impede sales. For example, federal regulations allow our products to be sold to, or on the order of, “licensed practitioners,” as determined on a state-by-state basis. As a result, in some states, non-physicians may legally purchase our products. However, a state could change its regulations at any time, thereby disallowing sales to particular types of end users. We cannot predict the impact or effect of future legislation or regulations at the federal or state levels.
Federal regulatory reforms and changes occurring at the FDA could adversely affect our ability to sell our products profitably and financial condition.
From time to time, legislation is drafted and introduced in Congress that could significantly change the statutory provisions governing the clearance or approval, manufacture and marketing of a device. It is impossible to predict whether legislative changes will be enacted or FDA regulations, guidance or interpretations changed, and what the impact of such changes, if any, may be.
In addition, FDA regulations and guidance are often revised or reinterpreted by the agency in ways that may significantly affect our business and our products. Changes in FDA regulations may lengthen the regulatory approval process for medical devices and require additional clinical data to support regulatory clearance for the sale and marketing of our new products. In addition, it may require additional safety monitoring, labeling changes, restrictions on product distribution or use, or other measures after the introduction of our products to market. Either of these changes lengthen the duration to market, increase our costs of doing business, adversely affect the future permitted uses of approved products, or otherwise adversely affect the market for our products.
If we fail to comply with the FDA’s Quality System Regulation and laser performance standards, our manufacturing operations could be halted, and our business would suffer.
We are currently required to demonstrate and maintain compliance with the FDA’s Quality System Regulation (the “QSR”). The QSR is a complex regulatory scheme that covers the methods and documentation of the design, testing, control, manufacturing, labeling, quality assurance, packaging, storage and shipping of our products. Because our products involve the use of lasers, our products also are covered by a performance standard for lasers set forth in FDA regulations. The laser performance standard imposes specific record-keeping, reporting, product testing and product labeling requirements. These requirements include affixing warning labels to laser products, as well as incorporating certain safety features in the design of laser products. The FDA enforces the QSR and laser performance standards through periodic unannounced inspections. We had a full quality system audit in 2008 and an FDA audit of compliance with laser performance standards in 2010 and a full quality system audit plus laser performance standard audit in August 2011 and a full quality system audit in October 2012. There were no significant findings as a result of these audits and our responses have been accepted by the FDA. Our failure to take satisfactory corrective action in response to an adverse QSR inspection or our failure to comply with applicable laser performance standards could result in enforcement actions, including a public warning letter, a shutdown of our manufacturing operations, a recall of our products, civil or criminal penalties, or other sanctions, such as those described in the preceding paragraph, which would cause our sales and business to suffer.
If we modify one of our FDA-approved devices, we may need to seek re-approval, which, if not granted, would prevent us from selling our modified products or cause us to redesign our products.
Any modifications to an FDA-cleared device that would significantly affect its safety or effectiveness or that would constitute a major change in its intended use would require a new 510(k) clearance or possibly a pre-market approval. For example, we designed a larger 40cm2 hand piece for our truSculpt product and had to get that approved by the FDA before we could market it, which approval was received in January 2012. We may not be able to obtain additional 510(k) clearance or pre-market approvals for new products or for modifications to, or additional indications for, our existing products in a timely fashion, or at all. Delays in obtaining future clearance would adversely affect our ability to introduce new or enhanced products in a timely manner, which in turn would harm our revenue and future profitability.
We have made modifications to our devices in the past and may make additional modifications in the future that we believe do not or will not require additional clearance or approvals. If the FDA disagrees, and requires new clearances or approvals for the modifications, we may be required to recall and to stop marketing the modified devices, which could harm our operating results and require us to redesign our products.
We may be unable to obtain or maintain international regulatory qualifications or approvals for our current or future products and indications, which could harm our business.
Sales of our products outside the U.S. are subject to foreign regulatory requirements that vary widely from country to country. In addition, exports of medical devices from the U.S. are regulated by the FDA. Complying with international regulatory requirements can be an expensive and time-consuming process and approval is not certain. The time required for obtaining clearance or approvals, if required by other countries, may be longer than that required for FDA clearance or approvals, and requirements for such clearances or approvals may significantly differ from FDA requirements. We may be unable to obtain or maintain regulatory qualifications, clearances or approvals in other countries. We may also incur significant costs in attempting to obtain and in maintaining foreign regulatory approvals or qualifications. If we experience delays in receiving necessary qualifications, clearances or approvals to market our products outside the U.S., or if we fail to receive those qualifications, clearances or approvals, we may be unable to market our products or enhancements in international markets effectively, or at all, which could have a material adverse effect on our business and growth strategy.
Any defects in the design, material or workmanship of our products may not be discovered prior to shipment to customers, which could materially increase our expenses, adversely impact profitability and harm our business.
The design of our products is complex. To manufacture them successfully, we must procure quality components and employ individuals with a significant degree of technical expertise. If our designs are defective, or the material components used in our products are subject to wearing out, or if suppliers fail to deliver components to specification, or if our employees fail to properly assemble, test and package our products, the reliability and performance of our products will be adversely impacted. As an example, in 2010, we incurred significant expenses for the voluntary recall of our Titan XL hand pieces.
If our products contain defects that cannot be repaired easily, inexpensively, or on a timely basis, we may experience:
| · | Damage to our brand reputation; |
| · | Loss of customer orders and delay in order fulfillment; |
| · | Increased costs due to product repair or replacement; |
| · | Inability to attract new customers; |
| · | Diversion of resources from our manufacturing and research and development departments into our service department; and |
| · | Legal action. |
The occurrence of any one or more of the foregoing could materially increase expenses, adversely impact profitability and harm our business.
We depend on skilled and experienced personnel to operate our business effectively. If we are unable to recruit, hire, train and retain these employees, our ability to manage and expand our business will be harmed, which would impair our future revenue and profitability.
Our success largely depends on the skills, experience and efforts of our officers and other key employees. Except for Change of Control and Severance Agreements for our executive officers and one key employee, we do not have employment contracts with any of our officers or other key employees. Any of our officers and other key employees may terminate their employment at any time. We do not have a succession plan in place for each of our officers and key employees. In addition, we do not maintain “key person” life insurance policies covering any of our employees. The loss of any of our senior management team members could weaken our management expertise and harm our business.
Our ability to retain our skilled labor force and our success in attracting and hiring new skilled employees are critical factors in determining whether we will be successful in the future. We may not be able to meet our future hiring needs or retain existing personnel. The staff we hire to perform administrative functions may be become stretched due to our increased growth and they may not be able to perform their jobs effectively or efficiently as a result.
We may face particularly significant challenges and risks in hiring, training, managing and retaining engineering and sales and marketing employees. Failure to attract, train and retain personnel, particularly technical and sales and marketing personnel, would materially harm our ability to compete effectively and grow our business.
Product liability suits could be brought against us due to a defective design, material or workmanship or misuse of our products and could result in expensive and time-consuming litigation, payment of substantial damages and an increase in our insurance rates.
If our products are defectively designed, manufactured or labeled, contain defective components or are misused, we may become subject to substantial and costly litigation by our customers or their patients. Misusing our products or failing to adhere to operating guidelines could cause significant eye and skin damage, and underlying tissue damage. In addition, if our operating guidelines are found to be inadequate, we may be subject to liability. We have been involved, and may in the future be involved, in litigation related to the use of our products. Product liability claims could divert management’s attention from our core business, be expensive to defend and result in sizable damage awards against us. We may not have sufficient insurance coverage for all future claims. We may not be able to obtain insurance in amounts or scope sufficient to provide us with adequate coverage against all potential liabilities. Any product liability claims brought against us, with or without merit, could increase our product liability insurance rates or prevent us from securing continuing coverage, could harm our reputation in the industry and could reduce product sales. In addition, we historically experienced steep increases in our product liability insurance premiums as a percentage of revenue. If our premiums continue to rise, we may no longer be able to afford adequate insurance coverage.
If customers are not trained and / or our products are used by non-physicians, it could result in product misuse and adverse treatment outcomes, which could harm our reputation, result in product liability litigation, distract management, result in additional costs, all of which could harm our business.
Because we do not require training for users of our products, and sell our products at times to non-physicians, there exists an increased potential for misuse of our products, which could harm our reputation and our business. U.S. federal regulations allow us to sell our products to or on the order of “licensed practitioners.” The definition of “licensed practitioners” varies from state to state. As a result, our products may be purchased or operated by physicians with varying levels of training, and in many states, by non-physicians, including nurse practitioners, chiropractors and technicians. Outside the U.S., many jurisdictions do not require specific qualifications or training for purchasers or operators of our products. We do not supervise the procedures performed with our products, nor do we require that direct medical supervision occur. We and our distributors generally offer but do not require product training to the purchasers or operators of our products. In addition, we sometimes sell our systems to companies that rent our systems to third parties and that provide a technician to perform the procedures. The lack of training and the purchase and use of our products by non-physicians may result in product misuse and adverse treatment outcomes, which could harm our reputation and our business, and, in the event these result in product liability litigation, distract management and subject us to liability, including legal expenses.
In the past we entered into strategic alliances to distribute third party products internationally. To successfully market and sell these products, we must address many issues that are unique to these businesses and could reduce our available cash reserves and negatively impact our profitability.
In the past we entered into distribution arrangements pursuant to which we utilize our sales force and distributors to sell products manufactured by other companies. In Japan we distribute a Q-switched laser product manufactured by a third party OEM. We also have an agreement with ZO (commencing in the fourth quarter of 2013) to distribute certain of their proprietary cosmeceuticals, or skin care products, in Japan. We previously had an agreement to distribute certain of Obagi’s cosmeceutical products but terminated that effective December 31, 2013. Each of these agreements requires us to purchase annual minimum dollar amounts of their product. If we do not make these minimum purchases, we could lose exclusivity for distributing these products to physicians in Japan. Finally, we also have an agreement with Merz Aesthetics to distribute its Radiesse® dermal filler product in Japan.
Each of these distribution agreements presents its own unique risks and challenges. For example, to sell cosmeceutical products we need to invest in creating a sales structure that is experienced in the sale of cosmeceuticals and not in capital equipment. We need to commit resources to training this sales force, obtaining regulatory licenses in Japan and developing new marketing materials to promote the sale of cosmeceutical products. In addition, the minimum commitments and other costs of distributing products manufactured by these companies may exceed the incremental revenue that we derive from the sale of their products thereby negatively impacting our profitability and reducing our available cash reserves.
Adverse conditions in the global banking industry and credit markets may adversely impact the value of our marketable investments or impair our liquidity.
We invest our excess cash primarily in money market funds and in highly liquid debt instruments of the U.S. government and its agencies and U.S. municipalities, in commercial paper and high grade corporate debt. As of December 31, 2013, our balance in marketable investments was $67 million. The longer the duration of a security, the more susceptible it is to changes in market interest rates and bond yields. As yields increase, those securities with a lower yield-at-cost show a mark-to-market unrealized loss. For example, assuming a hypothetical increase in interest rates of one percentage point, the fair value of our total investment portfolio as of December 31, 2013 would have potentially decreased by approximately $788,000, resulting in an unrealized loss that would subsequently adversely impact our earnings. As a result, changes in the market interest rates will affect our future net income (loss).
The price of our common stock may fluctuate substantially due to several factors, some of which are discussed below. Further, we have a limited number of shares of common stock outstanding, a large portion of which is held by a small number of investors, which could result in the increase in volatility of our stock price.
As of December 2013, approximately 53% of our outstanding shares of common stock were held by 10 institutional investors. As a result of our relatively small public float, our common stock may be less liquid than the stock of companies with broader public ownership. Among other things, trading of a relatively small volume of our common stock may have a greater impact on the trading price for our shares than would be the case if our public float were larger. The public market price of our common stock has in the past fluctuated substantially and, due to the current concentration of stockholders, it may continue to do so in the future. The market price for our common stock could also be affected by a number of other factors, including:
| · | Litigation surrounding executive compensation has increased with the passage of the Dodd-Frank Wall Street Reform and Consumer Protection Act. If we are involved in a lawsuit related to compensation matters or any other matters not covered by our D&O insurance, there could be material expenses involved, fines, or remedial actions which could negatively affect our stock price; |
| · | The general market conditions unrelated to our operating performance; |
| · | Sales of large blocks of our common stock, including sales by our executive officers, directors and our large institutional investors; |
| · | Quarterly variations in our, or our competitors’, results of operations; |
| · | Changes in analysts’ estimates, investors’ perceptions, recommendations by securities analysts or our failure to achieve analysts’ estimates; |
| · | The announcement of new products or service enhancements by us or our competitors; |
| · | The announcement of the departure of a key employee or executive officer by us or our competitor; |
| · | Regulatory developments or delays concerning our, or our competitors’ products; and |
| · | The initiation of litigation by us or against us. |
Actual or perceived instability and / or volatility in our stock price could reduce demand from potential buyers of our stock, thereby causing our stock price to either remain depressed or to decline further.
Our manufacturing operations are dependent upon third-party suppliers, making us vulnerable to supply shortages and price fluctuations, which could harm our business.
Many of the components and materials that comprise our products are currently manufactured by a limited number of suppliers. A supply interruption or an increase in demand beyond our current suppliers’ capabilities could harm our ability to manufacture our products until a new source of supply is identified and qualified. Our reliance on these suppliers subjects us to a number of risks that could harm our business, including:
| · | Interruption of supply resulting from modifications to or discontinuation of a supplier’s operations; |
| · | Delays in product shipments resulting from uncorrected defects, reliability issues or a supplier’s variation in a component; |
| · | A lack of long-term supply arrangements for key components with our suppliers; |
| · | Inability to obtain adequate supply in a timely manner, or on reasonable terms; |
| · | Inability to redesign one or more components in our systems in the event that a supplier discontinues manufacturing such components and we are unable to source it from other suppliers on reasonable terms; |
| · | Difficulty locating and qualifying alternative suppliers for our components in a timely manner; |
| · | Production delays related to the evaluation and testing of products from alternative suppliers and corresponding regulatory qualifications; and |
| · | Delay in supplier deliveries. |
Any interruption in the supply of components or materials, or our inability to obtain substitute components or materials from alternate sources at acceptable prices in a timely manner, could impair our ability to meet the demand of our customers, which would have an adverse effect on our business.
Intellectual property rights may not provide adequate protection for some or all of our products, which may permit third parties to compete against us more effectively.
We rely on patent, copyright, trade secret and trademark laws and confidentiality agreements to protect our technology and products. At December 31, 2013, we had 30 issued U.S. patents. Some of our components, such as our laser module, electronic control system and high-voltage electronics, are not, and in the future may not be, protected by patents. Additionally, our patent applications may not issue as patents or, if issued, may not issue in a form that will be advantageous to us. Any patents we obtain may be challenged, invalidated or legally circumvented by third parties. Consequently, competitors could market products and use manufacturing processes that are substantially similar to, or superior to, ours. We may not be able to prevent the unauthorized disclosure or use of our technical knowledge or other trade secrets by consultants, vendors, former employees or current employees, despite the existence generally of confidentiality agreements and other contractual restrictions. Monitoring unauthorized uses and disclosures of our intellectual property is difficult, and we do not know whether the steps we have taken to protect our intellectual property will be effective. Moreover, the laws of many foreign countries will not protect our intellectual property rights to the same extent as the laws of the U.S.
The absence of complete intellectual property protection exposes us to a greater risk of direct competition. Competitors could purchase one of our products and attempt to replicate some or all of the competitive advantages we derive from our development efforts, design around our protected technology, or develop their own competitive technologies that fall outside of our intellectual property rights. If our intellectual property is not adequately protected against competitors’ products and methods, our competitive position and our business could be adversely affected.
We may be involved in future costly intellectual property litigation, which could impact our future business and financial performance.
Our competitors or other patent holders may assert that our present or future products and the methods we employ are covered by their patents. In addition, we do not know whether our competitors own or will obtain patents that they may claim prevent, limit or interfere with our ability to make, use, sell or import our products. Although we may seek to resolve any potential future claims or actions, we may not be able to do so on reasonable terms, or at all. If, following a successful third-party action for infringement, we cannot obtain a license or redesign our products, we may have to stop manufacturing and selling the applicable products and our business would suffer as a result. In addition, a court could require us to pay substantial damages, and prohibit us from using technologies essential to our products, any of which would have a material adverse effect on our business, results of operations and financial condition.
We may become involved in litigation not only as a result of alleged infringement of a third party’s intellectual property rights but also to protect our own intellectual property. For example, we have been, and may hereafter become, involved in litigation to protect the trademark rights associated with our company name or the names of our products. Infringement and other intellectual property claims, with or without merit, can be expensive and time-consuming to litigate, and could divert management’s attention from our core business.
We offer credit terms to some qualified customers and also to leasing companies to finance the purchase of our products. In the event that any of these customers default on the amounts payable to us, our earnings may be adversely affected.
While we qualify customers to whom we offer credit terms (generally net 30 to 90 days), we cannot provide any assurance that the financial position of these customers will not change adversely before we receive payment. Our general and administrative expenses and earnings are negatively impacted by customer defaults and cause an increase in the allowance for doubtful accounts. In the event that there is a default by any customers to whom we have provided credit terms in the future, we may recognize a bad debt charge in our general and administrative expenses and this could negatively affect our earnings and results of operations.
The expense and potential unavailability of insurance coverage for our customers could adversely affect our ability to sell our products, and therefore our financial condition.
Some of our customers and prospective customers have had difficulty in procuring or maintaining liability insurance to cover their operation and use of our products. Medical malpractice carriers are withdrawing coverage in certain states or substantially increasing premiums. If this trend continues or worsens, our customers may discontinue using our products and potential customers may opt against purchasing laser and light based products due to the cost or inability to procure insurance coverage. The unavailability of insurance coverage for our customers and prospects could adversely affect our ability to sell our products, and that could harm our financial condition.
Healthcare reform legislation will continue to adversely affect our profitability and financial condition.
In December 2009, the President and members of Congress passed legislation relating to healthcare reform. Procedures performed by our products are not reimbursed by insurance companies or federal or state governments and as a result this legislation had a limited impact on our business. Medical device manufacturers have to pay an excise tax of 2.3% on certain U.S. medical device revenues. Though there are some exceptions, this excise tax applies to all of our product and upgrade revenue from the U.S. and will continue to have an adverse effect on our operating profitability and financial condition.
Any acquisitions that we make could disrupt our business and harm our financial condition.
From time to time we evaluate potential strategic acquisitions of complementary businesses, products or technologies. We may also consider joint ventures and other collaborative projects. We may not be able to identify appropriate acquisition candidates or strategic partners, or successfully negotiate, finance or integrate any businesses, products or technologies that we acquire. Furthermore, the integration of any acquisition and management of any collaborative project may divert management’s time and resources from our core business and disrupt our operations and we may incur significant legal, accounting and banking fees in connection with such a transaction. In addition, if we purchase a company that is not profitable, our cash balances may be reduced or depleted. We have limited experience as a team with acquiring companies and products. If we decide to expand our product offerings beyond laser and other energy-based products, we may spend time and money on projects that do not increase our revenue. Any cash acquisition we pursue would diminish our available cash balances to us for other uses, and any stock acquisition could be dilutive to our stockholders.
While we from time to time evaluate potential acquisitions of businesses, products and technologies, and anticipate continuing to make these evaluations, we have no present understandings, commitments or agreements with respect to any material acquisitions or collaborative projects.
Anti-takeover provisions in our Amended and Restated Certificate of Incorporation and Bylaws, and Delaware law, contain provisions that could discourage a takeover.
Our Amended and Restated Certificate of Incorporation and Bylaws, and Delaware law, contain provisions that might enable our management to resist a takeover, and might make it more difficult for an investor to acquire a substantial block of our common stock. These provisions include:
| · | A classified board of directors; |
| · | Advance notice requirements to stockholders for matters to be brought at stockholder meetings; |
| · | Limitations on stockholder actions by written consent; and |
| · | The right to issue preferred stock without stockholder approval, which could be used to dilute the stock ownership of a potential hostile acquirer. |
These provisions, as well as Change of Control and Severance Agreements entered into with each of our executive officers and one key employee, might discourage, delay or prevent a change in control of our company or a change in our management. The existence of these provisions could adversely affect the voting power of holders of common stock and limit the price that investors might be willing to pay in the future for shares of our common stock.
Not applicable.
Our corporate headquarters and U.S. operations are located in an approximately 66,000 square foot facility in Brisbane, California. We lease these premises under a non-cancelable operating lease which expires on December 31, 2017. In addition, we have leased office facilities in certain countries as follows:
|
Country
|
|
Square Footage
|
|
Lease termination or Expiration
|
|
Japan
|
|
Approximately 5,896
|
|
Two leases, one of which expires in March 2015 and one which expires in December 2015.
|
|
France
|
|
Approximately 2,239
|
|
One lease which expires in October 2021 but can be terminated with six months’ notice prior to October 2015 and 2018.
|
We believe that these facilities are adequate for our current and future needs for at least the next twelve months.
We are not a party to any pending litigation that we believe will have a material impact to our results of operations.
Not applicable.
PART II
| ITEM 5. | MARKET FOR THE REGISTRANT’S COMMON EQUITY, RELATED STOCKHOLDER MATTERS AND ISSUER PURCHASES OF EQUITY SECURITIES |
Stock Exchange Listing
Our common stock trades on The NASDAQ Global Select Market under the symbol “CUTR.” As of February 28, 2014, the closing sale price of our common stock was $10.70 per share.
Common Stockholders
We had 9 stockholders of record as of February 28, 2014. Since many stockholders choose to hold their shares under the name of their brokerage firm we estimate that the actual number of stockholders was approximately 2,500 shareholders.
Stock Prices
The following table sets forth quarterly high and low closing sales prices of our common stock for the indicated fiscal periods:
|
Common Stock
|
||||||||||||||||
|
2013
|
2012
|
|||||||||||||||
|
High
|
Low
|
High
|
Low
|
|||||||||||||
|
4th Quarter
|
$
|
10.56
|
$
|
8.39
|
$
|
9.77
|
$
|
7.34
|
||||||||
|
3rd Quarter
|
10.18
|
8.89
|
7.60
|
6.46
|
||||||||||||
|
2nd Quarter
|
13.70
|
8.62
|
9.13
|
6.47
|
||||||||||||
|
1st Quarter
|
13.03
|
8.95
|
9.67
|
7.09
|
||||||||||||
Issuer Purchases of Equity Securities
The following table summarizes the activity related to stock repurchases for the year ended December 31, 2013 (in thousands except per share data):
|
Period
|
Total Number of Shares Purchased
|
Average Price Paid per Share
|
Total Number of Shares Purchased as Part of Publicly Announced Plans or Programs
|
Approximate Dollar Value of Shares That May Yet Be Purchased Under the Plans or Programs
|
||||||||||||
|
August 1-30, 2013
|
546
|
$
|
9.46
|
546
|
$
|
14,833
|
||||||||||
|
September 1-30, 2013
|
251
|
$
|
9.70
|
251
|
$
|
12,400
|
||||||||||
|
November 1-30, 2013
|
264
|
$
|
9.10
|
264
|
$
|
10,000
|
||||||||||
|
|
1,061
|
$
|
9.43
|
1,061
|
$
|
10,000
|
||||||||||
On August 5, 2013, our Board of Directors modified Cutera, Inc.’s stock buyback program, originally adopted in November 2012, to permit an additional $10 million of its issued and outstanding common shares to be repurchased. As modified, the stock buyback program permits us to purchase an aggregate of $20 million of our common stock through a 10b5-1 program based on predetermined pricing and volume parameters, as well as open-market purchase that are subject to management discretion and regulatory restrictions.
In the year ended December 31, 2013, we repurchased 1,060,447 shares of our common stock for approximately $10.0 million. As of December 31, 2013, there remained an additional $10.0 million of our common stock to be purchased under the modified stock buyback program. The number of shares to be repurchased, and the timing of such repurchases, will be based on several factors, including the price of the Company's common stock, regulatory restrictions, and general market and business conditions.
Sales of Unregistered Securities
We did not sell any unregistered securities during the period covered by this Annual Report on Form 10-K.
Securities Authorized for Issuance under Equity Compensation Plans
The information required by this Item regarding equity compensation plans is incorporated by reference to the information set forth in Part III Item 12 of this Annual Report on Form 10-K.
Performance Graph
Below is a graph showing the cumulative total return to our stockholders during the period from December 31, 2008 through December 31, 2013 in comparison to the cumulative return on the NASDAQ Composite Index (U.S.) and the NASDAQ Medical Equipment Index during that same period.
The information under “Performance Graph” is not deemed filed with the Securities and Exchange Commission and is not to be incorporated by reference in any filing of Cutera under the Securities Act of 1933, as amended, or the Securities Exchange Act of 1934, as amended, whether made before or after the date of this 10-K and irrespective of any general incorporation language in those filings.
Dividend Policy
We have never paid a cash dividend and have no present intention to pay cash dividends in the foreseeable future. We intend to retain any future earnings for use in our business.
The table set forth below contains certain consolidated financial data for each of our last five fiscal years. This data should be read in conjunction with the detailed information, financial statements and related notes, as well as Management’s Discussion and Analysis of Financial Condition and Results of Operations included elsewhere herein.
|
|
Year Ended December 31,
|
|||||||||||||||||||
|
Consolidated Statements of Operations Data (in thousands, except per share data):
|
2013
|
2012
|
2011
|
2010
|
2009
|
|||||||||||||||
|
Net revenue
|
$
|
74,594
|
$
|
77,277
|
$
|
60,290
|
$
|
53,274
|
$
|
53,682
|
||||||||||
|
Cost of revenue
|
32,712
|
35,737
|
25,978
|
23,058
|
21,759
|
|||||||||||||||
|
Gross profit
|
41,882
|
41,540
|
34,312
|
30,216
|
31,923
|
|||||||||||||||
|
Operating expenses:
|
||||||||||||||||||||
|
Sales and marketing
|
27,984
|
28,664
|
25,499
|
24,735
|
24,286
|
|||||||||||||||
|
Research and development
|
9,216
|
8,427
|
9,141
|
7,004
|
6,810
|
|||||||||||||||
|
General and administrative
|
9,938
|
11,276
|
10,104
|
9,576
|
10,320
|
|||||||||||||||
|
Litigation settlement
|
—
|
—
|
—
|
—
|
850
|
|||||||||||||||
|
Total operating expenses
|
47,138
|
48,367
|
44,744
|
41,315
|
42,266
|
|||||||||||||||
|
Loss from operations
|
(5,256
|
)
|
(6,827
|
)
|
(10,432
|
)
|
(11,099
|
)
|
(10,343
|
)
|
||||||||||
|
Interest and other income, net
|
455
|
497
|
614
|
583
|
1,572
|
|||||||||||||||
|
Loss before income taxes
|
(4,801
|
)
|
(6,330
|
)
|
(9,818
|
)
|
(10,516
|
)
|
(8,771
|
)
|
||||||||||
|
Income tax (benefit) provision
|
(54
|
)
|
218
|
243
|
2
|
8,908
|
||||||||||||||
|
Net loss
|
$
|
(4,747
|
)
|
$
|
(6,548
|
)
|
$
|
(10,061
|
)
|
$
|
(10,518
|
)
|
$
|
(17,679
|
)
|
|||||
|
Net loss per share:
|
||||||||||||||||||||
|
Basic and diluted
|
$
|
(0.33
|
)
|
$
|
(0.46
|
)
|
$
|
(0.73
|
)
|
$
|
(0.78
|
)
|
$
|
(1.33
|
)
|
|||||
|
Weighted-average number of shares used in per share calculations:
|
||||||||||||||||||||
|
Basic and diluted
|
14,421
|
14,089
|
13,807
|
13,540
|
13,279
|
|||||||||||||||
|
|
As of December 31,
|
|||||||||||||||||||
|
Consolidated Balance Sheet Data (in thousands):
|
2013
|
2012
|
2011
|
2010
|
2009
|
|||||||||||||||
|
Cash and cash equivalents
|
$
|
16,242
|
$
|
23,546
|
$
|
14,020
|
$
|
12,519
|
$
|
22,829
|
||||||||||
|
Marketable investments
|
66,831
|
62,026
|
74,666
|
77,484
|
76,780
|
|||||||||||||||
|
Long-term investments
|
—
|
—
|
3,027
|
6,784
|
7,275
|
|||||||||||||||
|
Working capital (current assets less current liabilities)
|
84,654
|
88,788
|
89,075
|
90,339
|
96,015
|
|||||||||||||||
|
Total assets
|
108,669
|
112,794
|
111,353
|
111,805
|
121,352
|
|||||||||||||||
|
Retained earnings (accumulated deficit)
|
(14,620
|
)
|
(9,873
|
)
|
(3,325
|
)
|
6,736
|
17,254
|
||||||||||||
|
Total stockholders’ equity
|
84,265
|
90,774
|
91,567
|
95,417
|
100,853
|
|||||||||||||||
The following discussion should be read in conjunction with our audited financial statements and notes thereto for the fiscal year ended December 31, 2013. This Annual Report on Form 10-K, including the following sections, contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Throughout this Report, and particularly in this Item 7, the forward-looking statements are based upon our current expectations, estimates and projections and that reflect our beliefs and assumptions based upon information available to us at the date of this Report. In some cases, you can identify these statements by words such as “may,” “might,” “will,” “should,” “expects,” “plans,” “anticipates,” “believes,” “estimates,” “predicts,” “potential” or “continue,” and other similar terms. These forward-looking statements are not guarantees of future performance and are subject to risks, uncertainties, and assumptions that are difficult to predict. Our actual results, performance or achievements could differ materially from those expressed or implied by the forward-looking statements. The forward-looking statements include, but are not limited to, statements relating to our future financial performance, the ability to grow our business, increase our revenue, manage expenses, generate additional cash, achieve and maintain profitability, develop and commercialize existing and new products and applications, improve the performance of our worldwide sales and distribution network, and to the outlook regarding long term prospects. We caution you not to place undue reliance on these forward-looking statements, which reflect management’s analysis only as of the date of this Annual Report on Form 10-K. We undertake no obligation to update forward-looking statements to reflect events or circumstances occurring after the date of this Form 10-K.
Some of the important factors that could cause our results to differ materially from those in our forward-looking statements, and a discussion of other risks and uncertainties, are discussed in Item 1A—Risk Factors commencing on page 17. We encourage you to read that section carefully as well as other risks detailed from time to time in our filings with the SEC.
Introduction
The Management’s Discussion and Analysis, or MD&A, is organized as follows:
| · | Executive Summary. This section provides a general description and history of our business, a brief discussion of our product lines and the opportunities, trends, challenges and risks we focus on in the operation of our business. |
| · | Critical Accounting Policies and Estimates. This section describes the key accounting policies that are affected by critical accounting estimates. |
| · | Recent Accounting Guidance. This section describes the issuance and effect of new accounting pronouncements that are and may be applicable to us. |
| · | Results of Operations. This section provides our analysis and outlook for the significant line items on our Consolidated Statements of Operations. |
| · | Liquidity and Capital Resources. This section provides an analysis of our liquidity and cash flows, as well as a discussion of our commitments that existed as of December 31, 2013. |
Executive Summary
Company Description.
We are a global medical device company specializing in the design, development, manufacture, marketing and servicing of laser and other energy based aesthetics systems for practitioners worldwide. We offer easy-to-use products based on four primary platforms—Xeo®, GenesisPlusTM, ExcelVTM, and truSculptTM— each of which enables physicians and other qualified practitioners to perform safe and effective aesthetic procedures for their customers. In addition to our four primary platforms, we offer other products, including CoolGlide®, Solera®, VariliteTM and Japan specific products such as myQTM.
The Xeo and Solera platforms offer multiple hand pieces and applications, which allow customers to upgrade their systems, which we treat as Upgrade revenue. In addition to systems and upgrade revenue, we generate revenue from the sale of post warranty service contracts, providing services for products that are out of warranty, Titan and truSculpt hand piece refills, and dermal fillers and cosmeceuticals.
Our corporate headquarters and U.S. operations are located in Brisbane, California, from where we conduct our manufacturing, warehousing, research and development, regulatory, sales and marketing, service, and administrative activities. In the U.S., we market, sell and service our products through direct sales and service employees, and a distribution relationship with PSS World Medical Shared Services, Inc. (“PSS”), a wholly owned subsidiary of PSS World Medical which has over 700 sales representatives serving physician offices throughout the U.S. We also sell certain items such as our Titan hand piece refills and marketing brochures online.
International sales are generally made through direct sales employees in Australia, Belgium, Canada, France and Japan. In addition, we have a worldwide distributor network in over 60 countries.
Products. Our revenue is derived from the sale of Products, Upgrades, Service, Titan and truSculpt hand piece refills, and Dermal fillers and cosmeceutical products. Product revenue represents the sale of a system. A system consists of a console that incorporates a universal graphic user interface, a laser and/or other energy based module, control system software and high voltage electronics; as well as one or more hand pieces. However, depending on the application, the laser or other energy based module is sometimes contained in the hand piece such as with our Pearl and Pearl Fractional applications instead of within the console.
We offer our customers the ability to select the system that best fits their practice at the time of purchase and then to cost-effectively add applications to their system as their practice grows. This provides customers the flexibility to upgrade their systems whenever they want and provides us with a source of recurring revenue which we classify as Upgrade revenue. Service revenue relates to amortization of prepaid service contracts, direct billings for detachable hand piece replacements and revenue for parts and labor on out-of-warranty products. For our Titan hand pieces, after a set number of treatments have been performed, the customer is required to send the hand piece back to the factory for refurbishment, which we refer to as ‘refilling’ the hand piece. In Japan, we distribute ZO’s and Obagi’s (through December 31, 2013 only) cosmeceutical products; and Merz Pharma GmbH’s (“Merz”) Radiesse® dermal filler product.
Significant Business Trends. We believe that our ability to grow revenue will be primarily dependent on the following:
| · | Continuing to expand our product offerings ─ both through internal development and sourcing from other vendors. |
| · | Ongoing investment in our global sales and marketing infrastructure. |
| · | Use of clinical results to support new aesthetic products and applications. |
| · | Enhanced luminary development and reference selling efforts (to develop a location where our products can be displayed and used to assist in selling efforts). |
| · | Customer demand for our products. |
| · | Consumer demand for the application of our products. |
| · | Marketing to physicians in the core dermatology and plastic surgeon specialties, as well as outside those specialties. |
| · | Generating ongoing revenue from our growing installed base of customers through the sale of Service, Upgrade, Titan hand piece refills, and Dermal fillers and cosmeceutical products. |
For a detailed discussion of the significant business trends impacting our business, please see Results of Operations below.
Factors that May Impact Future Performance
Our industry is impacted by numerous competitive, regulatory and other significant factors. Our industry is highly competitive and our future performance depends on our ability to compete successfully. Additionally, our future performance is dependent upon our ability to continue to expand our product offerings with innovative technologies, obtain regulatory clearances for our products, protect the proprietary technology of our products and our manufacturing processes, manufacture our products cost-effectively, and successfully market and distribute our products in a profitable manner. If we fail to execute on the aforementioned initiatives, our business would be adversely affected. A detailed discussion of these and other factors that could impact our future performance are provided in Part I, Item 1A “Risk Factors.”
Critical Accounting Policies and Estimates
The preparation of our Consolidated Financial Statements and related disclosures in conformity with generally accepted accounting principles in the U.S. (“GAAP”) requires us to make estimates, judgments and assumptions that affect the reported amounts of assets, liabilities, revenue and expenses. These estimates, judgments and assumptions are based on historical experience and on various other factors that we believe are reasonable under the circumstances. We periodically review our estimates and make adjustments when facts and circumstances dictate. To the extent that there are material differences between these estimates and actual results, our financial condition or results of operations will be affected.
Critical accounting estimates, as defined by the Securities and Exchange Commission (“SEC”), are those that are most important to the portrayal of our financial condition and results of operations and require our management’s most difficult and subjective judgments and estimates of matters that are inherently uncertain. Our critical accounting estimates are as follows:
Revenue Recognition
We earn revenue from the sale of Products, Upgrades, Titan and truSculpt hand piece refills, and Dermal fillers and cosmeceuticals. We recognize revenue when persuasive evidence of an arrangement exists, transfer of title to the customer has occurred, the sales price is fixed or determinable, and collectability is probable. We defer revenue in the event that any of these revenue recognition criteria is not met.
| · | Persuasive evidence of an arrangement exists: We use customer purchase agreements or contracts, or customer purchase orders to determine the existence of an arrangement. |
| · | Transfer of title: Our standard terms generally specify that title transfers upon shipment to the customer. We generally use third party shipping documents to verify that title has transferred. For service revenue, we use the date that services have been rendered; |
| · | Sales price is fixed or determinable: We assess whether the sales price is fixed or determinable at the time of the transaction. Sales prices are documented in the customer purchase agreement or purchase order received prior to shipment. Our standard terms do not allow for trial or evaluation periods, rights of return or refund, payments contingent upon the customer obtaining financing or other terms that could impact the customer's obligation; and |
| · | Collectability is probable: We assess whether collection is reasonably assured based on a number of factors, including receipt of cash or credit card payment, customer's past transaction history, credit worthiness, or the receipt of an irrevocable letter of credit. |
Multiple-Element Arrangements
For System or Upgrade sales, all of the tangible products, including the embedded software, are delivered to the customer at the time of sale. In some circumstances, in conjunction with the purchase of a System or Upgrade, customers purchase Service contracts for one or more years to cover their products. For these transactions, the following multiple-element arrangement exists:
a tangible product delivered to the customer at the inception of the revenue arrangement; and
a service contract for delivery of services to the customer over a contractually stated period of time defined in the service contract.
For multiple-element arrangements, judgments are required as to the allocation of the proceeds received from an arrangement to the multiple elements of the arrangement. For multiple element arrangements entered into on or after January 1, 2010, we allocate revenue to all deliverables based on their relative selling prices. Because we have neither vendor-specific objective evidence (“VSOE”) nor third-party evidence of selling price (“TPE”) for our systems, the allocation of revenue has been based on our best estimate of selling prices (“BESP”). The objective of BESP is to determine the price at which we would transact a sale if the product or service was sold on a stand-alone basis. We determine BESP for our deliverables by considering multiple factors including, but not limited to, features and functionality of the system, geographies, type of customer and market conditions.
Revenue under service contracts is recognized on a straight-line basis over the period of the applicable service contract. Service revenue, not under a service contract, is recognized as the services are provided.
Hand Piece Refills
When customers purchase a hand piece refill, we ship a previously refurbished unit and recognize revenue upon shipment. With respect to our truSculpt product, prior to the third quarter of 2013, we sold the system and hand piece and then charged the customer an incremental fee for any future refills and we treated the refills as a separate deliverable under FASB ASC 605-25. In addition, we also provided promotions that included an unlimited number of “free” hand piece replacements during a stated trial period of 3 months or 12 months. We determined that these free refills were an undelivered element under FASB ASC 605-25 in the original revenue transaction. As such, we deferred the relative fair value related to the estimated number of hand piece replacements to be delivered during the promotional period and recognized that deferred revenue over the free refills promotion period. Commencing with the third quarter of 2013, we included unlimited hand piece replacements in the truSculpt standard warranty contract and concluded that this no longer was a separate deliverable under the multiple-element arrangement revenue guidance. Following this change, we recognized the revenue under the warranty model, in which the revenue for the system sale was recognized up-front along with an estimate of the costs which will be incurred under the warranty obligation recorded in cost of revenue.
Shipping and handling costs
We expense shipping and handling costs as incurred and include them in cost of revenue. In those cases where we bill shipping and handling costs to customers, we classify the amounts billed as revenue.
Stock-based Compensation Expense
Stock options
We account for stock-based compensation in accordance with the fair value recognition provisions of U.S. GAAP. We use the Black-Scholes-Merton option-pricing model which requires the input of highly subjective assumptions. These assumptions include:
| · | Estimating the length of time employees will retain their vested stock options before exercising them (“expected term”); |
| · | Estimated volatility of our common stock price over the expected term; |
| · | Number of options that will ultimately not complete their vesting requirements (“forfeiture rate”); and |
| · | Expected risk-free interest rate and dividend rate over the expected term. |
The assumptions for expected volatility and expected term are the two assumptions that significantly affect the grant date fair value.
The expected term represents the weighted-average period that our stock options are expected to be outstanding. The expected term is based on the observed and expected time to post-vesting exercise of options by employees. We use historical exercise patterns of previously granted options in relation to stock price movements to derive an employee behavioral pattern used to forecast expected exercise patterns.
We estimate volatility based on historical volatility and we also consider implied volatility when there is sufficient volume of freely traded options with comparable terms and exercise prices in the open market.
U.S. GAAP requires us to develop an estimate of the number of share-based awards that will be forfeited due to employee turnover. Adjustments in the estimated forfeiture rates can have a significant effect on our reported share-based compensation, as we recognize the cumulative effect of the rate adjustments for all expense amortization in the period the estimated forfeiture rates were adjusted. We estimate and adjust forfeiture rates based on a periodic review of recent forfeiture activity and expected future employee turnover. If a revised forfeiture rate is higher than previously estimated forfeiture rate, we may make an adjustment that will result in a decrease to the expense recognized in the financial statements during the period when the rate was changed. Adjustments in the estimated forfeiture rates could also cause changes in the amount of expense that we recognize in future periods.
Changes in expected risk-free interest rate and dividend rate do not significantly impact the calculation of fair value, and determining this input is not highly subjective.
Changes in the subjective assumptions of expected term, volatility and forfeiture rate can materially affect the estimate of fair value of stock-based compensation and, consequently, the related amount recognized on the Consolidated Statements of Income.
Restricted Stock Units
We grant restricted stock unit (“RSU”) awards to our management employees, officers and directors. RSUs are measured based on the fair market values of the underlying stock on the dates of grant and the stock based compensation expense is recognized over the vesting period using the straight-line method. Shares are issued on the vesting dates net of the minimum statutory tax withholding requirements to be paid by us on behalf of our employees. As a result, the actual number of shares issued will be fewer than the actual number of RSUs outstanding. Furthermore, we record the liability for withholding amounts to be paid by us as a reduction to additional paid-in capital.
Performance Stock Units
Performance stock unit (“PSU”) awards were granted to our officers in 2013 and 2012. The final number of shares of common stock issuable at the end of the performance measurement period, subject to the recipient’s continued service through that date, is determined based on the degree of achievement of the performance goals. The stock-based compensation expenses for the PSUs is measured based on the fair market value on the dates of grant of the target number of underlying shares. Stock based compensation expense is recognized over the vesting period using the straight-line method and the expected degree of achievement of the performance goals. At the vest date, we issue fully-paid up common stock, net of the minimum statutory tax withholding requirements to be paid by us on behalf of our officers. As a result, the actual number of shares issued is less than the original number of PSUs outstanding. Furthermore, we record the liability for withholding amounts to be paid by us as a reduction to additional paid-in capital.
Intangible Assets.
Our intangible assets include identifiable intangibles and goodwill. Identifiable intangibles include sub-licenses, rights acquired from a former distributor and those acquired in conjunction with an acquisition in 2012. All of our identifiable intangibles have finite lives.
In February 2012, we acquired the global aesthetic business unit of IRIDEX Corporation, which included various laser systems (such as the VariLite and Gemini) and an installed base of customers, whose products are being serviced by us. This acquisition was considered a business combination for accounting purposes, and as such, in addition to valuing all the assets, we recorded goodwill associated with the expected synergies from leveraging the customer relationships and integrating new product offerings into our business. The fair values of the assets acquired were determined to be $4.8 million of net tangible and intangible assets and $1.3 million of goodwill.
Identifiable intangible assets with finite lives are subject to impairment testing and are reviewed for impairment when events or circumstances indicate that such assets may not be recoverable at their carrying value. We evaluate the recoverability of the carrying value of these identifiable intangibles based on estimated undiscounted cash flows to be generated from such assets. If the cash flow estimates or the significant operating assumptions upon which they are based change in the future, we may be required to record additional impairment charges. When events or changes in circumstances indicate that the carrying amount of long-lived assets may not be recoverable, we recognize such impairment in the event the net book value of such assets exceeds the future undiscounted cash flows attributable to such assets.
The valuation and classification of intangible assets and goodwill and the assignment of useful amortization lives for the intangible assets involves judgments and the use of estimates. The evaluation of these intangibles and goodwill for impairment under established accounting guidelines is required on a recurring basis. Changes in business conditions could potentially require future adjustments to asset valuations. When we determine that the useful lives of assets are shorter than we had originally estimated, we accelerate the rate of amortization over the assets’ new, shorter useful lives. No impairment charge or accelerated amortization was recorded for the years ended December 31, 2013, 2012, and 2011. A considerable amount of judgment is required in assessing impairment, which includes financial forecasts. Should conditions be different from management’s current estimates, material write-downs of long-lived assets may be required, which would adversely affect our operating results.
Valuation of Inventories
We state our inventories at the lower of cost or market, computed on a standard cost basis, which approximates actual cost on a first-in, first-out basis and market being determined as the lower of replacement cost or net realizable value. Standard costs are monitored and updated quarterly or as necessary, to reflect changes in raw material costs, labor to manufacture the product and overhead rates. We provide for excess and obsolete inventories when conditions indicate that the selling price could be less than cost due to physical deterioration, usage, obsolescence, reductions in estimated future demand and reductions in selling prices. Inventory provisions are measured as the difference between the cost of inventory and estimated market value and charged to cost of revenue to establish a lower cost basis for the inventories. We balance the need to maintain strategic inventory levels with the risk of obsolescence due to changing technology and customer demand levels. Unfavorable changes in market conditions may result in a need for additional inventory provisions that could adversely impact our gross margins. Conversely, favorable changes in demand could result in higher gross margins when product that had previously been written off is sold.
Warranty Obligations
We provide a one-year standard warranty on all systems. Warranty coverage provided is for labor and parts necessary to repair the systems during the warranty period. Commencing with the third quarter of 2013, for sales of our truSculpt product, we included free hand piece refills during the warranty period. We provide for the estimated future costs of warranty obligations in cost of revenue when the related revenue is recognized. The accrued warranty costs represent our best estimate at the time of sale, and as reviewed and updated quarterly, of the total costs that we expect to incur during the warranty period to repair or replace product parts that fail, including the refurbishment of any truSculpt refills included as part of the original sale. Accrued warranty costs include costs of material, technical support labor and associated overhead. The amount of accrued estimated warranty costs obligation for established products is primarily based on historical experience as to product failures adjusted for current information on repair costs. Actual warranty costs could differ from the estimated amounts. On a quarterly basis, we review the accrued balances of our warranty obligations and update based on historical warranty cost trends. If we were required to accrue additional warranty cost in the future due to actual product failure rates, material usage, service delivery costs or overhead costs differing from our estimates, revisions to the estimated warranty liability would be required, which would negatively impact our operating results.
Provision for Income Taxes
We are subject to taxes on earnings in both the U.S. and various foreign jurisdictions. As a global taxpayer, significant judgments and estimates are required in evaluating our uncertain tax positions and determining our provision for income taxes on earnings. We perform a two-step approach to recognizing and measuring uncertain tax positions. The first step is to evaluate the tax position for recognition by determining if the weight of available evidence indicates that it is more likely than not that the position will be sustained on audit, including resolution of related appeals or litigation processes, if any. The second step is to measure the tax benefit as the largest amount that is more than 50% likely of being realized upon settlement. Although we believe we have adequately reserved for our uncertain tax positions, no assurance can be given that the final tax outcome of these matters will not be different. We adjust these reserves in light of changing facts and circumstances, such as the closing of a tax audit or the refinement of an estimate. To the extent that the final tax outcome of these matters is different than the amounts recorded, such differences will impact the provision for income taxes in the period in which such determination is made. The provision for income taxes includes the impact of reserve provisions and changes to reserves that are considered appropriate, as well as the related net interest.
Our effective tax rates have differed from the statutory rate primarily due to changes in the valuation allowance, foreign operations, research and development tax credits, state taxes, and certain benefits realized related to stock option activity. Our current effective tax rate does not assume U.S. taxes on undistributed profits of foreign subsidiaries. These earnings could become subject to incremental foreign withholding or U.S. federal and state taxes, should they either be deemed or actually remitted to the U.S. The effective tax rate was approximately 1% in 2013, (3)% in 2012, and (2)% in 2011. Our future effective tax rates could be adversely affected by earnings being lower in countries where we have lower statutory rates and being higher in countries where we have higher statutory rates, or by changes in tax laws, accounting principles, interpretations thereof, net operating loss carryback, research and development tax credits, and due to changes in the valuation allowance of our U.S. deferred tax assets. In addition, we are subject to the examination of our income tax returns by the Internal Revenue Service and other tax authorities. We regularly assess the likelihood of adverse outcomes resulting from these examinations to determine the adequacy of our provision for income taxes.
At December 31, 2013, we had an aggregate of approximately $2.6 million of unremitted earnings of foreign subsidiaries that have been, or are intended to be, indefinitely reinvested for continued use in foreign operations. Depending on the timing and nature of the distribution, if the total undistributed earnings of foreign subsidiaries were remitted while the Company is able to utilize its net operating losses, it is likely there would be no material additional tax resulting from the distribution.
Our deferred tax assets and liabilities are recognized for the expected future tax consequences of temporary differences between the financial reporting and tax bases of assets and liabilities, and for operating losses and tax credit carryforwards. A valuation allowance reduces deferred tax assets to estimated realizable value, which assumes that it is more likely than not that we will be able to generate sufficient future taxable income in certain tax jurisdictions to realize the net carrying value. We have fully reserved our U.S. federal and state deferred tax assets due to our history of operating losses.
Litigation
We have been, and may in the future become, subject to legal proceedings related to securities litigation, intellectual property, product liability claims, contractual disputes and other matters. Based on all available information at the balance sheet dates, we assess the likelihood of any adverse judgments or outcomes for these matters, as well as potential ranges of probable loss. If losses are probable and reasonably estimable, we record an estimated liability.
Results of Operations
The following table sets forth selected consolidated financial data expressed as a percentage of net revenue.
|
|
Year Ended December 31,
|
|||||||||||
|
|
2013
|
2012
|
2011
|
|||||||||
|
|
||||||||||||
|
Net revenue
|
100
|
%
|
100
|
%
|
100
|
%
|
||||||
|
Cost of revenue
|
44
|
%
|
46
|
%
|
43
|
%
|
||||||
|
Gross profit
|
56
|
%
|
54
|
%
|
57
|
%
|
||||||
|
Operating expenses:
|
||||||||||||
|
Sales and marketing
|
38
|
%
|
37
|
%
|
42
|
%
|
||||||
|
Research and development
|
12
|
%
|
11
|
%
|
15
|
%
|
||||||
|
General and administrative
|
13
|
%
|
15
|
%
|
17
|
%
|
||||||
|
Total operating expenses
|
63
|
%
|
63
|
%
|
74
|
%
|
||||||
|
Loss from operations
|
(7
|
)%
|
(9
|
)%
|
(17
|
)%
|
||||||
|
Interest and other income, net
|
1
|
%
|
1
|
%
|
1
|
%
|
||||||
|
Loss before income taxes
|
(6
|
)%
|
(8
|
)%
|
(16
|
)%
|
||||||
|
Income tax (benefit) provision
|
—
|
%
|
—
|
%
|
1
|
%
|
||||||
|
Net loss
|
(6
|
)%
|
(8
|
)%
|
(17
|
)%
|
||||||
Net Revenue
The following table sets forth selected consolidated revenue by major geographic area and product category with changes thereof.
|
|
Year Ended December 31,
|
|||||||||||||||||||
|
(Dollars in thousands)
|
2013
|
% Change
|
2012
|
% Change
|
2011
|
|||||||||||||||
|
Revenue mix by geography:
|
||||||||||||||||||||
|
United States
|
$
|
31,487
|
(1
|
)%
|
$
|
31,949
|
37
|
%
|
$
|
23,313
|
||||||||||
|
Percent of total
|
42
|
%
|
41
|
%
|
39
|
%
|
||||||||||||||
|
|
||||||||||||||||||||
|
Japan
|
$
|
14,205
|
(20
|
)%
|
$
|
17,826
|
19
|
%
|
$
|
15,019
|
||||||||||
|
Asia, excluding Japan
|
11,263
|
27
|
%
|
8,902
|
79
|
%
|
4,984
|
|||||||||||||
|
Europe
|
7,358
|
48
|
%
|
4,958
|
39
|
%
|
3,571
|
|||||||||||||
|
Rest of the world
|
10,281
|
(25
|
)%
|
13,642
|
2
|
%
|
13,403
|
|||||||||||||
|
Total international revenue
|
43,107
|
(5
|
)%
|
45,328
|
23
|
%
|
36,977
|
|||||||||||||
|
Percent of total
|
58
|
%
|
59
|
%
|
61
|
%
|
||||||||||||||
|
|
||||||||||||||||||||
|
Total consolidated revenue
|
$
|
74,594
|
(3
|
)%
|
$
|
77,277
|
28
|
%
|
$
|
60,290
|
||||||||||
|
|
||||||||||||||||||||
|
Revenue mix by product category:
|
||||||||||||||||||||
|
Products and upgrades
|
$
|
48,374
|
(2
|
)%
|
$
|
49,605
|
33
|
%
|
$
|
37,208
|
||||||||||
|
Titan and truSculpt hand piece refills
|
4,267
|
11
|
%
|
4,807
|
3
|
%
|
4,686
|
|||||||||||||
|
Dermal fillers and cosmeceuticals
|
4,264
|
(24
|
)%
|
5,645
|
13
|
%
|
4,985
|
|||||||||||||
|
Total product revenue
|
56,905
|
(5
|
)%
|
60,057
|
28
|
%
|
46,879
|
|||||||||||||
|
Service
|
17,689
|
3
|
%
|
17,220
|
28
|
%
|
13,411
|
|||||||||||||
|
Total consolidated revenue
|
$
|
74,594
|
(3
|
)%
|
$
|
77,277
|
28
|
%
|
$
|
60,290
|
||||||||||
Revenue by Geography:
Our U.S. revenue decreased by 1% and our international revenue decreased by 5% in 2013, compared to 2012. We believe the decrease in U.S. revenues was attributable to several factors, including:
| · | Reduced productivity of our U.S. sales force, caused in part by field sales and management turnover; |
| · | A reduction in our GenesisPlus revenue, due in part to the reorganization and consolidation of our podiatry sales force into the general aesthetics sales force; and |
| · | A decline in Xeo product revenue; which was partially offset by |
| · | Continued growth of ExcelV shipments, which began shipping in the second quarter of 2011; and |
| · | An increase in truSculpt revenue, which commenced shipments in the third quarter of 2012. |
Our total international revenue decreased by 5% in 2013, compared to 2012, and represented 58% of our total revenue. The decrease in international revenue was primarily a result of the decline in 2013 of the Japanese Yen versus the U.S. Dollar compared to 2012, partially offset by growth in revenue from France and several of our international distributors.
Revenue by Product Category:
Our product and upgrade revenue decreased by 2% in 2013 and increased by 33% in 2012, compared to the respective prior year periods. The 2013 decrease in product and upgrade revenue was primarily attributable to a decline of the Japanese Yen versus the U.S. Dollar and the decline of GensisPlus sales, partially offset by continued growth in ExcelV sales. The 2012 increase in product and upgrade revenue was primarily attributable to the continued growth of ExcelV shipments, which began shipping in 2011, the commencement of truSculpt shipments in the third quarter of 2012 and incremental revenue from the February 2012 Iridex aesthetic acquisition.
Our service revenue increased by 3% in 2013 and by 28% in 2012, compared to the respective prior year periods. The ratable recognition of service contract fees is the primary component of our service revenue. The increase in 2013 was primarily due to an expanded customer base as well as one additional month of service revenue in 2013, versus 2012, relating to the acquisition of the Iridex aesthetic business in February 2012. The increase in 2012 was primarily the result of the Iridex business acquisition.
Our Titan and truSculpt hand piece refill revenue decreased by 11% in 2013 and increased by 3% in 2012, compared to the respective prior year periods. The decrease in 2013 was due primarily to declines in Titan hand piece refill revenue caused by reduced utilization and partly due to decline in the Japanese Yen versus the U.S. Dollar, which was partially offset by an increase in revenue from truSculpt refills that started shipping in the fourth quarter of 2012. Commencing in the third quarter of 2013, we have repositioned our truSculpt product to include the refurbishment of the hand pieces as part of the original system warranty or ongoing service contracts, thereby enabling our customers unlimited usage as part of the original system warranty. Because very few truSculpt hand piece replacements were sold separately, the impact of the change in our agreements with our customers has been immaterial on our revenue and financial statements. The increase in 2012 was due primarily to the introduction of truSculpt refills in the fourth quarter of 2012.
Our Dermal filler and cosmeceutical business decreased by 24% in 2013, compared to 2012, and increased by 13% in 2012 compared to 2011. The decrease in 2013 is primarily the result of the devaluation of the Japanese yen versus the U.S. dollar. The increase in 2012 was due primarily to the higher number of customers purchasing Obagi products, which we began distributing in Japan in the first quarter of 2010, and due to the expansion of cosmeceutical product lines being distributed.
Gross Profit
|
Year Ended December 31,
|
||||||||||||||||||||
|
(Dollars in thousands)
|
2013
|
% Change
|
2012
|
% Change
|
2011
|
|||||||||||||||
|
Gross Profit
|
$
|
41,882
|
1
|
%
|
$
|
41,540
|
21
|
%
|
$
|
34,312
|
||||||||||
|
As a percentage of total revenue
|
56
|
%
|
54
|
%
|
57
|
%
|
||||||||||||||
Our cost of revenue consists primarily of materials, personnel expenses, royalty expense, warranty and manufacturing overhead expenses. Gross margin as a percentage of net revenue improved to 56% in 2013, compared to 2012, which was primarily attributable to the following:
| · | A partial shift in product mix towards higher margin products; |
| · | Improved gross margin from our Service business, due primarily to reduced material expenses resulting from improved reliability of our products; |
| · | Results of cost reduction initiatives; and |
| · | Reduced amortization of intangibles related to the acquisition of Iridex’s aesthetic business. |
Our gross margin as a percentage of net revenue declined to 54% in 2012, compared to 2011, which was primarily attributable to the following:
| · | A product mix shift towards lower margin products; |
| · | An increase in Service revenue primarily as a result of the acquisition of the Iridex service business that has a lower margin than our blended margin; |
| · | Amortization of intangibles related to the acquisition of Iridex’s aesthetic business in the first quarter of 2012; and |
| · | An increase in sales through distributors, which typically has a lower margin than our direct revenue. |
Sales and Marketing
|
Year Ended December 31,
|
||||||||||||||||||||
|
(Dollars in thousands)
|
2013
|
% Change
|
2012
|
% Change
|
2011
|
|||||||||||||||
|
Sales and marketing
|
$
|
27,984
|
(2
|
)%
|
$
|
28,664
|
12
|
%
|
$
|
25,499
|
||||||||||
|
As a percentage of total revenue
|
38
|
%
|
37
|
%
|
42
|
%
|
||||||||||||||
Sales and marketing expenses consist primarily of personnel expenses, expenses associated with customer-attended workshops and trade shows, post-marketing studies and advertising. Sales and marketing expenses decreased $680,000 in 2013, compared to 2012, which was primarily attributable to the following:
| · | $1.0 million of decreased Japan expenses resulting primarily from the appreciation of the U.S. Dollar against the Japanese Yen (the change in the U.S. Dollar to Japanese Yen exchange rate between 2012 and 2011 was insignificant); |
| · | $312,000 of decreased North American travel and entertainment expenses; partially offset by |
| · | $523,000 of increased North American product demonstration, promotional and marketing expenses. |
In 2012, sales and marketing expenses increased by $3.2 million compared to 2011. This increase was primarily attributable to:
| · | $2.2 million increase in personnel expenses attributable primarily to higher headcount and commission expenses due to higher revenue; |
| · | $660,000 of higher product demonstration related expenses; and |
| · | $418,000 increase in travel, entertainment and sales meeting expenses due to increased headcount and sales activity. |
Sales and marketing expenses as a percentage of net revenue, increased to 38% in 2013, compared to 37% in 2012. This increase was due to lower revenue levels than in 2012. Sales and marketing expenses as a percentage of net revenue, decreased to 37% in 2012, compare to 42% in 2011. The decrease in 2012 was due primarily to a larger increase in our revenue, compared to the increase in expenses, in 2012.
Research and Development (“R&D”)
|
Year Ended December 31,
|
||||||||||||||||||||
|
(Dollars in thousands)
|
2013
|
% Change
|
2012
|
% Change
|
2011
|
|||||||||||||||
|
Research and development
|
$
|
9,216
|
9
|
%
|
$
|
8,427
|
(8
|
)%
|
$
|
9,141
|
||||||||||
|
As a percentage of total revenue
|
12
|
%
|
11
|
%
|
15
|
%
|
||||||||||||||
Research and development expenses consist primarily of personnel expenses, clinical, regulatory and material costs. R&D expenses increased $789,000 in 2013, compared to 2012, which was primarily attributable to:
| · | $1.1 million increase in material spending related to new product development; partially offset by |
| · | A decrease of $237,000 in outside consulting expenses. |
In 2012, R&D expenses decreased by $714,000, compared to 2011, which primarily attributable to:
| · | $444,000 decrease in personnel expenses due to lower headcount; and |
| · | A decrease in material spending of $107,000 due to the timing, complexity and material component costs of the product being developed. |
General and Administrative (“G&A”)
|
|
Year Ended December 31,
|
|||||||||||||||||||
|
(Dollars in thousands)
|
2013
|
% Change
|
2012
|
% Change
|
2011
|
|||||||||||||||
|
General and administrative
|
$
|
9,938
|
(12
|
)%
|
$
|
11,276
|
12
|
%
|
$
|
10,104
|
||||||||||
|
As a percentage of total revenue
|
13
|
%
|
15
|
%
|
17
|
%
|
||||||||||||||
General and administrative expenses consist primarily of: personnel expenses, legal fees, accounting, audit and tax consulting fees, and other general and administrative expenses. G&A expenses decreased by $1.3 million in 2013, compared to 2012, which was primarily attributable to:
| · | $1.0 million of decreased personnel related expenses; |
| · | $532,000 of reduced legal fees and costs of settlements; |
| · | A reduction of $527,000 of integration expenses associated with the Iridex business acquisition incurred in 2012; |
| · | $292,000 of reduced accounting fees; partially offset by, |
| · | $800,000 of management consulting fees in 2013; and |
| · | $343,000 of increased expenses due to the commencement of the U.S. medical excise tax from January 1, 2013. |
In 2012, G&A expenses increased by $1.2 million, compared to 2011. This increase was primarily attributable to:
| · | $527,000 of integration expenses associated with the Iridex business acquisition; |
| · | $366,000 of higher legal fees and costs of settlements; |
| · | $207,000 of higher accounting fees; |
| · | $187,000 of higher personnel expenses; partially offset by, |
| · | $162,000 decrease in facilities costs due the relocation of our offices in Tokyo, Japan and the closure of our office in Switzerland in 2011. |
Interest and Other Income, Net
The components of “Interest and Other Income, Net” are as follows:
|
Year Ended December 31,
|
||||||||||||||||||||
|
(Dollars in thousands)
|
2013
|
% Change
|
2012
|
% Change
|
2011
|
|||||||||||||||
|
Interest income
|
$
|
421
|
(12
|
)%
|
$
|
481
|
(19
|
)%
|
$
|
594
|
||||||||||
|
Other income (expense), net
|
34
|
113
|
%
|
16
|
(20
|
)%
|
20
|
|||||||||||||
|
Total interest and other income, net
|
$
|
455
|
(8
|
)%
|
$
|
497
|
(19
|
)%
|
$
|
614
|
||||||||||
Interest income decreased 12% in 2013, compared to 2012, and decreased 19% in 2012, compared to 2011. The decrease in interest income in 2013 was primarily attributable to a decrease in our cash, cash equivalents and marketable investments balances and decreased yields on our investments.The decreases in interest income in 2012 was primarily attributable to a decrease in our cash, cash equivalents and marketable investments balances. Our cash, cash equivalents, marketable investments and long-term investments were $83.1 million at December 31, 2013, $85.6 million at December 31, 2012 and $91.7 million at December 31, 2011.
Income tax (benefit) provision
|
Year Ended December 31,
|
||||||||||||||||||||
|
(Dollars in thousands)
|
2013
|
$ Change
|
2012
|
$ Change
|
2011
|
|||||||||||||||
|
Loss before income taxes
|
$
|
(4,801
|
)
|
$
|
1,529
|
$
|
(6,330
|
)
|
$
|
3,488
|
$
|
(9,818
|
)
|
|||||||
|
Income tax (benefit) provision
|
(54
|
)
|
(272
|
)
|
218
|
(25
|
)
|
243
|
||||||||||||
|
Effective tax rate
|
1
|
%
|
(3
|
)%
|
(2
|
)%
|
||||||||||||||
We recorded an income tax benefit of $54,000 in 2013, and despite a loss we recorded a provision of $218,000 and $243,000 in 2012, and 2011 respectively. Our tax benefit for 2013 is primarily related to releases of reserves for Uncertain Tax Positions due to lapses in the applicable statutes of limitations, offset by foreign tax expenses. Our tax provisions for 2012 and 2011 are primarily related to foreign tax expenses. A full valuation allowance was applied against all U.S. federal and state deferred tax assets arising during each of these years.
Liquidity and Capital Resources
Liquidity is the measurement of our ability to meet potential cash requirements, fund the planned expansion of our operations and acquire businesses. Our sources of cash include operations, stock option exercises, and employee stock purchases. We actively manage our cash usage and investment of liquid cash to ensure the maintenance of sufficient funds to meet our daily needs. The majority of our cash and investments are held in U.S. banks and our foreign subsidiaries maintain a limited amount of cash in their local banks to cover their short-term operating expenses. The following table summarizes our cash and cash equivalents, marketable investments and long-term investments (in thousands):
|
As of December 31,
|
||||||||||||
|
(Dollars in thousands)
|
2013
|
2012
|
Change
|
|||||||||
|
Cash, cash equivalents and marketable securities:
|
||||||||||||
|
Cash and cash equivalents
|
$
|
16,242
|
$
|
23,546
|
$
|
(7,304
|
)
|
|||||
|
Marketable investments
|
66,831
|
62,026
|
4,805
|
|||||||||
|
Total
|
$
|
83,073
|
$
|
85,572
|
$
|
(2,499
|
)
|
|||||
Cash Flows
In summary, our cash flows were as follows:
|
|
Year ended December 31,
|
|||||||||||
|
(Dollars in thousands)
|
2013
|
2012
|
2011
|
|||||||||
|
Cash flows provided by (used in):
|
||||||||||||
|
Operating activities
|
$
|
3,513
|
$
|
(2,300
|
)
|
$
|
(5,168
|
)
|
||||
|
Investing activities
|
(5,848
|
)
|
10,153
|
5,287
|
||||||||
|
Financing activities
|
(4,969
|
)
|
1,673
|
1,382
|
||||||||
|
Net (decrease) increase in cash and cash equivalents
|
$
|
(7,304
|
)
|
$
|
9,526
|
$
|
1,501
|
|||||
Cash Flows from Operating Activities
We generated net cash of $3.5 million in operating activities during 2013, which was primarily attributable to:
| · | $3.1 million generated from an increase in deferred revenue due primarily to a two-for-one service contract pricing promotion; |
| · | $2.1 million generated from the reduction of inventories; partially offset by |
| · | $857,000 used as a result of an increase in accounts receivable that resulted from increased product sales in December 2013 compared to December 2012; and |
| · | $371,000 used in a reduction in accrued liabilities. |
We used net cash of $2.3 million in operating activities during 2012, which was primarily attributable to:
| · | $3.7 million used as a result of an increase in accounts receivable that resulted from increased product sales in the three-month period ended December 31, 2012, compared to the same period in 2011; |
| · | $1.9 million used from net loss of $6.5 million after adjusting for non-cash related items of $4.7 million, consisting primarily of stock-based compensation expense of $3.2 million and depreciation and amortization expense of $1.6 million; partially offset by |
| · | $1.9 million generated from an increase in deferred revenue due primarily to an increase in our service business following the acquisition of the Iridex aesthetic customer base and a two-for-one service contract pricing promotion; and |
| · | $1.2 million generated from the reduction of inventories resulting from the increase in revenue in 2012. |
Cash Flows from Investing Activities
We used net cash of $5.8 million in investing activities in 2013, which was primarily attributable to:
| · | $56.8 million of cash used to purchase marketable investments; |
| · | $517,000 of cash used to purchase property and equipment; partially offset by |
| · | $51.6 million in net proceeds from the sales and maturities of marketable investments. |
We generated net cash of $10.2 million from investing activities in 2012, which was primarily attributable to:
| · | $74.6 million in net proceeds from the sales and maturities of marketable investments; partially offset by |
| · | $58.8 million of cash used to purchase marketable investments; |
| · | $5.1 million of cash used for the Iridex acquisition; and |
| · | $516,000 of cash used to purchase property and equipment. |
Cash Flows from Financing Activities
Net cash used in financing activities in 2013 was $5.0 million, which resulted from:
| · | $10.0 million of cash used to repurchase common stock; partially offset by |
| · | $5.2 million generated from the issuance of stock through our stock option and employee stock purchase plan. |
Net cash provided by financing activities in 2012 was $1.7 million, which resulted from the issuance of stock through our stock option and employee stock purchase plans.
Adequacy of cash resources to meet future needs
We had cash, cash equivalents and marketable investments of $83.1 million as of December 31, 2013. We believe that our existing cash resources are sufficient to meet our anticipated cash needs for working capital and capital expenditures for at least the next several years.
Contractual Obligations
The following are our contractual obligations, consisting of future minimum lease commitments related to facility and vehicle leases as of December 31, 2013:
|
Payments Due by Period ($’000’s)
|
||||||||||||||||||||
|
Contractual Obligations
|
Total
|
Less Than
1 Year
|
1-3 Years
|
3-5 Years
|
More Than
5 Years
|
|||||||||||||||
|
Operating leases
|
$
|
5,996
|
$
|
1,793
|
$
|
2,857
|
$
|
1,346
|
$
|
—
|
||||||||||
|
Capital leases
|
493
|
155
|
338
|
—
|
—
|
|||||||||||||||
|
Total leases
|
$
|
6,489
|
$
|
1,948
|
$
|
3,195
|
$
|
1,346
|
$
|
—
|
||||||||||
Purchase Commitments
We maintain certain open inventory purchase commitments with our suppliers to ensure a smooth and continuous supply for key components. Our liability in these purchase commitments is generally restricted to a forecasted time-horizon as agreed between the parties. These forecasted time-horizons can vary among different suppliers. Our open inventory purchase commitments were not material at December 31, 2013. As a result, this amount is not included in the contractual obligations table above.
Income Tax Liability
We have included in our Consolidated Balance Sheet $108,000 in long-term income tax liability with respect to unrecognized tax benefits and accrued interest as of December 31, 2013. At this time, we are unable to make a reasonably reliable estimate of the timing of payments in individual years beyond 12 months due to uncertainties in the timing of tax audit outcomes. As a result, this amount is not included in the contractual obligations table above.
Other
In the normal course of business, we enter into agreements that contain a variety of representations, warranties, and indemnification obligations. For example, we have entered into indemnification agreements with each of our directors and executive officers. Our exposure under the various indemnification obligations is unknown and not reasonably estimable as they involve future claims that may be made against us. As such, we have not accrued any amounts for such obligations.
Interest Rate Sensitivity
Our exposure to interest rate risk relates primarily to our investment portfolio. Fixed rate securities may have their fair market value adversely impacted due to fluctuations in interest rates, while floating rate securities may produce less income than expected if interest rates fall. Due in part to these factors, our future investment income may fall short of expectation due to changes in interest rates or we may suffer losses in principal if forced to sell securities which have declined in market value due to changes in interest rates. The primary objective of our investment activities is to preserve principal while at the same time maximizing yields without significantly increasing risk. To achieve this objective, we invest in debt instruments of the U.S. Government and its agencies and municipal bonds, and, by policy, restrict our exposure to any single type of investment or issuer by imposing concentration limits. To minimize the exposure due to adverse shifts in interest rates, we maintain investments at a weighted average maturity of generally less than eighteen months. Based on discounted cash flow modeling with respect to our total investment portfolio as of December 31, 2013 and 2012, assuming a hypothetical increase in interest rates of one percentage point, the fair value of our total investment portfolio would have potentially declined by approximately $788,000 and $745,000 respectively.
Foreign Currency Exchange
In 2013, 2012 and 2011, approximately 58%, 59% and 61% of our total revenue was sourced from countries other than the U.S. In 2013, 54% of our total international revenue was denominated in U.S. Dollars and substantially all of the remaining 46% was revenue was denominated in Japanese Yen and Euros.
In 2013, the Japanese Yen, compared to the U.S. Dollar, devalued by approximately 22% and had a significant adverse foreign exchange impact on our revenue − both from a remeasurement loss upon the conversion of our Japanese Yen denominated revenue as well as the additional negative revenue impact due to the effective price increase for the local customers importing our U.S. Dollar denominated systems into Japan. In addition, the Japanese Yen devaluation had a favorable foreign currency translation impact on our local cost of sales and operating expenses.
We have historically not engaged in hedging activities relating to our non-U.S. dollar operations.
CUTERA, INC. AND SUBSIDIARY COMPANIES
ANNUAL REPORT ON FORM 10-K
INDEX TO CONSOLIDATED FINANCIAL STATEMENTS
The following Consolidated Financial Statements of the Registrant and its subsidiaries are required to be included in Item 8:
|
|
Page
|
|
45
|
|
|
|
|
|
47
|
|
|
|
|
|
48
|
|
|
|
|
|
49
|
|
|
|
|
|
50
|
|
|
|
|
|
51
|
|
|
|
|
|
52
|
The following Consolidated Financial Statement Schedule of the Registrant and its subsidiaries for the years ended December 31, 2013, 2012 and 2011 is filed as a part of this Report as required to be included in Item 15(a) and should be read in conjunction with the Consolidated Financial Statements of the Registrant and its subsidiaries:
|
Schedule
|
|
|
Page
|
|
II
|
|
72
|
All other required schedules are omitted because of the absence of conditions under which they are required or because the required information is given in the Consolidated Financial Statements or the Notes thereto.
The Board of Directors and Stockholders of Cutera, Inc.
We have audited the accompanying consolidated balance sheets of Cutera, Inc. as of December 31, 2013 and 2012, and the related consolidated statements of operations, comprehensive loss, stockholders' equity, and cash flows for each of the two years in the period ended December 31, 2013. Our audit also included the financial statement schedule listed in the Index at Item 15(a) for each of the two years in the period ended December 31, 2013. These financial statements and schedule are the responsibility of the Company's management. Our responsibility is to express an opinion on these financial statements and schedule based on our audit.
We conducted our audit in accordance with the standards of the Public Company Accounting Oversight Board (United States). Those standards require that we plan and perform the audit to obtain reasonable assurance about whether the financial statements are free of material misstatement. An audit includes examining, on a test basis, evidence supporting the amounts and disclosures in the financial statements. An audit also includes assessing the accounting principles used and significant estimates made by management, as well as evaluating the overall financial statement presentation. We believe that our audit provides a reasonable basis for our opinion.
In our opinion, the financial statements referred to above present fairly, in all material respects, the consolidated financial position of Cutera, Inc. at December 31, 2013, and the consolidated results of its operations and its cash flows for each of the two years in the period ended December 31, 2013, in conformity with U.S. generally accepted accounting principles. Also, in our opinion, the related financial statement schedule, when considered in relation to the basic financial statements taken as a whole, presents fairly in all material respects the information set forth therein.
We also have audited, in accordance with the standards of the Public Company Accounting Oversight Board (United States), Cutera, Inc.'s internal control over financial reporting as of December 31, 2013, based on criteria established in Internal Control—Integrated Framework issued by the Committee of Sponsoring Organizations of the Treadway Commission (1992 Framework) and our report dated March 17, 2014 expressed an unqualified opinion thereon.
|
/s/ Ernst & Young LLP
|
|
Redwood City, California
|
|
March 17, 2014
|
Report of Independent Registered Public Accounting Firm
To the Board of Directors and Stockholders of Cutera, Inc.:
In our opinion, the consolidated statements of operations, comprehensive loss, stockholders' equity and of cash flows for the year ended December 31, 2011, present fairly, in all material respects, the results of the operations and cash flows of Cutera, Inc. and its subsidiaries for the year ended December 31, 2011, in conformity with accounting principles generally accepted in the United States of America. In addition, in our opinion, the financial statement schedule for the year ended December 31, 2011 present fairly, in all material respects, the information set forth therein when read in conjunction with the related consolidated financial statements. These financial statements and financial statement schedule are the responsibility of the Company's management. Our responsibility is to express an opinion on these financial statements and financial statement schedule based on our audit. We conducted our audit of these statements in accordance with the standards of the Public Company Accounting Oversight Board (United States). Those standards require that we plan and perform the audit to obtain reasonable assurance about whether the financial statements are free of material misstatement. An audit includes examining, on a test basis, evidence supporting the amounts and disclosures in the financial statements, assessing the accounting principles used and significant estimates made by management, and evaluating the overall financial statement presentation. We believe that our audit provides a reasonable basis for our opinion.
|
/s/PricewaterhouseCoopers LLP
|
|
|
|
San Jose, CA
|
|
March 15, 2012
|
CONSOLIDATED BALANCE SHEETS
(in thousands, except share and per share data)
|
|
December 31,
|
|||||||
|
|
2013
|
2012
|
||||||
|
Assets
|
||||||||
|
Current assets:
|
||||||||
|
Cash and cash equivalents
|
$
|
16,242
|
$
|
23,546
|
||||
|
Marketable investments
|
66,831
|
62,026
|
||||||
|
Accounts receivable, net of allowance for doubtful accounts of $19 and $0, respectively
|
9,679
|
8,841
|
||||||
|
Inventories
|
9,006
|
11,114
|
||||||
|
Deferred tax assets
|
31
|
40
|
||||||
|
Other current assets and prepaid expenses
|
1,507
|
1,439
|
||||||
|
Total current assets
|
103,296
|
107,006
|
||||||
|
Property and equipment, net
|
1,362
|
933
|
||||||
|
Deferred tax assets, net of current portion
|
329
|
553
|
||||||
|
Intangibles, net
|
2,019
|
2,566
|
||||||
|
Goodwill
|
1,339
|
1,339
|
||||||
|
Other long-term assets
|
324
|
397
|
||||||
|
Total assets
|
$
|
108,669
|
$
|
112,794
|
||||
|
Liabilities and Stockholders’ Equity
|
||||||||
|
Current liabilities:
|
||||||||
|
Accounts payable
|
$
|
1,820
|
$
|
2,107
|
||||
|
Accrued liabilities
|
9,328
|
9,493
|
||||||
|
Deferred revenue
|
7,494
|
6,618
|
||||||
|
Total current liabilities
|
18,642
|
18,218
|
||||||
|
Deferred revenue, net of current portion
|
4,340
|
2,102
|
||||||
|
Income tax liability
|
108
|
412
|
||||||
|
Other long-term liabilities
|
1,314
|
1,288
|
||||||
|
Total liabilities
|
24,404
|
22,020
|
||||||
|
Commitments and contingencies (Note 11)
|
||||||||
|
Stockholders’ equity:
|
||||||||
|
Convertible preferred stock, $0.001 par value:
|
||||||||
|
Authorized: 5,000,000 shares; Issued and outstanding: none
|
—
|
—
|
||||||
|
Common stock, $0.001 par value:
|
||||||||
|
Authorized: 50,000,000 shares; Issued and outstanding: 13,931,833 and 14,233,476 shares at December 31, 2013 and 2012, respectively
|
14
|
14
|
||||||
|
Additional paid-in capital
|
98,820
|
100,552
|
||||||
|
Accumulated deficit
|
(14,620
|
)
|
(9,873
|
)
|
||||
|
Accumulated other comprehensive income (loss)
|
51
|
81
|
||||||
|
Total stockholders’ equity
|
84,265
|
90,774
|
||||||
|
Total liabilities and stockholders’ equity
|
$
|
108,669
|
$
|
112,794
|
||||
The accompanying notes are an integral part of these consolidated financial statements.
CONSOLIDATED STATEMENTS OF OPERATIONS
(in thousands, except per share data)
|
|
Year Ended December 31,
|
|||||||||||
|
|
2013
|
2012
|
2011
|
|||||||||
|
Net revenue:
|
||||||||||||
|
Products
|
$
|
56,905
|
$
|
60,057
|
$
|
46,879
|
||||||
|
Service
|
17,689
|
17,220
|
13,411
|
|||||||||
|
Total net revenue
|
74,594
|
77,277
|
60,290
|
|||||||||
|
Cost of revenue:
|
||||||||||||
|
Products
|
24,179
|
26,911
|
17,545
|
|||||||||
|
Service
|
8,533
|
8,826
|
8,433
|
|||||||||
|
Total cost of revenue
|
32,712
|
35,737
|
25,978
|
|||||||||
|
Gross profit
|
41,882
|
41,540
|
34,312
|
|||||||||
|
Operating expenses:
|
||||||||||||
|
Sales and marketing
|
27,984
|
28,664
|
25,499
|
|||||||||
|
Research and development
|
9,216
|
8,427
|
9,141
|
|||||||||
|
General and administrative
|
9,938
|
11,276
|
10,104
|
|||||||||
|
Total operating expenses
|
47,138
|
48,367
|
44,744
|
|||||||||
|
Loss from operations
|
(5,256
|
)
|
(6,827
|
)
|
(10,432
|
)
|
||||||
|
Interest and other income, net
|
455
|
497
|
614
|
|||||||||
|
Loss before income taxes
|
(4,801
|
)
|
(6,330
|
)
|
(9,818
|
)
|
||||||
|
Income tax (benefit) provision
|
(54
|
)
|
218
|
243
|
||||||||
|
Net loss
|
$
|
(4,747
|
)
|
$
|
(6,548
|
)
|
$
|
(10,061
|
)
|
|||
|
|
||||||||||||
|
Net loss per share:
|
||||||||||||
|
Basic and diluted
|
$
|
(0.33
|
)
|
$
|
(0.46
|
)
|
$
|
(0.73
|
)
|
|||
|
Weighted-average number of shares used in per share calculations:
|
||||||||||||
|
Basic and diluted
|
14,421
|
14,089
|
13,807
|
|||||||||
The accompanying notes are an integral part of these consolidated financial statements.
CONSOLIDATED STATEMENTS OF COMPREHENSIVE LOSS
(in thousands)
|
|
Year Ended December 31,
|
|||||||||||
|
|
2013
|
2012
|
2011
|
|||||||||
|
Net loss
|
$
|
(4,747
|
)
|
$
|
(6,548
|
)
|
$
|
(10,061
|
)
|
|||
|
Other comprehensive income (loss):
|
||||||||||||
|
Available-for-sale investments
|
||||||||||||
|
Net change in unrealized (loss) gain on available-for-sale investments
|
(21
|
)
|
959
|
723
|
||||||||
|
Less: Reclassification adjustment for net gains on investments recognized during the year
|
(9
|
)
|
(19
|
)
|
(5
|
)
|
||||||
|
Net change in unrealized (loss) gain on available-for-sale investments
|
(30
|
)
|
940
|
718
|
||||||||
|
Tax provision (benefit)
|
—
|
18
|
(197
|
)
|
||||||||
|
Other comprehensive income (loss), net of tax
|
(30
|
)
|
922
|
915
|
||||||||
|
Comprehensive loss
|
$
|
(4,777
|
)
|
$
|
(5,626
|
)
|
$
|
(9,146
|
)
|
|||
The accompanying notes are an integral part of these consolidated financial statements.
CONSOLIDATED STATEMENTS OF STOCKHOLDERS’ EQUITY
(in thousands, except share amounts)
|
|
Common Stock
|
Additional
Paid-in
Capital
|
Retained Earnings
(Accumulated Deficit)
|
Accumulated
Other
Comprehensive
Income (loss)
|
Total
Stockholders’
Equity
|
|||||||||||||||||||
|
|
Shares
|
Amount
|
||||||||||||||||||||||
|
|
||||||||||||||||||||||||
|
Balance at December 31, 2010
|
13,629,713
|
$
|
14
|
$
|
90,423
|
$
|
6,736
|
$
|
(1,756
|
)
|
$
|
95,417
|
||||||||||||
|
Issuance of common stock for employee purchase plan
|
45,161
|
—
|
276
|
—
|
—
|
276
|
||||||||||||||||||
|
Exercise of stock options
|
207,624
|
—
|
1,230
|
—
|
—
|
1,230
|
||||||||||||||||||
|
Issuance of common stock in settlement of restricted stock units, net of shares withheld for employee taxes, and stock awards
|
65,897
|
—
|
(146
|
)
|
—
|
—
|
(146
|
)
|
||||||||||||||||
|
Stock-based compensation expense
|
—
|
—
|
3,907
|
—
|
—
|
3,907
|
||||||||||||||||||
|
Tax benefit from exercises of stock-based payment awards
|
—
|
—
|
29
|
—
|
—
|
29
|
||||||||||||||||||
|
Net loss
|
—
|
—
|
—
|
(10,061
|
)
|
—
|
(10,061
|
)
|
||||||||||||||||
|
Net change in unrealized gain (loss) on available-for-sale investments (net of $197 of tax benefit)
|
—
|
—
|
—
|
—
|
915
|
915
|
||||||||||||||||||
|
Balance at December 31, 2011
|
13,948,395
|
14
|
95,719
|
(3,325
|
)
|
(841
|
)
|
91,567
|
||||||||||||||||
|
Issuance of common stock for employee purchase plan
|
46,982
|
—
|
289
|
—
|
—
|
289
|
||||||||||||||||||
|
Exercise of stock options
|
211,551
|
—
|
1,480
|
—
|
—
|
1,480
|
||||||||||||||||||
|
Issuance of common stock in settlement of restricted stock units, net of shares withheld for employee taxes, and stock awards
|
26,548
|
—
|
(101
|
)
|
—
|
—
|
(101
|
)
|
||||||||||||||||
|
Stock-based compensation expense
|
—
|
—
|
3,159
|
—
|
—
|
3,159
|
||||||||||||||||||
|
Tax benefit from exercises of stock-based payment awards
|
—
|
—
|
6
|
—
|
—
|
6
|
||||||||||||||||||
|
Net loss
|
—
|
—
|
—
|
(6,548
|
)
|
—
|
(6,548
|
)
|
||||||||||||||||
|
Net change in unrealized gain (loss) on available-for-sale investments (net of $18 of tax provision)
|
—
|
—
|
—
|
—
|
922
|
922
|
||||||||||||||||||
|
Balance at December 31, 2012
|
14,233,476
|
14
|
100,552
|
(9,873
|
)
|
81
|
90,774
|
|||||||||||||||||
|
Issuance of common stock for employee purchase plan
|
51,338
|
—
|
362
|
—
|
—
|
362
|
||||||||||||||||||
|
Exercise of stock options
|
612,210
|
1
|
5,048
|
—
|
—
|
5,049
|
||||||||||||||||||
|
Issuance of common stock in settlement of restricted stock units, net of shares withheld for employee taxes, and stock awards
|
95,256
|
—
|
(222
|
)
|
—
|
—
|
(222
|
)
|
||||||||||||||||
|
Repurchase of common stock
|
(1,060,447
|
)
|
(1
|
)
|
(10,030
|
)
|
—
|
(10,031
|
)
|
|||||||||||||||
|
Stock-based compensation expense
|
—
|
—
|
3,110
|
—
|
—
|
3,110
|
||||||||||||||||||
|
Net loss
|
—
|
—
|
—
|
(4,747
|
)
|
—
|
(4,747
|
)
|
||||||||||||||||
|
Net change in unrealized gain (loss) on available-for-sale investments
|
—
|
—
|
—
|
—
|
(30
|
)
|
(30
|
)
|
||||||||||||||||
|
Balance at December 31, 2013
|
13,931,833
|
$
|
14
|
$
|
98,820
|
$
|
(14,620
|
)
|
$
|
51
|
$
|
84,265
|
||||||||||||
The accompanying notes are an integral part of these consolidated financial statements.
CONSOLIDATED STATEMENTS OF CASH FLOWS
(in thousands)
|
|
Year Ended December 31,
|
|||||||||||
|
|
2013
|
2012
|
2011
|
|||||||||
|
Cash flows from operating activities:
|
||||||||||||
|
Net loss
|
$
|
(4,747
|
)
|
$
|
(6,548
|
)
|
$
|
(10,061
|
)
|
|||
|
Adjustments to reconcile net loss to net cash used in operating activities:
|
||||||||||||
|
Stock-based compensation
|
3,110
|
3,160
|
3,907
|
|||||||||
|
Tax benefit (deficit) from stock-based compensation
|
—
|
6
|
29
|
|||||||||
|
Excess tax benefit related to stock-based compensation
|
—
|
(6
|
)
|
(22
|
)
|
|||||||
|
Depreciation and amortization
|
1,304
|
1,606
|
637
|
|||||||||
|
Other
|
243
|
(87
|
)
|
107
|
||||||||
|
Changes in assets and liabilities:
|
||||||||||||
|
Accounts receivable
|
(857
|
)
|
(3,690
|
)
|
(1,000
|
)
|
||||||
|
Inventories
|
2,108
|
1,167
|
(4,281
|
)
|
||||||||
|
Other current assets and prepaid expenses
|
345
|
859
|
2,604
|
|||||||||
|
Other long-term assets
|
73
|
89
|
(486
|
)
|
||||||||
|
Accounts payable
|
(287
|
)
|
(466
|
)
|
1,277
|
|||||||
|
Accrued liabilities
|
(371
|
)
|
(177
|
)
|
2,970
|
|||||||
|
Other long-term liabilities
|
(218
|
)
|
(62
|
)
|
45
|
|||||||
|
Deferred revenue
|
3,114
|
1,915
|
(895
|
)
|
||||||||
|
Income tax liability
|
(304
|
)
|
(66
|
)
|
1
|
|||||||
|
Net cash provided by (used in) operating activities
|
3,513
|
(2,300
|
)
|
(5,168
|
)
|
|||||||
|
Cash flows from investing activities:
|
||||||||||||
|
Acquisition of property, equipment and software
|
(517
|
)
|
(516
|
)
|
(751
|
)
|
||||||
|
Acquisition of intangible asset
|
(155
|
)
|
—
|
—
|
||||||||
|
Business acquisition
|
—
|
(5,091
|
)
|
—
|
||||||||
|
Disposal of property and equipment
|
63
|
—
|
36
|
|||||||||
|
Proceeds from sales of marketable and long-term investments
|
15,578
|
31,564
|
21,198
|
|||||||||
|
Proceeds from maturities of marketable investments
|
36,030
|
43,009
|
47,935
|
|||||||||
|
Purchase of marketable investments
|
(56,847
|
)
|
(58,813
|
)
|
(63,131
|
)
|
||||||
|
Net cash (used in) provided by investing activities
|
(5,848
|
)
|
10,153
|
5,287
|
||||||||
|
Cash flows from financing activities:
|
||||||||||||
|
Repurchase of common stock
|
(10,031
|
)
|
—
|
—
|
||||||||
|
Proceeds from exercise of stock options and employee stock purchase plan
|
5,189
|
1,667
|
1,360
|
|||||||||
|
Payments on capital lease obligation
|
(127
|
)
|
—
|
—
|
||||||||
|
Excess tax benefit related to stock-based compensation
|
—
|
6
|
22
|
|||||||||
|
Net cash provided by financing activities
|
(4,969
|
)
|
1,673
|
1,382
|
||||||||
|
Net (decrease) increase in cash and cash equivalents
|
(7,304
|
)
|
9,526
|
1,501
|
||||||||
|
Cash and cash equivalents at beginning of year
|
23,546
|
14,020
|
12,519
|
|||||||||
|
Cash and cash equivalents at end of year
|
$
|
16,242
|
$
|
23,546
|
$
|
14,020
|
||||||
|
Supplemental cash flow information:
|
||||||||||||
|
Cash paid for interest
|
$
|
19
|
$
|
—
|
$
|
—
|
||||||
|
Cash paid (received) for income taxes
|
337
|
307
|
(1,345
|
)
|
||||||||
|
Supplemental non-cash investing and financing activites:
|
||||||||||||
|
Assets acquired under capital lease
|
$
|
577
|
$
|
—
|
$
|
—
|
||||||
The accompanying notes are an integral part of these consolidated financial statements.
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS
NOTE 1—SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES
Description of Operations and Principles of Consolidation
Cutera, Inc. (“Cutera” or the “Company”) is a global provider of laser and other energy based aesthetic systems for practitioners worldwide. The Company designs, develops, manufactures, and markets the Xeo, GenesisPlus, ExcelV, and truSculpt for use by physicians and other qualified practitioners to allow its customers to offer safe and effective aesthetic treatments to their customers. In addition to the Company’s four primary platforms, the Company offers other products, including CoolGlide, Solera, VariLite and Japan specific products such as myQ. The Xeo and Solera platforms offer multiple hand pieces and applications, which allow customers to upgrade their systems (“Upgrade” revenue). In addition to systems and upgrade revenue, the Company generates revenue from the sale of post warranty service contracts, providing services for products that are out of warranty, Titan and truSculpt hand piece refills, and distributing third party manufactured dermal fillers and cosmeceuticals.
Headquartered in Brisbane, California, the Company has wholly-owned subsidiaries in Australia, Belgium, Canada, France and Japan, that market, sell and service its products outside of the U.S. The Consolidated Financial Statements include the accounts of the Company and its subsidiaries. All inter-company transactions and balances have been eliminated.
Use of Estimates
The preparation of Consolidated Financial Statements in conformity with generally accepted accounting principles in the United States of America (“GAAP”) requires the Company’s management to make estimates and assumptions that affect the amounts reported and disclosed in the financial statements and the accompanying notes. Actual results could differ materially from those estimates. On an ongoing basis, the Company evaluates their estimates, including those related to warranty obligation, sales commission, accounts receivable and sales allowances, fair values of long-term investments, fair values of acquired intangible assets, useful lives of intangible assets and property and equipment, fair values of options to purchase the Company’s common stock, recoverability of deferred tax assets, and effective income tax rates, among others. Management bases their estimates on historical experience and on various other assumptions that are believed to be reasonable, the results of which form the basis for making judgments about the carrying values of assets and liabilities.
Cash, Cash Equivalents, and Marketable Investments
The Company invests its cash primarily in money market funds and in highly liquid debt instruments of U.S. federal and municipal governments and their agencies, commercial paper and corporate debt securities. All highly liquid investments with stated maturities of three months or less from date of purchase are classified as cash equivalents; all highly liquid investments with stated maturities of greater than three months are classified as marketable investments. The majority of the Company’s cash and investments are held in U.S. banks and its foreign subsidiaries maintain a limited amount of cash in their local banks to cover their short term operating expenses.
The Company determines the appropriate classification of its investments in marketable securities at the time of purchase and re-evaluates such designation at each balance sheet date. The Company’s marketable securities have been classified and accounted for as available-for-sale. Investments with remaining maturities more than one year are viewed by the Company as available to support current operations, and are classified as current assets under the caption marketable investments in the accompanying Consolidated Balance Sheets. Investments in marketable securities are carried at fair value, with the unrealized gains and losses reported as a component of stockholders’ equity. Any realized gains or losses on the sale of marketable securities are determined on a specific identification method, and such gains and losses are reflected as a component of interest and other income, net.
Fair Value Measurements
Fair value is defined as the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. In determining fair value, the Company utilizes valuation techniques that maximize the use of observable inputs and minimize the use of unobservable inputs to the extent possible as well as considers counterparty credit risk in its assessment of fair value. Carrying amounts of the Company’s financial instruments, including cash equivalents, marketable investments, accounts receivable, accounts payable and accrued liabilities, approximate their fair values as of the balance sheet dates because of their generally short maturities.
The fair value hierarchy distinguishes between (1) market participant assumptions developed based on market data obtained from independent sources (observable inputs) and (2) an entity’s own assumptions about market participant assumptions developed based on the best information available in the circumstances (unobservable inputs). The fair value hierarchy consists of three broad levels, which gives the highest priority to unadjusted quoted prices in active markets for identical assets or liabilities (Level 1) and the lowest priority to unobservable inputs (Level 3). The three levels of the fair value hierarchy are described below:
| · | Level 1: Quoted prices (unadjusted) in active markets that are accessible at the measurement date for assets or liabilities. |
| · | Level 2: Directly or indirectly observable inputs as of the reporting date through correlation with market data, including quoted prices for similar assets and liabilities in active markets and quoted prices in markets that are not active. Level 2 also includes assets and liabilities that are valued using models or other pricing methodologies that do not require significant judgment since the input assumptions used in the models, such as interest rates and volatility factors, are corroborated by readily observable data from actively quoted markets for substantially the full term of the financial instrument. |
| · | Level 3: Unobservable inputs that are supported by little or no market activity and reflect the use of significant management judgment. These values are generally determined using pricing models for which the assumptions utilize management’s estimates of market participant assumptions. |
Impairment of Marketable Investments
After determining the fair value of available-for-sales debt instruments, gains or losses on these securities are recorded to other comprehensive income, until either the security is sold or the Company determines that the decline in value is other-than-temporary. The primary differentiating factors that the Company considers in classifying impairments as either temporary or other-than-temporary impairments is the intent and ability to retain the investment in the issuer for a period of time sufficient to allow for any anticipated recovery in market value, the length of the time and the extent to which the market value of the investment has been less than cost, the financial condition and near-term prospects of the issuer. There were no other-than-temporary impairments in the years ended December 31, 2013, 2012, and 2011.
Allowance for Sales Returns and Doubtful Accounts
The allowance for sales returns is based on the Company’s estimates of potential future product returns and other allowances related to current period product revenue. The Company analyzes historical returns, current economic trends and changes in customer demand and acceptance of our products.
The allowance for doubtful accounts is based on the Company’s assessment of the collectability of customer accounts. The Company regularly reviews the allowance by considering factors such as historical experience, credit quality, the age of the accounts receivable balances, and current economic conditions that may affect a customer’s ability to pay.
Concentration of Credit Risk and Other Risks and Uncertainties
Financial instruments that potentially subject the Company to concentrations of risk consist principally of cash, cash equivalents, marketable investments and accounts receivable. The Company’s cash and cash equivalents are primarily invested in deposits and money market accounts with three major financial institutions in the U.S. In addition, the Company has operating cash balances in banks in each of the international locations in which it operates. Deposits in these banks may exceed the amount of insurance provided on such deposits, if any. Management believes that these financial institutions are financially sound and, accordingly, believes that minimal credit risk exists. The Company has not experienced any losses on its deposits of cash and cash equivalents.
The Company invests in debt instruments, including bonds of the U.S. Government, its agencies and municipalities. The Company has also invested in other high grade investments such as commercial paper and corporate bonds. By policy, the Company restricts its exposure to any single issuer by imposing concentration limits. To minimize the exposure due to adverse shifts in interest rates, the Company maintains investments at an average maturity (interest reset date for auction-rate securities and variable rate demand notes) of generally less than eighteen months.
Accounts receivable are typically unsecured and are derived from revenue earned from worldwide customers. The Company performs credit evaluations of its customers and maintains reserves for potential credit losses. No single customer represented more than 10% of net accounts receivable as of either December 31, 2013 or 2012.
During the years ended December 31, 2013, 2012, and 2011, domestic revenue accounted for 42%, 41%, and 39%, respectively, of total revenue, while international revenue accounted for 58%, 59%, and 61%, respectively, of total revenue, for each of the years. No single customer represented more than 10% of total revenue for any of the years ended December 31, 2013, 2012, and 2011.
The Company is also subject to risks common to companies in the medical device industry, including, but not limited to, new technology innovations, dependence on key personnel, dependence on key suppliers, protection of proprietary technology, product liability, Food and Drug Administration and/ or international regulatory approvals required for new products and compliance with government regulations.
Inventories
Inventories are stated at the lower of cost or market, cost being determined on a standard cost basis (which approximates actual cost on a first-in, first-out basis) and market being determined as the lower of replacement cost or net realizable value.
The Company includes demonstration units within inventories. Demonstration units are carried at cost and amortized over an estimated economic life of two years Amortization expense related to demonstration units is recorded in cost of revenue or in the respective operating expense line based on which function and purpose for which it is being used for. Proceeds from the sale of demonstration units are recorded as revenue and all costs incurred to refurbish the systems prior to sale are charged to cost of revenue.
Property and Equipment
Property and equipment are stated at cost, net of accumulated depreciation. Depreciation is on a straight-line basis over the estimated useful lives of the assets, generally as follows:
|
|
|
|
|
|
|
Useful Lives
|
|
Leasehold improvements
|
|
Lesser of useful life or term of lease
|
|
Office equipment and furniture
|
|
3 years
|
|
Machinery and equipment
|
|
3 years
|
Upon sale or retirement of assets, the costs and related accumulated depreciation and amortization are removed from the balance sheet and the resulting gain or loss is reflected in operating expenses. Maintenance and repairs are charged to operations as incurred.
Depreciation expense related to property, equipment and leasehold improvements was $602,000, $436,000 and $446,000 in 2013, 2012, and 2011 respectively. Amortization expense for vehicles leased under capital leases is included in depreciation expense.
Goodwill and Intangible Assets
Goodwill, which represents the excess of the purchase price over the fair value of net tangible and identifiable intangible assets, is not subject to amortization, but is subject to at least an annual assessment for impairment, applying a fair-value based test.
The Company’s intangible assets are comprised of purchased technology sub-licenses, acquired customer relationships, and those assets acquired in conjunction with an asset acquisition in February 2012 including, existing customer relationships, product portfolio and a manufacturing process for the products acquired. All identifiable intangibles have finite lives and are carried at cost, net of accumulated amortization. Amortization is recorded using the straight-line method, over their respective useful lives, which range from approximately 11 months to 10 years.
Impairment of Long-lived Assets
Goodwill is not amortized, but is tested for impairment at least annually or as circumstances indicate their value may no longer be recoverable. The goodwill impairment test is generally performed annually during the fourth fiscal quarter (or earlier if impairment indicators arise). The Company continues to operate in one segment, which is considered to be the sole reporting unit and therefore, goodwill was tested for impairment at the enterprise level. As of December 31, 2013, there has been no impairment of goodwill.
The Company evaluates the recoverability of its long-lived assets, which include amortizable intangible and tangible assets. Acquired intangible assets with definite useful lives are amortized over their useful lives. The Company evaluates long-lived assets for impairment whenever events or changes in circumstances indicate that the carrying value of long-lived assets may not be recoverable. The Company recognizes such impairment in the event the net book value of such assets exceeds the future undiscounted cash flows attributable to such assets. No impairment losses were incurred in the periods presented.
Warranty Obligations
The Company provides a one-year standard warranty on all systems. Warranty coverage provided is for labor and parts necessary to repair the systems during the warranty period.
The Company accounts for the estimated warranty cost of the standard warranty coverage as a charge to costs of revenue when revenue is recognized. The estimated warranty cost is based on historical product performance. To determine the estimated warranty reserve, the Company utilizes actual service records to calculate the average service expense per system and applies this to the equivalent number of units exposed under warranty. The Company updates these estimated charges every quarter.
Revenue Recognition
Product, Upgrade, Titan hand piece refill, and Dermal filler and cosmeceutical revenue is recognized when title and risk of ownership has been transferred, provided that:
| · | Persuasive evidence of an arrangement exists; |
| · | The price is fixed or determinable; |
| · | Delivery has occurred or services have been rendered; and |
| · | Collectability is probable. |
Transfer of title and risk of ownership occurs when the product is shipped to the customer or when the customer receives the product, depending on the nature of the arrangement. Revenue is recorded net of customer and distributor discounts. For sales transactions when collectability is not reasonably assured, the Company recognizes revenue upon receipt of cash payment. Sales to customers and distributors do not include any return or exchange rights. In addition, the Company’s distributor agreements obligate the distributor to pay the Company for the sale regardless of whether the distributor is able to resell the product. Shipping and handling charges are invoiced to customers based on the amount of products sold. Shipping and handling fees are recorded as revenue and the related expense as a component of cost of revenue.
Multiple-element arrangements
A multiple-element arrangement includes the sale of one or more tangible product offerings with one or more associated services offerings, each of which are individually considered separate units of accounting. The Company determined that its multiple-element arrangements are generally comprised of the following elements that are recognized as separate units of accounting: system and upgrade sales; and service contracts.
For multiple-element arrangements revenue is allocated to each element based on their relative selling prices. Relative selling prices would be based first on vendor specified objective evidence (“VSOE”), then on third-party evidence of selling price (“TPE”) when VSOE does not exist, and then on best estimate of selling price (“BESP”) when VSOE and TPE do not exist. Because the Company has neither VSOE nor TPE for its systems, the allocation of revenue has been based on the Company’s BESPs. The objective of BESP is to determine the price at which the Company would transact a sale if the product was sold on a stand-alone basis. The Company determines BESP for its systems by considering multiple factors including, but not limited to, prices charged for stand-alone sales, features and functionality of the system, geographies, type of customer, and market conditions. Revenue allocated to each element is then recognized when the other revenue recognition criteria are met for each element.
In the first and second quarter of 2013, with respect to the sale of its truSculpt product, the Company provided promotions that included an unlimited number of “free” hand piece replacements during a stated trial period of 3 months or 12 months. These free refills were treated as an undelivered element under FASB ASC 605-25 in the original revenue transaction. The Company deferred the relative fair value related to the estimated number of hand piece replacements to be delivered during the promotional period and recognized that deferred revenue over the free refills promotion period. Commencing with the third quarter of 2013, the Company included unlimited refills as part of the truSculpt standard warranty and determined that this was no longer a separate deliverable under the multiple-element arrangement revenue guidance. Following this change, the Company recognized the revenue under the warranty model, in which the revenue for the system sale was recognized up-front along with an estimate of the costs which will be incurred under the warranty obligation recorded in cost of revenue.
The Company also offers customers extended service contracts. Revenue under service contracts is recognized on a straight-line basis over the period of the applicable service contract. Service revenue, from customers whose systems are not under a service contact, is recognized as the services are provided. Service revenue for the years ended December 31, 2013, 2012, and 2011 was $17.7 million, $17.2 million, and $13.4 million, respectively.
Cost of Revenue
Cost of revenue consists primarily of material, finished and semi-finished products purchased from third-party manufacturers, labor, stock-based compensation expenses, overhead involved in our internal manufacturing processes, technology license amortization and royalties, and costs associated with product warranties.
The Company's system sales includes a control console, universal graphic user interface, control system software, high voltage electronics and a combination of applications (referred to as hand pieces). Hand pieces are programmed to have a limited number of uses to ensure the safety of the device to patients. The Company sells refurbished hand pieces, or "refills", of its Titan product and provides for refurbishment of other hand pieces under warranty or service contracts. When customers purchase a replacement hand piece (or “refill”) or are provided a replacement hand piece under a warranty or service contract, Cutera ships a previously refurbished unit. Upon the receipt of the expended hand piece from the customer the Company capitalizes the expended hand piece as inventory at the estimated fair value. Cost of revenue includes the costs incurred to refurbish hand pieces.
Research and Development Expenditures
Costs related to research, design, development and testing of products are charged to research and development expense as incurred. Expenses incurred primarily relate to employees, facilities, material, third party contractors and clinical and regulatory fees.
Advertising Costs
Advertising costs are included as part of sales and marketing expense and are expensed as incurred. Advertising expenses were $1.6 million in 2013 and $1.3 million in both 2012 and 2011.
Stock-based Compensation
The Company accounts for stock-based employee compensation plans under the fair value recognition and measurement provisions under U.S. GAAP. The Company’s stock-based compensation cost is measured at the grant date, based on the fair value of the award, and is recognized as expense over the requisite service period. The Company elected to use the Black-Scholes-Merton (“BSM”) pricing model to determine the fair value of stock options on the dates of grant. Restricted stock units (“RSUs”), performance stock units (“PSUs”) and stock awards are measured based on the fair market values of the underlying stock on the dates of grant. Shares are issued on the vesting dates, net of the tax withholding requirements to be paid by the Company on behalf of its employees. As a result, the actual number of shares issued will be fewer than the actual number of RSUs outstanding. Furthermore, the Company records the liability for withholding amounts to be paid by us as a reduction to additional paid-in capital when the shares are issued. Also, the Company recognizes stock-based compensation using the straight-line method.
U.S. GAAP requires the cash flows resulting from the tax benefits due to tax deductions in excess of the compensation cost recognized for stock-based awards for options exercised and RSUs vested during the period (excess tax benefits) to be classified as financing cash flows.
Income Taxes
The Company recognizes income taxes under the liability method. The Company recognizes deferred income taxes for differences between the financial reporting and tax bases of assets and liabilities at enacted statutory tax rates in effect for the years in which differences are expected to reverse. The Company recognizes the effect on deferred taxes of a change in tax rates in income in the period that includes the enactment date. For deferred tax assets which are not subject to a valuation allowance, the Company has determined that its future taxable income will be sufficient to recover all of the deferred tax assets. However, should there be a change in their ability to recover the deferred tax assets, the Company could be required to record a valuation allowance against the net carrying value of its deferred tax assets. This would result in an increase to the Company’s tax provision in the period in which they determined that the recovery was not probable.
The measurement of deferred taxes often involves an exercise of judgment related to the computation and realization of tax basis. The deferred tax assets and liabilities reflect management’s assessment that tax positions taken, and the resulting tax basis, are more likely than not to be sustained if they are audited by taxing authorities. Also, assessing tax rates that the Company expects to apply and determining the years when the temporary differences are expected to affect taxable income requires judgment about the future apportionment of our income among the states in which the Company operates. These matters, and others, involve the exercise of significant judgment. Any changes in our practices or judgments involved in the measurement of deferred tax assets and liabilities could materially impact our financial condition or results of operations.
Valuation allowances are established when necessary to reduce deferred income tax assets to amounts that the Company believes are more likely than not to be recovered. The Company evaluates its deferred tax assets quarterly to determine whether adjustments to our valuation allowance are appropriate. In making this evaluation, the Company relies on its recent history of pre-tax earnings, estimated timing of future deductions and benefits represented by the deferred tax assets, and its forecasts of future earnings, the latter two of which involve the exercise of significant judgment. The Company maintains a full valuation allowance against its U.S. federal and state deferred tax asset due to a history of operating losses.
The Company establishes reserves for uncertain tax positions in accordance with the Income Taxes subtopic of the ASC. The subtopic prescribes the minimum recognition threshold a tax position is required to meet before being recognized in the financial statements. Additionally, the subtopic provides guidance on derecognition, measurement, classification, interest and penalties, and transition of uncertain tax positions. The impact of an uncertain income tax position on income tax expense must be recognized at the largest amount that is more-likely-than-not to be sustained. An uncertain income tax position will not be recognized if it has less than a 50% likelihood of being sustained. The Company has provided taxes and related interest and penalties due for potential adjustments that may result from examinations of open U.S. Federal, state and foreign tax years. The Company will reverse the liability and recognize a tax benefit during the period in which the Company makes the determination that the tax position is effectively settled through examination, negotiation, or litigation, or the statute of limitations for the relevant taxing authority to examine and challenge the tax position has expired. The Company will record an additional charge in the Company’s provision for taxes in the period in which the Company determines that the recorded tax liability is less than the Company expects the ultimate assessment to be.
Computation of Net Loss per Share
Basic net income per share is computed using the weighted-average number of shares outstanding during the period. Diluted net income per share is computed using the weighted-average number of shares and dilutive potential shares outstanding during the period. Dilutive potential shares primarily consist of employee stock options. Dilute earnings per share is the same as basic earnings per share for the periods presented because the inclusion of outstanding common stock equivalents would be anti-dilutive.
U.S. GAAP requires that employee equity share options, non-vested shares and similar equity instruments granted by the Company be treated as potential common shares outstanding in computing diluted earnings per share. In periods of net income, diluted shares outstanding include the dilutive effect of in-the-money options, which is calculated based on the average share price for each fiscal period using the treasury stock method. Under the treasury stock method, the amount the employee must pay for exercising stock options, the amount of compensation cost for future service that the Company has not yet recognized, and the amount of tax benefits that would be recorded in additional-paid-in-capital (“APIC”) when the award becomes deductible are all assumed to be used to repurchase shares.
Comprehensive Loss
Comprehensive loss includes all changes in stockholders’ equity except those resulting from investments or contributions by stockholders. For the periods presented, the accumulated other comprehensive income consisted solely of the unrealized gains or losses on the Company's available-for-sale investments, net of tax.
Foreign Currency
The U.S. dollar is the functional currency of the Company’s subsidiaries. Monetary and non-monetary assets and liabilities are remeasured into U.S. dollars at the applicable period end exchange rate. Sales and operating expenses are remeasured at average exchange rates in effect during each period, except for those expenses related to non-monetary assets which are remeasured at historical exchange rates. Gains or losses resulting from foreign currency transactions are included in net income (loss) and are insignificant for each of the three years ended December 31, 2013. The effect of exchange rate changes on cash and cash equivalents was insignificant for each of the three years presented in the period ended December 31, 2013.
Segments
The Company operates in one segment. Management uses one measurement of profitability and does not segregate its business for internal reporting. As of December 31, 2013 and 2012, 83% and 85%, respectively, of all long-lived assets were maintained in the U.S. See Note 10 for details relating to revenue by geography.
NOTE 2—INVESTMENT SECURITIES
The following tables summarize cash, cash equivalents and marketable securities (in thousands):
|
|
December 31,
|
|||||||
|
|
2013
|
2012
|
||||||
|
Cash and cash equivalents:
|
||||||||
|
Cash
|
$
|
3,816
|
$
|
2,198
|
||||
|
Cash equivalents:
|
||||||||
|
Money market funds
|
9,926
|
17,348
|
||||||
|
Commercial paper
|
2,500
|
4,000
|
||||||
|
Total cash and cash equivalents
|
16,242
|
23,546
|
||||||
|
|
||||||||
|
Marketable securities:
|
||||||||
|
U.S. government notes
|
10,522
|
4,009
|
||||||
|
U.S. government agencies
|
25,858
|
24,958
|
||||||
|
Municipal securities
|
2,039
|
4,206
|
||||||
|
Commercial paper
|
10,242
|
10,519
|
||||||
|
Corporate debt securities
|
18,170
|
18,334
|
||||||
|
Total marketable securities
|
66,831
|
62,026
|
||||||
|
|
||||||||
|
Total cash, cash equivalents and marketable securities
|
$
|
83,073
|
$
|
85,572
|
||||
The following table summarizes unrealized gains and losses related to our marketable investments (in thousands):
|
December 31, 2013
|
Amortized Cost
|
Gross Unrealized Gains
|
Gross Unrealized Losses
|
Fair Market Value
|
||||||||||||
|
Cash and cash equivalents
|
$
|
16,242
|
$
|
—
|
$
|
—
|
$
|
16,242
|
||||||||
|
|
||||||||||||||||
|
Marketable investments
|
||||||||||||||||
|
U.S. government notes
|
10,516
|
11
|
(5
|
)
|
10,522
|
|||||||||||
|
U.S. government agencies
|
25,823
|
38
|
(3
|
)
|
25,858
|
|||||||||||
|
Municipal securities
|
2,043
|
1
|
(5
|
)
|
2,039
|
|||||||||||
|
Commercial paper
|
10,239
|
3
|
—
|
10,242
|
||||||||||||
|
Corporate debt securities
|
18,109
|
61
|
—
|
18,170
|
||||||||||||
|
Total marketable securities
|
66,730
|
114
|
(13
|
)
|
66,831
|
|||||||||||
|
|
||||||||||||||||
|
Total cash, cash equivalents and marketable securities
|
$
|
82,972
|
$
|
114
|
$
|
(13
|
)
|
$
|
83,073
|
|||||||
|
December 31, 2012
|
Amortized Cost
|
Gross Unrealized Gains
|
Gross Unrealized Losses
|
Fair Market Value
|
||||||||||||
|
Cash and cash equivalents
|
$
|
23,546
|
$
|
—
|
$
|
—
|
$
|
23,546
|
||||||||
|
|
||||||||||||||||
|
Marketable investments
|
||||||||||||||||
|
U.S. government notes
|
4,005
|
4
|
—
|
4,009
|
||||||||||||
|
U.S. government agencies
|
24,910
|
48
|
—
|
24,958
|
||||||||||||
|
Municipal securities
|
4,184
|
23
|
(1
|
)
|
4,206
|
|||||||||||
|
Commercial paper
|
10,515
|
4
|
—
|
10,519
|
||||||||||||
|
Corporate debt securities
|
18,281
|
59
|
(6
|
)
|
18,334
|
|||||||||||
|
Total marketable securities
|
61,895
|
138
|
(7
|
)
|
62,026
|
|||||||||||
|
|
||||||||||||||||
|
Total cash, cash equivalents and marketable securities
|
$
|
85,441
|
$
|
138
|
$
|
(7
|
)
|
$
|
85,572
|
|||||||
No investments were in a continuous unrealized loss position for longer than 12 months.
The following table summarizes the estimated fair value of our marketable investments classified by the contractual maturity date of the security as of December 31, 2013 (in thousands):
|
|
Amount
|
|||
|
Due in less than one year (fiscal year 2014)
|
$
|
26,685
|
||
|
Due in 1 to 3 years (fiscal year 2015 - 2016)
|
40,146
|
|||
|
|
$
|
66,831
|
||
Fair Value Measurements
The following table summarizes financial assets measured and recognized at fair value on a recurring basis and classified under the appropriate level of the fair value hierarchy as described above (in thousands):
|
December 31, 2013
|
Level 1
|
Level 2
|
Level 3
|
Total
|
||||||||||||
|
Cash equivalents:
|
||||||||||||||||
|
Money market funds
|
$
|
9,926
|
$
|
—
|
$
|
—
|
$
|
9,926
|
||||||||
|
Commercial paper
|
—
|
2,500
|
—
|
2,500
|
||||||||||||
|
Short term marketable investments:
|
||||||||||||||||
|
Available-for-sale securities
|
—
|
66,831
|
—
|
66,831
|
||||||||||||
|
Total assets at fair value
|
$
|
9,926
|
$
|
69,331
|
$
|
—
|
$
|
79,257
|
||||||||
|
December 31, 2012
|
Level 1
|
Level 2
|
Level 3
|
Total
|
||||||||||||
|
Cash equivalents:
|
||||||||||||||||
|
Money market funds
|
$
|
17,348
|
$
|
—
|
$
|
—
|
$
|
17,348
|
||||||||
|
Commercial paper
|
—
|
4,000
|
—
|
4,000
|
||||||||||||
|
Short term marketable investments:
|
||||||||||||||||
|
Available-for-sale securities
|
—
|
62,026
|
—
|
62,026
|
||||||||||||
|
Total assets at fair value
|
$
|
17,348
|
$
|
66,026
|
$
|
—
|
$
|
83,374
|
||||||||
The Company’s Level 1 financial assets are money market funds with fair values are based on quoted market prices The Company’s Level 2 investments include U.S. government-backed securities and corporate securities that are valued based upon observable inputs that may include benchmark yields, reported trades, broker/dealer quotes, issuer spreads, two-sided markets, benchmark securities, bids, offers and reference data including market research publications. The average remaining maturity of the Company’s Level 2 investments as of December 31, 2013 is less than 36 months and all of these investments are rated by S&P and Moody’s at A or better.
The table presented below summarizes the change in carrying value associated with Level 3 financial assets, which represents the Company’s investment in long term Auction Rate Securities, for the year ended December 31, 2012 (in thousands):
|
|
Amount
|
|||
|
Balance at December 31, 2011
|
$
|
3,027
|
||
|
Total gains or losses (realized or unrealized)
|
||||
|
Included in other comprehensive income (loss)
|
262
|
|||
|
Settlements
|
(3,289
|
)
|
||
|
Balance at December 31, 2012 and 2013
|
$
|
—
|
||
NOTE 3—ACQUISITION
On February 2, 2012, Cutera acquired certain assets and liabilities of Iridex’s global aesthetics business unit for $5.1 million in cash. This business is engaged in developing, manufacturing, marketing and servicing laser-based medical systems and delivery devices. The business purpose of this transaction was to acquire access to an expanded installed base of customers, add to Cutera’s product offerings and acquire a recurring stream of service revenue. This acquisition was considered a business combination for accounting purposes, and as such, in addition to valuing all the assets, the Company recorded goodwill associated with the expected synergies from leveraging the customer relationships and integrating new product offerings into the Company’s business.
The fair values of the assets acquired were determined to be $4.8 million of net tangible and intangible assets and $1.3 million of goodwill. The customer relationship intangible assets are being amortized over 5 years on a straight-line basis. Other intangible assets are being amortized over 11 months to 5 years from the date of acquisition on a straight-line basis.
The following table summarizes the fair value as of February 2, 2012 of the net assets acquired (in thousands):
|
Purchase price paid
|
$
|
5,091
|
||
|
|
||||
|
Assets (liabilities acquired):
|
||||
|
Inventory
|
1,552
|
|||
|
Customer relationship intangible assets
|
2,510
|
|||
|
Other identified intangible assets
|
780
|
|||
|
Goodwill
|
1,339
|
|||
|
Deferred service revenue
|
(780
|
)
|
||
|
Accrued warranty liability
|
(310
|
)
|
||
|
Total
|
$
|
5,091
|
The identifiable intangible assets and goodwill identified above shall be deductible for income taxes over a useful economic life of 15 years.
The Company acquired the Iridex aesthetics business unit on February 2, 2012. Disclosure of the amounts of revenue and earnings of the assets and liabilities of the acquired Iridex aesthetics business, separately from the Company’s, is not practicable because the acquired business was immediately integrated into the Company's operations. Based on Iridex’s Form 10-K for the year ended December 2011, the revenue of the aesthetics business unit was reported to be $10.8 million and the earnings were $469,000 for the fiscal year ended December 31, 2011.
NOTE 4—BALANCE SHEET DETAIL
Inventories
Inventories consist of the following (in thousands):
|
|
December 31,
|
|||||||
|
|
2013
|
2012
|
||||||
|
Raw materials
|
$
|
5,989
|
$
|
7,221
|
||||
|
Finished goods
|
3,017
|
3,893
|
||||||
|
Total
|
$
|
9,006
|
$
|
11,114
|
||||
Property and Equipment, net
Property and equipment, net consists of the following (in thousands):
|
|
December 31,
|
|||||||
|
|
2013
|
2012
|
||||||
|
Leasehold improvements
|
$
|
625
|
$
|
620
|
||||
|
Office equipment and furniture
|
3,285
|
2,888
|
||||||
|
Machinery and equipment
|
3,876
|
3,252
|
||||||
|
|
7,786
|
6,760
|
||||||
|
Less: Accumulated depreciation
|
(6,424
|
)
|
(5,827
|
)
|
||||
|
Property and equipment, net
|
$
|
1,362
|
$
|
933
|
||||
During 2013, the Company financed vehicles for some of its sales employees in North America. As of December 31, 2013 the gross capitalized value of the leased vehicles was $577,000 and the related accumulated depreciation was $98,000.
Goodwill and Other Intangible Assets
Goodwill and other intangible assets comprise a patent sublicense acquired from Palomar in 2006; a technology sublicense acquired in 2002 (fully amortized as of December 31, 2012 and removed from the balance sheet in 2013); intangible assets and goodwill related to the acquisition of Iridex’s aesthetic business unit; and, customer relationships in the Benelux countries acquired from a former distributor in 2013). The components of intangible assets at December 31, 2013 and 2012 were as follows (in thousands):
|
|
Gross
Carrying
Amount
|
Accumulated
Amortization
Amount
|
Net
Amount
|
|||||||||
|
December 31, 2013
|
||||||||||||
|
Patent sublicense
|
$
|
1,218
|
$
|
1,068
|
$
|
150
|
||||||
|
Customer relationship intangible related to acquisition
|
2,510
|
962
|
1,548
|
|||||||||
|
Other identified intangible assets related to acquisition
|
780
|
607
|
173
|
|||||||||
|
Other intangible
|
155
|
6
|
149
|
|||||||||
|
Goodwill
|
1,339
|
—
|
1,339
|
|||||||||
|
Total
|
$
|
6,002
|
$
|
2,643
|
$
|
3,359
|
||||||
|
December 31, 2012
|
||||||||||||
|
Patent sublicense
|
$
|
1,218
|
$
|
931
|
$
|
287
|
||||||
|
Technology sublicense
|
538
|
538
|
—
|
|||||||||
|
Customer relationship intangible related to acquisition
|
2,510
|
460
|
2,050
|
|||||||||
|
Other identified intangible assets related to acquisition
|
780
|
551
|
229
|
|||||||||
|
Goodwill
|
1,339
|
—
|
1,339
|
|||||||||
|
Total
|
$
|
6,385
|
$
|
2,480
|
$
|
3,905
|
||||||
Amortization expense for intangible assets was $702,000 in 2013, $1.2 million in 2012, and $191,000 in 2011.
Based on intangible assets recorded at December 31, 2013, and assuming no subsequent additions to, or impairment of the underlying assets, the remaining estimated annual amortization expense is expected to be as follows (in thousands):
|
Year ending December 31,
|
Amount
|
|||
|
2014
|
$
|
773
|
||
|
2015
|
641
|
|||
|
2016
|
558
|
|||
|
2017
|
47
|
|||
|
Total
|
$
|
2,019
|
||
Accrued Liabilities
Accrued liabilities consist of the following (in thousands):
|
|
December 31,
|
|||||||
|
|
2013
|
2012
|
||||||
|
Payroll and related expenses
|
$
|
4,753
|
$
|
4,721
|
||||
|
Sales tax
|
1,307
|
1,085
|
||||||
|
Warranty
|
1,202
|
1,212
|
||||||
|
Other
|
2,066
|
2,475
|
||||||
|
Total
|
$
|
9,328
|
$
|
9,493
|
||||
NOTE 5—WARRANTY AND SERVICE CONTRACTS
The Company has a direct field service organization in the U.S. Internationally, the Company provides direct service support through its wholly-owned subsidiaries in Australia, Canada, France and Japan as well as through a network of distributors and third-party service providers in several other countries where it does not have a direct presence. The Company provides a warranty with its products, depending on the type of product. After the original warranty period, maintenance and support are offered on a service contract basis or on a time and materials basis. The Company currently provides for the estimated cost to repair or replace products under warranty at the time of sale.
Warranty Accrual (in thousands)
|
|
December 31,
|
|||||||
|
|
2013
|
2012
|
||||||
|
Balance at beginning of year
|
$
|
1,212
|
$
|
1,121
|
||||
|
Add: Accruals for warranties issued during the year
|
3,420
|
3,525
|
||||||
|
Less: Settlements made during the year
|
(3,430
|
)
|
(3,434
|
)
|
||||
|
Balance at end of year
|
$
|
1,202
|
$
|
1,212
|
||||
Deferred Service Contract Revenue (in thousands)
|
|
December 31,
|
|||||||
|
|
2013
|
2012
|
||||||
|
Balance at beginning of year
|
$
|
8,539
|
$
|
5,838
|
||||
|
Add: Payments received
|
15,026
|
14,112
|
||||||
|
Less: Revenue recognized
|
(11,928
|
)
|
(11,411
|
)
|
||||
|
Balance at end of year
|
$
|
11,637
|
$
|
8,539
|
||||
Costs incurred under service contracts amounted to $6.9 million in 2013, $7.2 million in 2012, and $4.6 million in 2011, and are recognized as incurred.
NOTE 6—STOCKHOLDERS’ EQUITY, STOCK PLANS AND STOCK-BASED COMPENSATION EXPENSE
As of December 31, 2013, the Company had the following stock-based employee compensation plans:
2004 Equity Incentive Plan and 1998 Stock Plan
In 1998, the Company adopted the 1998 Stock Plan, or 1998 Plan, under which 4,650,000 shares of the Company’s common stock were reserved for issuance to employees, directors and consultants.
On January 12, 2004, the Board of Directors adopted the 2004 Equity Incentive Plan. A total of 1,750,000 shares of common stock were originally reserved for issuance pursuant to the 2004 Equity Incentive Plan. In addition, the shares reserved for issuance under the 2004 Equity Incentive Plan included shares reserved but un-issued under the 1998 Plan and shares returned to the 1998 Plan as the result of termination of options or the repurchase of shares.
Options granted under the 1998 Plan and 2004 Equity Incentive Plan may be incentive stock options or non-statutory stock options. Stock purchase rights may also be granted under the 2004 Equity Incentive Plan. Incentive stock options may only be granted to employees. The Board of Directors determines the period over which options become exercisable. Options granted under the Plan to employees generally vest over a four year term from the vesting commencement date and become exercisable 25% on the first anniversary of the vesting commencement date and an additional 1/48th on the last day of each calendar month until all of the shares have become exercisable. During 2013, 2012 and 2011 the officers of the Company were granted options that vest over a three year term at the rate of 1/3rd on the one year anniversary of the vesting commencement date and 1/36th thereafter. The contractual term of the options granted in 2013, 2012 and 2011 was seven years.
In accordance with the 2004 Equity Incentive Plan, prior to 2012, the Company’s non-employee directors were granted $60,000 of grant date fair value, fully vested, stock awards annually on the date of the Company’s Annual Meeting of stockholders. Commencing with 2012, the Company’s non-employee directors get $60,000 of RSUs annually that cliff-vest on the one year anniversary of the grant date. In the years ended December 31, 2013, 2012and 2011, the Company issued 40,674, 52,938 and 37,925 shares of stock, respectively.
In addition, in the years ended December 31, 2013 and 2012, the Company’s Board of Directors granted 148,004 and 95,250, respectively, of RSUs to certain members of the Company’s management. These RSUs vest at the rate of one-third on June 1of the year of grant, and one-third in each of the subsequent two years. The Company measured the fair market values of the underlying stock on the dates of grant and recognizes the stock-based compensation expense using the straight-line method over the vesting period.
2004 Employee Stock Purchase Plan
On January 12, 2004, the Board of Directors adopted the 2004 Employee Stock Purchase Plan. Under the 2004 Employee Stock Purchase Plan, or 2004 ESPP, eligible employees are permitted to purchase common stock at a discount through payroll deductions. The 2004 ESPP offering and purchase periods are for approximately six months. The 2004 ESPP has an evergreen provision based on which shares of common stock eligible for purchase are increased on the first day of each fiscal year by an amount equal to the lesser of:
| i. | 600,000 shares; |
| ii. | 2.0% of the outstanding shares of common stock on such date; or |
| iii. | an amount as determined by the Board of Directors. |
The Company’s Board of Directors did not increase the shares available for future grant on January 1, 2014, 2013, 2012 and 2011. The price of the common stock purchased is the lower of 85% of the fair market value of the common stock at the beginning or end of a six month offering period. Under the 2004 ESPP the Company issued 51,338 shares in 2013 and 46,982 shares in 2012. At December 31, 2013, 958,616 shares remained available for future issuance.
Option Activity
Activity under the 1998 Plan and 2004 Equity Incentive Plan is summarized as follows:
|
|
Options Outstanding
|
|||||||||||||||||||
|
|
Shares
Available
For Grant
|
Number of
Shares
|
Weighted-
Average
Exercise
Price
|
Weighted-Average
Remaining
Contractual Life
(in years)
|
Aggregate
Intrinsic
Value
(in $ millions)(1)
|
|||||||||||||||
|
Balances as of December 31, 2010
|
1,005,447
|
3,296,419
|
$
|
10.93
|
4.4
|
1.1
|
||||||||||||||
|
Options granted
|
(1,206,500
|
)
|
1,206,500
|
$
|
8.61
|
|||||||||||||||
|
Options exercised
|
—
|
(207,624
|
)
|
$
|
5.92
|
|||||||||||||||
|
Options cancelled (expired or forfeited)
|
746,273
|
(746,273
|
)
|
$
|
13.40
|
|||||||||||||||
|
Stock awards granted
|
(77,225
|
)
|
—
|
—
|
||||||||||||||||
|
Restricted stock units cancelled (expired or forfeited)
|
6,542
|
—
|
—
|
|||||||||||||||||
|
Balances as of December 31, 2011
|
474,537
|
3,549,022
|
$
|
9.92
|
4.6
|
$
|
0.4
|
|||||||||||||
|
Additional shares reserved (2)
|
1,910,000
|
—
|
—
|
|||||||||||||||||
|
Options granted
|
(921,500
|
)
|
921,500
|
$
|
7.04
|
|||||||||||||||
|
Options exercised
|
—
|
(211,551
|
)
|
$
|
7.00
|
|||||||||||||||
|
Options cancelled (expired or forfeited)
|
470,732
|
(470,732
|
)
|
$
|
9.45
|
|||||||||||||||
|
Stock awards granted
|
(314,159
|
)
|
—
|
—
|
||||||||||||||||
|
Restricted stock units cancelled (expired or forfeited)
|
24,746
|
—
|
—
|
|||||||||||||||||
|
Balances as of December 31, 2012
|
1,644,356
|
3,788,239
|
$
|
9.44
|
4.3
|
$
|
2.6
|
|||||||||||||
|
Options granted
|
(1,007,166
|
)
|
1,007,166
|
$
|
8.97
|
|||||||||||||||
|
Options exercised
|
—
|
(612,210
|
)
|
$
|
8.16
|
|||||||||||||||
|
Options cancelled (expired or forfeited)
|
391,033
|
(391,033
|
)
|
10.37
|
||||||||||||||||
|
Stock awards granted
|
(399,997
|
)
|
—
|
—
|
||||||||||||||||
|
Restricted stock units cancelled (expired or forfeited)
|
81,257
|
—
|
—
|
|||||||||||||||||
|
Balances as of December 31, 2013
|
709,483
|
3,792,162
|
$
|
9.42
|
4.2
|
$
|
5.1
|
|||||||||||||
|
Exercisable as of December 31, 2013
|
2,221,657
|
$
|
10.14
|
3.0
|
$
|
2.3
|
||||||||||||||
| (1) | Based on the closing stock price of the Company’s stock of $10.18 on December 31, 2013, $9.00 on December 31, 2012, $7.45 on December 30, 2011 and $8.29 on December 31, 2010. |
| (2) | Approved by stock holders in 2012. |
The aggregate intrinsic value in the table above represents the total pre-tax intrinsic value (the aggregate difference between the Company’s closing stock price on the last trading day of the fiscal year and the exercise price, multiplied by the number of in-the-money options) that would have been received by the option holders had all option holders exercised their options on December 31, 2013. The aggregate intrinsic amount changes based on the fair market value of the Company’s common stock. Total intrinsic value of options exercised was $2.1 million in 2013, $397,000 in 2012, and $521,000 in 2011. The options outstanding and exercisable at December 31, 2013 were in the following exercise price ranges:
|
Options Outstanding
|
Options Exercisable
|
|||||||||||||||||
|
Range of Exercise Prices
|
Number
Outstanding
|
Weighted-Average
Remaining
Contractual Life
(in years)
|
Number
Outstanding
|
Weighted-Average
Exercise
Price
|
||||||||||||||
|
$
|
6.54
|
19,292
|
2.30
|
19,292
|
$
|
6.54
|
||||||||||||
|
$
|
6.88
|
628,329
|
5.54
|
239,088
|
6.88
|
|||||||||||||
|
$
|
7.11–$ 8.52
|
191,548
|
2.91
|
145,738
|
8.29
|
|||||||||||||
|
$
|
8.66
|
397,231
|
2.43
|
397,231
|
8.66
|
|||||||||||||
|
$
|
8.72
|
564,751
|
4.37
|
376,169
|
8.72
|
|||||||||||||
|
$
|
8.80
|
688,000
|
6.46
|
—
|
—
|
|||||||||||||
|
$
|
8.81–$9.74
|
231,978
|
5.46
|
56,522
|
9.39
|
|||||||||||||
|
$
|
10.24
|
491,137
|
3.36
|
446,826
|
10.24
|
|||||||||||||
|
$
|
10.43–$14.14
|
402,708
|
1.65
|
363,603
|
11.57
|
|||||||||||||
|
$
|
14.78–$25.73
|
177,188
|
1.61
|
177,188
|
19.85
|
|||||||||||||
|
$
|
6.54–$25.73
|
3,792,162
|
4.18
|
2,221,657
|
$
|
10.14
|
||||||||||||
As of December 31, 2012 there were 2,224,660 options that were exercisable at a weighted average exercise price of $10.50.
RSU and Stock Awards Activity Table
Information with respect to restricted stock units’ activity is as follows (in thousands):
|
|
Number
of
Shares
|
Weighted-Average
Grant-
Date Fair
Value
|
Aggregate
Fair Value(1)
(in thousands)
|
Aggregate
Intrinsic Value(2)
(in thousands)
|
||||||||||||
|
Outstanding at December 31, 2010
|
67,096
|
$
|
10.24
|
$
|
556
|
|||||||||||
|
Granted
|
77,225
|
$
|
8.32
|
|||||||||||||
|
Vested (3)
|
(82,526
|
)
|
$
|
8.93
|
$
|
691
|
(4)
|
|||||||||
|
Forfeited
|
(6,542
|
)
|
$
|
9.99
|
||||||||||||
|
Outstanding at December 31, 2011
|
55,253
|
$
|
9.55
|
$
|
412
|
|||||||||||
|
Granted
|
148,188
|
$
|
6.85
|
|||||||||||||
|
Vested (3)
|
(41,522
|
)
|
$
|
9.79
|
$
|
279
|
(5)
|
|||||||||
|
Forfeited
|
(13,210
|
)
|
$
|
7.39
|
||||||||||||
|
Outstanding at December 31, 2012
|
148,709
|
$
|
6.99
|
$
|
1,338
|
|||||||||||
|
Granted
|
188,678
|
$
|
8.94
|
|||||||||||||
|
Vested (3)
|
(119,505
|
)
|
$
|
7.68
|
$
|
1,091
|
(6)
|
|||||||||
|
Forfeited
|
(38,417
|
)
|
$
|
8.11
|
||||||||||||
|
Outstanding at December 31, 2013
|
179,465
|
$
|
8.34
|
$
|
1,827
|
|||||||||||
| (1) | Represents the value of the Company’s stock on the date that the restricted stock units vest. |
| (2) | Based on the closing stock price of the Company’s stock of $10.18 on December 31, 2013, $9.00 on December 31, 2012, $7.45 on December 30, 2011 and $8.29 on December 31, 2010. |
| (3) | The number of restricted stock units vested includes shares that the Company withheld on behalf of the employees to satisfy the statutory tax withholding requirements. |
| (4) | On the grant date, the fair value for these vested awards was $737,000. |
| (5) | On the grant date, the fair value for these vested awards was $407,000. |
| (6) | On the grant date, the fair value for these vested awards was $917,000. |
Performance Stock Units
In 2013 and 2012, the Company granted its executive officers 33,751 and 42,250 PSUs that vest on June 1, 2014 and 2013, respectively, subject to the recipient’s continued service through that date. At the vest date, the Company issues fully-paid up common stock based on the percentage achievement of each performance goal. For the June 1, 2013 to 2014 PSUs, there are three performance goals. For the June 1, 2012 to 2013 PSUs, there were also three performance goals, related to Company revenue and profitability targets, based on which the Company issued 35,154 shares of common stock on June 1, 2013.
Stock-Based Compensation
Stock-based compensation expense for stock options, restricted stock units, stock awards and ESPP shares for the year ended December 31, 2013, 2012 and 2011 was as follows (in thousands):
|
|
Year Ended December 31,
|
|||||||||||
|
|
2013
|
2012
|
2011
|
|||||||||
|
Stock options
|
$
|
2,201
|
$
|
2,421
|
$
|
3,047
|
||||||
|
RSUs
|
631
|
501
|
775
|
|||||||||
|
PSUs
|
162
|
138
|
—
|
|||||||||
|
ESPP
|
116
|
100
|
85
|
|||||||||
|
Total stock-based compensation expense
|
$
|
3,110
|
$
|
3,160
|
$
|
3,907
|
||||||
As of December 31, 2013, the unrecognized compensation cost, net of expected forfeitures, was $4.3 million for stock options and stock awards, which will be recognized using the straight-line attribution method over an estimated weighted-average remaining amortization period of 2.56 years. For the ESPP, the unrecognized compensation cost, net of expected forfeitures, was $38,000, which will be recognized using the straight- line attribution method over an estimated weighted-average amortization period 0.33 years.
The amount of cash received from the exercise of stock options and employee stock purchases, net of taxes withheld and paid was $5.2 million in 2013, $1.7 million in 2012, and $1.4 million in 2011, and the total direct tax benefit (deficit) realized, including the excess tax benefit (deficit), from stock-based award activity was $6,000 in 2012, and $29,000 in 2011. There was no direct tax benefit (deficit) in 2013. The Company elected to account for the indirect effects of stock-based awards—primarily the research and development tax credit—through the Statement of Operations.
Total stock-based compensation expense recorded by department during the year ended December 31, 2013, 2012 and 2011 was as follows (in thousands):
|
|
Year Ended December 31,
|
|||||||||||
|
|
2013
|
2012
|
2011
|
|||||||||
|
Cost of revenue
|
$
|
638
|
$
|
658
|
$
|
659
|
||||||
|
Sales and marketing
|
744
|
657
|
788
|
|||||||||
|
Research and development
|
397
|
514
|
698
|
|||||||||
|
General and administrative
|
1,331
|
1,331
|
1,762
|
|||||||||
|
Total stock-based compensation expense
|
$
|
3,110
|
$
|
3,160
|
$
|
3,907
|
||||||
Valuation Assumptions and Fair Value of Stock Options and ESPP Grants
The Company uses the Black-Scholes option pricing model to estimate the fair value of options granted under its equity incentive plans and rights to acquire stock granted under its employee stock purchase plan. The Company based the weighted average estimated values of employee stock option grants and rights granted under the employee stock purchase plan, as well as the weighted average assumptions used in calculating these values, on estimates at the date of grant, as follows:
|
|
Stock Options
|
Stock Purchase Plan
|
||||||||||||||||||||||
|
|
2013
|
2012
|
2011
|
2013
|
2012
|
2011
|
||||||||||||||||||
|
Estimated fair value of grants during the year
|
$
|
3.22
|
$
|
2.47
|
$
|
3.10
|
$
|
2.84
|
$
|
2.16
|
$
|
2.06
|
||||||||||||
|
Expected term (in years)(1)
|
4.30
|
4.17
|
4.15
|
0.50
|
0.50
|
0.50
|
||||||||||||||||||
|
Risk-free interest rate(2)
|
1.13
|
%
|
0.45
|
%
|
1.41
|
%
|
0.08
|
%
|
0.15
|
%
|
0.08
|
%
|
||||||||||||
|
Volatility(3)
|
43
|
%
|
44
|
%
|
43
|
%
|
44
|
%
|
43
|
%
|
39
|
%
|
||||||||||||
|
Dividend yield(4)
|
—
|
%
|
—
|
%
|
—
|
%
|
—
|
%
|
—
|
%
|
—
|
%
|
||||||||||||
| (1) | The expected term represents the period during which the Company’s stock-based awards are expected to be outstanding. The estimated term is based on historical experience of similar awards, giving consideration to the contractual terms of the awards, vesting requirements, and expectation of future employee behavior, including post-vesting terminations. |
| (2) | The risk-free interest rate is based on U.S. Treasury debt securities with maturities close to the expected term of the option as of the date of grant. |
| (3) | Estimated volatility is based on historical volatility. The Company also considers implied volatility when there is sufficient volume of freely traded options with comparable terms and exercise prices in the open market. |
| (4) | The Company has not historically issued any dividends and does not expect to do so in the foreseeable future. |
The Company periodically estimates forfeiture rates based on its historical experience within separate groups of employees and adjusts the stock-based payment expense accordingly.
RSU Withholdings
For RSU’s granted to employees, the number of shares issued on the date the RSUs vest is net of the tax withholding requirements paid on behalf of the employees. The Company withheld 24,249 in 2013, 14,974 in 2012, and 16,629 in 2011, shares of common stock to satisfy its employees’ tax obligations of $222,000 in 2013, $101,000 in 2012, and $146,000 in 2011. The Company paid this amount in cash to the appropriate taxing authorities. Although shares withheld are not issued, they are treated as common stock repurchases for accounting and disclosure purposes, as they reduce the number of shares that would have been issued upon vesting.
Share Repurchase Program
On August 5, 2013, the Company’s Board of Directors modified Cutera, Inc.’s stock buyback program, originally adopted in November 2012, to permit an additional $10 million of its issued and outstanding common shares to be repurchased. As modified, the stock buyback program permits the Company to purchase an aggregate of $20 million of its common stock through a 10b5-1 program based on predetermined pricing and volume as well as open-market purchases that are subject to management discretion and regulatory restrictions
In the year ended December 31, 2013, the Company repurchased 1,060,447 shares of its common stock at an average price of $9.43 per share, for approximately $10.0 million. As of December 31, 2013, there remained an additional $10.0 million of the Company's common stock to be purchased under the modified stock buyback program. The number of shares to be repurchased and the timing of such repurchases will be based on several factors, including the price of the Company's common stock, regulatory restrictions, and general market and business conditions.
NOTE 7—INCOME TAXES
The Company files income tax returns in the U.S. federal and various state and local jurisdictions and foreign jurisdictions. The Company’s loss before provision for income taxes consisted of the following (in thousands):
|
Year Ended December 31,
|
||||||||||||
|
2013
|
2012
|
2011
|
||||||||||
|
U.S.
|
$
|
(4,919
|
)
|
$
|
(6,767
|
)
|
$
|
(10,458
|
)
|
|||
|
Foreign
|
118
|
|
437
|
640
|
||||||||
|
Loss before income taxes
|
$
|
(4,801
|
)
|
$
|
(6,330
|
)
|
$
|
(9,818
|
)
|
|||
The components of the provision for income taxes are as follows (in thousands):
|
|
Year Ended December 31,
|
|||||||||||
|
|
2013
|
2012
|
2011
|
|||||||||
|
Current:
|
||||||||||||
|
Federal
|
$
|
(329
|
)
|
$
|
(13
|
)
|
$
|
(52
|
)
|
|||
|
State
|
7
|
(56
|
)
|
69
|
||||||||
|
Foreign
|
159
|
366
|
208
|
|||||||||
|
|
(163
|
)
|
297
|
225
|
||||||||
|
Deferred:
|
||||||||||||
|
Federal
|
33
|
(12
|
)
|
(13
|
)
|
|||||||
|
State
|
—
|
—
|
13
|
|||||||||
|
Foreign
|
76
|
(67
|
)
|
18
|
||||||||
|
|
109
|
(79
|
)
|
18
|
||||||||
|
Tax (benefit) provision
|
$
|
(54
|
)
|
$
|
218
|
$
|
243
|
|||||
The Company’s deferred tax asset consists of the following (in thousands):
|
|
Years Ended December 31,
|
|||||||
|
|
2013
|
2012(1)
|
||||||
|
Net operating loss
|
11,014
|
9,828
|
||||||
|
Stock based compensation
|
3,806
|
5,561
|
||||||
|
Other accruals and reserves
|
3,686
|
3,259
|
||||||
|
Credits
|
3,121
|
2,261
|
||||||
|
Capital loss
|
-
|
796
|
||||||
|
Foreign
|
360
|
436
|
||||||
|
Accrued warranty
|
441
|
466
|
||||||
|
Depreciation and amortization
|
224
|
180
|
||||||
|
Other
|
470
|
(450
|
)
|
|||||
|
Deferred tax assets before valuation allowance
|
23,122
|
22,337
|
||||||
|
Valuation allowance
|
(22,762
|
)
|
(21,907
|
)
|
||||
|
Net deferred tax assets after valuation allowance
|
360
|
430
|
||||||
|
Deferred tax liability on indefinite-lived tangible assets
|
(39
|
)
|
—
|
|||||
|
Net deferred tax assets
|
321
|
430
|
||||||
(1) The Company revised its 2012 deferred tax asset balances relating to its net operating loss, stock-based compensation, other assets and valuation allowance. These changes had no impact to the balance sheet, statement of operations, earnings per share, statement of cash flows, or statement of equity for any period presented.
The Company’s deferred tax asset balance is reported in the following captions in the Consolidated Balance Sheets (in thousands):
|
|
December 31,
|
|||||||
|
|
2013
|
2012
|
||||||
|
Deferred tax asset (current portion)
|
$
|
31
|
$
|
40
|
||||
|
Deferred tax asset, net of current portion
|
329
|
553
|
||||||
|
Accrued liabilities (current deferred tax liability)
|
—
|
(163
|
)
|
|||||
|
Accrued liabilities (non-current deferred tax liability)
|
(39
|
)
|
—
|
|||||
|
Net deferred tax asset after valuation allowance
|
$
|
321
|
$
|
430
|
||||
The differences between the U.S. federal statutory income tax rates to the Company’s effective tax rate are as follows:
|
Year Ended December 31,
|
||||||||||||
|
2013
|
2012*
|
2011*
|
||||||||||
|
U.S. federal statutory income tax rate
|
35.00
|
%
|
35.00
|
%
|
35.00
|
%
|
||||||
|
State tax rate, net of federal benefit
|
1.57
|
3.28
|
2.56
|
|||||||||
|
Benefit for research and development credit
|
19.91
|
3.40
|
6.02
|
|||||||||
|
Foreign rate differential
|
(4.53
|
)
|
(1.49
|
)
|
—
|
|||||||
|
Changes in unrecognized tax benefits
|
2.60
|
1.06
|
(0.02
|
)
|
||||||||
|
Foreign income inclusion
|
—
|
(0.05
|
)
|
(2.15
|
)
|
|||||||
|
Income tax refund
|
0.19
|
1.07
|
2.34
|
|||||||||
|
Stock-based compensation
|
(34.33
|
)
|
(21.31
|
)
|
(15.82
|
)
|
||||||
|
Meals and entertainment
|
(2.10
|
)
|
(1.68
|
)
|
(0.88
|
)
|
||||||
|
Tax effect of other comprehensive income
|
—
|
0.28
|
(2.01
|
)
|
||||||||
|
Valuation allowance
|
(17.82
|
)
|
(21.15
|
)
|
(28.51
|
)
|
||||||
|
Other
|
0.63
|
(1.86
|
)
|
0.99
|
||||||||
|
Effective tax rate
|
1.12
|
%
|
(3.45
|
)%
|
(2.48
|
)%
|
||||||
(*) The Company revised the effective tax rate reconciliation above for the years ended December 31, 2011 and 2012 for changes to its deferred tax assets for stock-based compensation and resulting valuation allowances. In addition the Company made reclassification changes to its 2011 and 2012 tax rate reconciliations to conform to current period presentation. These changes had no impact to the Company’s balance sheets, statement of operations, earnings per share, statement of cash flows, or statement of equity for any period presented.
The Company recognizes deferred tax assets for the expected future tax consequences of temporary differences between the financial reporting and tax bases of assets and liabilities, and for operating losses and tax credit carryforwards. The Company records a valuation allowance to reduce the deferred tax assets to their estimated realizable value, when it is more likely than not that it will not be able to generate sufficient future taxable income to realize the net carrying value. The Company has recorded a full valuation allowance against its U.S. federal and state deferred tax assets due to its history of operating losses. There was a net increase in the valuation allowance of $0.9 million, $1.4 million, and $2.8 million in the years ended December 31, 2013, 2012 and 2011, respectively
As of December 31, 2013, the Company had cumulative net operating loss carry-forwards for federal and state income tax reporting purposes of approximately $30.0 million and $10.0 million, respectively. The federal net operating loss carry-forwards expire through the year 2033 and the state net operating loss carry-forwards expire at various dates through the year 2032. The Company maintained a valuation allowance against these net operating loss carry-forwards as of December 31, 2013.
As of December 31, 2013, the Company had research and development tax credits for federal and state income tax purposes of approximately $3.6 million and $4.5 million, respectively. The federal research and development tax credits expire through the year 2033. The state research and development credits can be carried forward indefinitely, except for $284,000, which will expire at various dates through the year 2020. The Company maintained a valuation allowance against these tax credits as of December 31, 2013.
Included in the net operating loss and research and development tax credit carryforwards are approximately $3.9 million of excess tax benefits from employee stock option exercises, for which the Company has not recorded a deferred tax asset. When such excess tax benefits are ultimately realized, the Company will record the deferred tax asset and the credit to additional paid in capital.
The Tax Reform Act of 1986 and similar state provisions limit the use of net operating loss and research and development credit carry-forwards in certain situations where equity transactions result in a change of ownership as defined by Internal Revenue Code Section 382. In the event the Company should experience an ownership change, as defined, utilization of its federal and state net operating loss carry-forwards and credits could be limited and may expire unutilized.
Undistributed earnings of the Company’s foreign subsidiaries of approximately $2.6 million at December 31, 2013, are considered to be indefinitely reinvested and, accordingly, no provision for federal and state income taxes has been provided thereon. If these foreign earnings were to be repatriated in the future, the related U.S. tax liability would be reduced by any foreign income taxes previously paid on these earnings.
Uncertain Tax Positions
The Company establishes reserves for uncertain tax positions based on the largest amount that is more-likely-than-not to be sustained. An uncertain income tax position will not be recognized if it has less than a 50% likelihood of being sustained. The Company has provided taxes and related interest and penalties due for potential adjustments that may result from examinations of open U.S. Federal, state and foreign tax years. If the Company ultimately determines that payment of these amounts are not more-likely-than-not, the Company will reverse the liability and recognize a tax benefit during the period in which the Company makes the determination. The Company will record an additional charge in the Company’s provision for taxes in the period in which the Company determines that the recorded tax liability is less than the Company expects the ultimate assessment to be. The Company’s policy is to include interest and penalties related to gross unrecognized tax benefits within the provision for income taxes.
The Company files U.S., state, and foreign income tax returns in jurisdictions with varying statutes of limitations. The 2004 through 2013 tax years generally remain subject to examination by U.S., federal and California state tax authorities due to the Company’s net operating loss and credit carryforwards. For significant foreign jurisdictions, the 2008 through 2013 tax years generally remain subject to examination by their respective tax authorities.
The following table summarizes the activity related to the Company’s gross unrecognized tax benefits in December 31, 2011 to December 31, 2013 (in thousands):
|
|
Year Ended December 31,
|
|||||||||||
|
|
2013
|
2012
|
2011
|
|||||||||
|
Balance at beginning of year
|
$
|
536
|
$
|
583
|
$
|
555
|
||||||
|
Increases related to prior year tax positions
|
36
|
—
|
—
|
|||||||||
|
Increases related to current year tax positions
|
116
|
29
|
44
|
|||||||||
|
Decreases related to lapsing of statute of limitations
|
(153
|
)
|
(76
|
)
|
(16
|
)
|
||||||
|
Balance at end of year
|
$
|
535
|
$
|
536
|
$
|
583
|
||||||
The Company’s total unrecognized tax benefits that, if recognized, would affect its effective tax rate were approximately $33,000 and $325,000 as of December 31, 2013 and 2012, respectively. The Company had accrued approximately $37,000 and $86,000 for payment of interest as of December 31, 2013 and 2012, respectively. Interest included in the provision for income taxes was not significant in all the periods presented. The Company has not accrued any penalties related to its uncertain tax positions as it believes that it is more likely than not that there will not be any assessment of penalties. The Company expects that the amount of unrecognized tax benefits will not materially change within the next 12 months.
NOTE 8—NET LOSS PER SHARE
Diluted earnings per share is the same as basic earnings per share for the periods presented because the inclusion of outstanding common stock equivalents would be anti-dilutive. The following number of weighted shares outstanding, prior to the application of the treasury stock method, were excluded from the computation of diluted net loss per common share for the years presented because including them would have had an anti-dilutive effect (in thousands):
|
|
Year Ended December 31,
|
|||||||||||
|
|
2013
|
2012
|
2011
|
|||||||||
|
Options to purchase common stock
|
3,830
|
3,746
|
3,667
|
|||||||||
|
Restricted stock units
|
173
|
97
|
61
|
|||||||||
|
Employee stock purchase plan shares
|
72
|
78
|
70
|
|||||||||
|
Performance stock units
|
34
|
8
|
—
|
|||||||||
|
Total
|
4,109
|
3,929
|
3,798
|
|||||||||
NOTE 9—DEFINED CONTRIBUTION PLAN
In the U.S., the Company has an employee savings plan (401(k) Plan) that qualifies as a deferred salary arrangement under Section 401(k) of the Internal Revenue Code. Eligible employees may make voluntary contributions to the 401(k) Plan up to 100% of their annual compensation, subject to statutory annual limitations. The Company made no discretionary contributions in 2011 under the 401(k) Plan, however in 2012 and 2013, the Company made discretionary contributions of $146,000 and $184,000 respectively.
For the Company’s Japanese subsidiary, it has established an employee retirement plan at its discretion. In addition, for some of the Company’s other foreign subsidiaries, the Company deposits funds with insurance companies, third-party trustees, or into government-managed accounts consistent with the requirements of local laws. The Company has fully funded or accrued for its obligations as of December 31, 2013, and the related expense for each of the three years then ended was not significant.
NOTE 10—SEGMENT INFORMATION AND REVENUE BY GEOGRAPY AND PRODUCTS
Operating segments are identified as components of an enterprise about which separate discrete financial information is available for evaluation by the chief operating decision maker, or decision-making group, in making decisions how to allocate resources and assess performance. The Company’s chief decision maker, as defined under the FASB’s ASC 280 guidance, is a combination of the Chief Executive Officer and the Executive Vice President and Chief Financial Officer. To date, the Company has viewed its operations, managed its business, and used one measurement of profitability for the one operating segment – the sale of aesthetic medical equipment and services, and distribution of cosmeceutical and dermal filler products, to qualified medical practitioners. In addition, substantially all of the Company’s long-lived assets are located in the U.S.
The following table summarizes revenue by geographic region, which is based on the shipping location of where the product is delivered, and product category (in thousands):
|
|
Year Ended December 31,
|
|||||||||||
|
|
2013
|
2012
|
2011
|
|||||||||
|
Revenue mix by geography:
|
||||||||||||
|
United States
|
$
|
31,487
|
$
|
31,949
|
$
|
23,313
|
||||||
|
Japan
|
14,205
|
17,826
|
15,019
|
|||||||||
|
Asia, excluding Japan
|
11,263
|
8,902
|
4,984
|
|||||||||
|
Europe
|
7,358
|
4,958
|
3,571
|
|||||||||
|
Rest of the world
|
10,281
|
13,642
|
13,403
|
|||||||||
|
Consolidated total
|
$
|
74,594
|
$
|
77,277
|
$
|
60,290
|
||||||
|
Revenue mix by product category:
|
||||||||||||
|
Products and upgrades
|
$
|
48,374
|
$
|
49,605
|
$
|
37,208
|
||||||
|
Titan and truSculpt hand piece refills
|
4,267
|
4,807
|
4,686
|
|||||||||
|
Dermal filler and cosmeceuticals
|
4,264
|
5,645
|
4,985
|
|||||||||
|
Total product revenue
|
56,905
|
60,057
|
46,879
|
|||||||||
|
Service
|
17,689
|
17,220
|
13,411
|
|||||||||
|
Consolidated total
|
$
|
74,594
|
$
|
77,277
|
$
|
60,290
|
||||||
NOTE 11—COMMITMENTS AND CONTINGENCIES
Facility Leases
As of December 31, 2013, the Company was committed to minimum lease payments for facilities and other leased assets under long-term non-cancelable operating leases as follows (in thousands):
|
Year Ending December 31,
|
Amount
|
|||
|
2014
|
$
|
1,793
|
||
|
2015
|
1,516
|
|||
|
2016
|
1,341
|
|||
|
2017
|
1,346
|
|||
|
Future minimum rental payments
|
$
|
5,996
|
||
Gross rent expense was $1.6 million in 2013, $1.6 million in 2012 and $1.9 million in 2011.
Vehicle Leases
As of December 31, 2013, the Company was committed to minimum lease payments for leased vehicles under long-term non-cancelable capital leases as follows (in thousands):
|
Year Ending December 31,
|
Amount
|
|||
|
2014
|
$
|
155
|
||
|
2015
|
155
|
|||
|
2016
|
183
|
|||
|
Future minimum lease payments
|
$
|
493
|
||
Purchase Commitments
The Company maintains certain open inventory purchase commitments with its suppliers to ensure a smooth and continuous supply for key components. The Company’s liability in these purchase commitments is generally restricted to a forecasted time-horizon as agreed between the parties. These forecasted time-horizons can vary among different suppliers. The Company’s open inventory purchase commitments with its suppliers were not significant at December 31, 2013 or 2012.
Indemnifications
In the normal course of business, the Company enters into agreements that contain a variety of representations, warranties, and indemnification obligations. For example, the Company has entered into indemnification agreements with each of its directors and executive officers and one other key employee. The Company’s exposure under its various indemnification obligations is unknown and not reasonably estimable as they involve future claims that may be made against the Company. As such, the Company has not accrued any amounts for such obligations.
Litigation and Litigation Settlements
The Company is named from time to time as a party to product liability and contractual lawsuits in the normal course of business. The Company routinely assesses the likelihood of any adverse judgments or outcomes related to legal matters and claims, as well as ranges of probable losses. A determination of the amount of the reserves required, if any, for these contingencies is made after analysis of each known issue, historical experience, whether it is more likely than not that the Company shall incur a loss, and whether the loss is estimable. As of December, 2013, the Company had accrued $72,000 related to pending product liability and contractual lawsuits.
SUPPLEMENTARY FINANCIAL DATA (UNAUDITED)
(In thousands, except per share amounts)
|
Quarter ended:
|
Dec. 31,
2013
|
Sept. 30,
2013
|
June 30,
2013
|
March 31,
2013
|
Dec. 31,
2012
|
Sept. 30,
2012
|
June 30,
2012
|
March 31,
2012
|
||||||||||||||||||||||||
|
Net revenue
|
$
|
22,239
|
$
|
16,828
|
$
|
19,560
|
$
|
15, 967
|
$
|
22,533
|
$
|
19,426
|
$
|
19,591
|
$
|
15,727
|
||||||||||||||||
|
Cost of revenue
|
9,202
|
7,651
|
8,442
|
7,417
|
9,790
|
8,828
|
9,274
|
7,845
|
||||||||||||||||||||||||
|
Gross profit
|
13,037
|
9,177
|
11,118
|
8,550
|
12,743
|
10,598
|
10,317
|
7,882
|
||||||||||||||||||||||||
|
Operating expenses:
|
||||||||||||||||||||||||||||||||
|
Sales and marketing
|
7,804
|
6,554
|
7,170
|
6,456
|
7,101
|
7,014
|
7,112
|
7,437
|
||||||||||||||||||||||||
|
Research and development
|
2,438
|
2,440
|
2,217
|
2,121
|
2,122
|
2,217
|
1,872
|
2,216
|
||||||||||||||||||||||||
|
General and administrative
|
3,135
|
2,160
|
2,354
|
2,289
|
2,452
|
2,475
|
2,854
|
3,495
|
||||||||||||||||||||||||
|
Total operating expenses
|
13,377
|
11,154
|
11,741
|
10,866
|
11,675
|
11,706
|
11,838
|
13,148
|
||||||||||||||||||||||||
|
Income (loss) from operations
|
(340
|
)
|
(1,977
|
)
|
(623
|
)
|
(2,316
|
)
|
1,068
|
(1,108
|
)
|
(1,521
|
)
|
(5,266
|
)
|
|||||||||||||||||
|
Interest and other income, net
|
105
|
140
|
75
|
135
|
105
|
152
|
144
|
96
|
||||||||||||||||||||||||
|
Income (loss) before income taxes
|
(235
|
)
|
(1,837
|
)
|
(548
|
)
|
(2,181
|
)
|
1,173
|
(956
|
)
|
(1,377
|
)
|
(5,170
|
)
|
|||||||||||||||||
|
Income tax provision (benefit)
|
43
|
(169
|
)
|
90
|
(18
|
)
|
96
|
(64
|
)
|
89
|
97
|
|||||||||||||||||||||
|
Net income (loss)
|
$
|
(278
|
)
|
$
|
(1,668
|
)
|
$
|
(638
|
)
|
$
|
(2,163
|
)
|
$
|
1,077
|
$
|
(892
|
)
|
$
|
(1,466
|
)
|
$
|
(5,267
|
)
|
|||||||||
|
Net income (loss) per share—basic
|
$
|
(0.02
|
)
|
$
|
(0.11
|
)
|
$
|
(0.04
|
)
|
$
|
(0.15
|
)
|
$
|
0.08
|
$
|
(0.06
|
)
|
$
|
(0.10
|
)
|
$
|
(0.38
|
)
|
|||||||||
|
Net income (loss) per share—diluted
|
$
|
(0.02
|
)
|
$
|
(0.11
|
)
|
$
|
(0.04
|
)
|
$
|
(0.15
|
)
|
$
|
0.08
|
$
|
(0.06
|
)
|
$
|
(0.10
|
)
|
$
|
(0.38
|
)
|
|||||||||
|
Weighted average number of shares used in per share calculations:
|
||||||||||||||||||||||||||||||||
|
Basic
|
14,016
|
14,541
|
14,723
|
14,408
|
14,173
|
14,127
|
14,095
|
13,960
|
||||||||||||||||||||||||
|
Diluted
|
14,016
|
14,541
|
14,723
|
14,408
|
14,272
|
14,127
|
14,095
|
13,960
|
||||||||||||||||||||||||
CUTERA, INC.
VALUATION AND QUALIFYING ACCOUNTS
(in thousands)
For the Years Ended December 31, 2013, 2012 and 2011
|
Balance at
Beginning
of Year
|
Additions
|
Deductions
|
Balance
at End of
Year
|
|||||||||||||
|
Deferred tax assets valuation allowance
|
||||||||||||||||
|
Year ended December 31, 2013
|
$
|
21,907
|
$
|
3,437
|
$
|
2,582
|
$
|
22,762
|
||||||||
|
Year ended December 31, 2012(1)
|
$
|
20,551
|
$
|
1,773
|
$
|
417
|
$
|
21,907
|
||||||||
|
Year ended December 31, 2011(1)
|
$
|
17,752
|
$
|
3,869
|
$
|
1,070
|
$
|
20,551
|
||||||||
|
Balance at
Beginning
of Year
|
Additions
|
Deductions
|
Balance
at End of
Year
|
|||||||||||||
|
Allowance for doubtful accounts receivable
|
||||||||||||||||
|
Year ended December 31, 2013
|
$
|
—
|
$
|
19
|
$
|
—
|
$
|
19
|
||||||||
|
Year ended December 31, 2012
|
$
|
8
|
$
|
66
|
$
|
74
|
$
|
—
|
||||||||
|
Year ended December 31, 2011
|
$
|
20
|
$
|
39
|
$
|
51
|
$
|
8
|
||||||||
| (1) | The Company revised the deferred tax assets valuation allowance balances for calendar 2011 and 2012 as a result of revisions to its deferred tax assets relating to stock-based compensation and the resulting valuation allowance for them. These changes had no impact to the Company’s balance sheets, statement of operations, earnings per share, statement of cash flows, or statement of equity for any period presented. |
| a. | For 2011, reduced the balance at the beginning of the year by $116,000 and increased the deductions for the year by $607,000, which resulted in a net change in the ending balance for the year by $723,000; |
| b. | For 2012, reduced the beginning balance by $723,000, and increased the deductions for the year by $276,000, which resulted in a net change in the ending balance for the year by $999,000. |
None.
Evaluation of Disclosure Controls and Procedures
Attached as exhibits to this Annual Report are certifications of the Company’s Chief Executive Officer (“CEO”) and Chief Financial Officer (“CFO”), which are required in accordance with Rule 13a-14 of the Securities Exchange Act of 1934, as amended (Exchange Act). This Controls and Procedures section includes the information concerning the controls evaluation referred to in the certifications, and it should be read in conjunction with the certifications for a more complete understanding of the topics presented.
The Company conducted an evaluation of the effectiveness of the design and operation of its disclosure controls and procedures (as defined in the Rules 13a-15(e) and 15d-15(e) under the Exchange Act) (Disclosure Controls) as of the end of the period covered by this Report required by Exchange Act Rules 13a-15(b) or 15d-15(b). The controls evaluation was conducted under the supervision and with the participation of the Company’s management, including the CEO and CFO. Based on this evaluation, the CEO and our CFO have concluded that as of the end of the period covered by this report the Company’s disclosure controls and procedures were effective at a reasonable assurance level.
Definition of Disclosure Controls
Disclosure Controls are controls and procedures designed to reasonably assure that information required to be disclosed in the Company’s reports filed under the Exchange Act, such as this Report, is recorded, processed, summarized and reported within the time periods specified in the SEC’s rules and forms. Disclosure Controls are also designed to reasonably assure that such information is accumulated and communicated to the Company’s management, including the CEO and CFO, as appropriate to allow timely decisions regarding required disclosure. The Company’s Disclosure Controls include components of its internal control over financial reporting, which consists of control processes designed to provide reasonable assurance regarding the reliability of its financial reporting and the preparation of financial statements in accordance with generally accepted accounting principles in the U.S. To the extent that components of the Company’s internal control over financial reporting are included within its Disclosure Controls, they are included in the scope of the Company’s annual controls evaluation.
Management’s Report on Internal Control over Financial Reporting
The Company’s management is responsible for establishing and maintaining adequate internal control over financial reporting as defined in Rules 13a-15(f) and 15d-15(f) under the Exchange Act. Under the supervision and with the participation of the Company’s management, including the CEO and CFO, the Company conducted an evaluation of the effectiveness of its internal control over financial reporting based on criteria established in the framework in Internal Control—Integrated Framework (1992)issued by the Committee of Sponsoring Organizations of the Treadway Commission (“COSO”). Based on this evaluation, the Company’s management concluded that the Company’s internal control over financial reporting was effective as of December 31, 2013. The effectiveness of our internal control over financial reporting as of December 31, 2013 has been audited by Ernst & Young LLP, an Independent Registered Public Accounting Firm, as stated in their report, which is included herein.
Limitations on the Effectiveness of Controls
The Company’s management, including the CEO and CFO, does not expect that the Company’s disclosure controls or internal control over financial reporting will prevent all error and all fraud. A control system, no matter how well designed and operated, can provide only reasonable, not absolute, assurance that the control system’s objectives will be met. Further, the design of a control system must reflect the fact that there are resource constraints, and the benefits of controls must be considered relative to their costs. Because of the inherent limitations in all control systems, no evaluation of controls can provide absolute assurance that all control issues and instances of fraud, if any, within the Company have been detected. These inherent limitations include the realities that judgments in decision making can be faulty and that breakdowns can occur because of simple error or mistake. Controls can also be circumvented by the individual acts of some persons, by collusion of two or more people, or by management override of the controls. The design of any system of controls is based in part on certain assumptions about the likelihood of future events, and there can be no assurance that any design will succeed in achieving its stated goals under all potential future conditions. Over time, controls may become inadequate because of changes in conditions or deterioration in the degree of compliance with policies or procedures. Because of the inherent limitations in a cost-effective control system, misstatements due to error or fraud may occur and not be detected.
Changes in Internal Control over Financial Reporting
There were no changes in the Company’s internal control over financial reporting that occurred during the most recent fiscal quarter that have materially affected, or are reasonably likely to materially affect, the Company’s internal control over financial reporting.
REPORT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM
The Board of Directors and Stockholders of Cutera, Inc.:
We have audited Cutera, Inc.'s internal control over financial reporting as of December 31, 2013, based on criteria established in Internal Control—Integrated Framework issued by the Committee of Sponsoring Organizations of the Treadway Commission (1992 Framework) (the COSO criteria). Cutera, Inc.'s management is responsible for maintaining effective internal control over financial reporting, and for its assessment of the effectiveness of internal control over financial reporting included in the accompanying Management's Report on Internal Control over Financial Reporting. Our responsibility is to express an opinion on the company's internal control over financial reporting based on our audit.
We conducted our audit in accordance with the standards of the Public Company Accounting Oversight Board (United States). Those standards require that we plan and perform the audit to obtain reasonable assurance about whether effective internal control over financial reporting was maintained in all material respects. Our audit included obtaining an understanding of internal control over financial reporting, assessing the risk that a material weakness exists, testing and evaluating the design and operating effectiveness of internal control based on the assessed risk, and performing such other procedures as we considered necessary in the circumstances. We believe that our audit provides a reasonable basis for our opinion.
A company's internal control over financial reporting is a process designed to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles. A company's internal control over financial reporting includes those policies and procedures that (1) pertain to the maintenance of records that, in reasonable detail, accurately and fairly reflect the transactions and dispositions of the assets of the company; (2) provide reasonable assurance that transactions are recorded as necessary to permit preparation of financial statements in accordance with generally accepted accounting principles, and that receipts and expenditures of the company are being made only in accordance with authorizations of management and directors of the company; and (3) provide reasonable assurance regarding prevention or timely detection of unauthorized acquisition, use or disposition of the company's assets that could have a material effect on the financial statements.
Because of its inherent limitations, internal control over financial reporting may not prevent or detect misstatements. Also, projections of any evaluation of effectiveness to future periods are subject to the risk that controls may become inadequate because of changes in conditions, or that the degree of compliance with the policies or procedures may deteriorate.
In our opinion, Cutera, Inc. maintained, in all material respects, effective internal control over financial reporting as of December 31, 2013, based on the COSO criteria.
We also have audited, in accordance with the standards of the Public Company Accounting Oversight Board (United States), the consolidated balance sheets of Cutera, Inc. as of December 31, 2013 and 2012, and the related consolidated statements of operations, comprehensive loss, stockholders’ equity, and cash flows for each of the two years in the period ended December 31, 2013, of Cutera, Inc. and our report dated March 17, 2014 expressed an unqualified opinion thereon.
|
/s/ Ernst & Young LLP
|
|
Redwood City, California
|
|
March 17, 2014
|
The Company has established that the 2014 Annual Meeting of Stockholders will be held at its principal executive offices located at 3240 Bayshore Blvd., Brisbane, CA 94005-1021 on June 18, 2014 at 10:00 a.m. and the record date for the purposes of voting in that meeting shall be April 22, 2014.
PART III
Certain information required by Part III is omitted from this Annual Report on Form 10-K because we will file a Definitive Proxy Statement (the “Proxy Statement”) for our 2014 Annual Meeting of Stockholders with the Securities and Exchange Commission within 120 days after the end of our fiscal year ended December 31, 2013.
The information required by this Item is incorporated herein by reference to the Proxy Statement.
The information required by this Item is incorporated herein by reference to the Proxy Statement.
| ITEM 12. | SECURITY OWNERSHIP OF CERTAIN BENEFICIAL OWNERS AND MANAGEMENT AND RELATED STOCKHOLDER MATTERS |
The information required by this Item is incorporated herein by reference to the Proxy Statement.
The information required by this Item is incorporated herein by reference to the Proxy Statement.
The information required by this Item is incorporated herein by reference to the Proxy Statement.
PART IV
| (1) | The financial statements required by Item 15(a) are filed as Item 8 of this annual report. |
| (2) | The financial statement schedule required by Item 15(a) filed as Item 8 of this annual report. |
| (3) | Exhibits. |
|
Exhibit No.
|
|
Description
|
|
3.2(1)
|
|
Amended and Restated Certificate of Incorporation of the Registrant (Delaware).
|
|
3.4(1)
|
|
Bylaws of the Registrant.
|
|
4.1(4)
|
|
Specimen Common Stock certificate of the Registrant.
|
|
10.1(1)
|
|
Form of Indemnification Agreement for directors and executive officers.
|
|
10.2(1)
|
|
1998 Stock Plan.
|
|
10.3(1)
|
|
2004 Equity Incentive Plan.
|
|
10.4(5)
|
|
2004 Employee Stock Purchase Plan.
|
|
10.6(1)
|
|
Brisbane Technology Park Lease dated August 5, 2003 by and between the Registrant and Gal-Brisbane, L.P. for office space located at 3240 Bayshore Boulevard, Brisbane, California.
|
|
10.10(2)
|
|
Settlement Agreement and Non-Exclusive Patent License, each between the Registrant and Palomar Medical Technologies, Inc. dated June 2, 2006.
|
|
10.11(3)
|
|
Form of Performance Unit Award Agreement.
|
|
10.13(4)†
|
|
Distribution Agreement between the Registrant and PSS World Medical Shared Services, Inc., a subsidiary of PSS World Medical dated October 1, 2006.
|
|
10.14(6)
|
|
Cutera, Inc. 2004 Equity Incentive Plan, as amended by its Board of Directors on April 27, 2012.
|
|
10.18(7)
|
|
Consulting Agreement dated March 2, 2009 by and between the Company and David A. Gollnick.
|
|
10.19(8)
|
|
First Amendment to Brisbane Technology Park Lease dated August 11, 2010 by and between the Company and BMR-Bayshore Boulevard LLC, as successor-in-interest to Gal-Brisbane, L.P., the original landlord, for office space located at 3240 Bayshore Boulevard.
|
|
10.20(9)
|
|
Change of Control and Severance Agreement dated January 5, 2011 by and between the Company and Len DeBenedictis, Chief Technology Officer of Cutera, Inc.
|
|
16.1(10)
|
|
Letter regarding change in certifying accountants.
|
|
|
Consent of Independent Registered Public Accounting Firm.
|
|
|
|
Consent of Independent Registered Public Accounting Firm.
|
|
|
24.1
|
|
Power of Attorney (see page 80).
|
|
|
Certification of Chief Executive Officer pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.
|
|
|
|
Certification of Chief Financial Officer pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.
|
|
|
|
Certification of Chief Executive Officer and Chief Financial Officer pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.
|
|
|
101(11)
|
|
The following materials from Cutera Inc.’s Annual Report on Form 10-K for the year ended December 31, 2012, formatted in XBRL (Extensible Business Reporting Language): (i) Consolidated Balance Sheets, (ii) Consolidated Statements of Income, (iii) Consolidated Statements of Comprehensive Loss, (iv) Consolidated Statement of Stockholders’ Equity, (v) Consolidated Statements of Cash Flows, and (vi) Notes to Consolidated Financial Statements, tagged at Level I through IV.
|
|
(1)
|
Incorporated by reference from our Registration Statement on Form S-1 (Registration No. 333-111928) which was declared effective on March 30, 2004.
|
|
(2)
|
Incorporated by reference from our Current Report on Form 8-K filed on June 2, 2006.
|
|
(3)
|
Incorporated by reference from our Quarterly Report on Form 10-Q filed on November 14, 2005.
|
|
(4)
|
Incorporated by reference from our Quarterly Report on Form 10-Q filed on November 8, 2006.
|
|
(5)
|
Incorporated by reference from our 2006 Annual Report on Form 10-K filed on March 16, 2007.
|
|
(6)
|
Incorporated by reference from our Definitive Proxy Statement on Form 14A filed with the SEC on April 30, 2012.
|
|
(7)
|
Incorporated by reference from our Current Report on Form 8-K filed on March 4, 2009.
|
|
(8)
|
Incorporated by reference from our Quarterly Report on Form 10-Q filed on November 1, 2010.
|
|
(9)
|
Incorporated by reference from our 2010 Annual Report on Form 10-K filed on March 15, 2011.
|
|
(10)
|
Incorporated by reference from Current Report on Form 8-K filed March, 26, 2012.
|
|
(11)
|
Filed herewith.
|
|
†
|
Confidential Treatment has been requested for certain portions of this exhibit.
|
SIGNATURES
Pursuant to the requirements of Section 13 or 15(d) of The Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized, in the city of Brisbane, State of California, on the 17th day of March, 2014.
|
|
CUTERA, INC.
|
|
|
|
|
|
|
|
|
|
By:
|
/s/ KEVIN P. CONNORS
|
|
|
|
|
Kevin P. Connors
|
|
|
|
|
President and Chief Executive Officer
|
|
Power of Attorney
KNOW ALL MEN AND WOMEN BY THESE PRESENTS, that each person whose signature appears below constitutes and appoints Kevin P. Connors, his attorney-in-fact, for him or her in any and all capacities, to sign any amendments to this Annual Report on Form 10-K, and to file the same, with exhibits thereto and other documents in connection therewith, with the U.S. Securities and Exchange Commission, hereby ratifying and confirming all that said attorney-in-fact, or his substitute, may do or cause to be done by virtue thereof.
Pursuant to the requirements of the Securities Exchange Act of 1934, this report has been signed below by the following persons on behalf of the registrant and in the capacities and on the dates indicated.
|
Signature
|
Title
|
Date
|
|
|
|
|
|
/s/ KEVIN P. CONNORS
|
|
March 17, 2014
|
|
Kevin P. Connors, President, Chief Executive Officer and Director (Principal Executive Officer)
|
|
|
|
|
|
|
|
/s/ RONALD J. SANTILLI
|
|
March 17, 2014
|
|
Ronald J. Santilli, Executive Vice President and Chief Financial Officer (Principal Accounting Officer)
|
|
|
|
|
|
|
|
/s/ DAVID B. APFELBERG
|
|
March 17, 2014
|
|
David B. Apfelberg, Director
|
|
|
|
|
|
|
|
/s/ GREGORY A. BARRETT
|
|
March 17, 2014
|
|
Gregory A. Barrett, Director
|
|
|
|
|
|
|
|
/s/ DAVID A. GOLLNICK
|
|
March 17, 2014
|
|
David A. Gollnick, Director
|
||
|
/s/ MARK LORTZ
|
March 17, 2014
|
|
|
Mark Lortz, Director
|
||
|
/s/ TIM O’SHEA
|
March 17, 2014
|
|
|
Tim O’Shea, Director
|
||
|
/s/ JERRY P. WIDMAN
|
March 17, 2014
|
|
|
Jerry P. Widman, Director
|
||
77